oxycodone profile

Oxycodone: A semisynthetic derivative of CODEINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5284603
CHEMBL ID	656
CHEBI ID	7852
SCHEMBL ID	2737
MeSH ID	M0015664

Synonym
AC-16043
oxycodonum
14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
oxicodona
CHEBI:7852 ,
(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
endine (australia)
hsdb 3142
oxycone
endone
codeinone, 7,8-dihydro-14-hydroxy-
morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-
supendol [canada]
morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-
brn 0043446
oxycodonum [inn-latin]
einecs 200-960-2
ossicodone [dcit]
nsc 19043
pancodone retard (united kingdom)
oxycodone [usan:inn:ban]
oxanest
oxicodona [inn-spanish]
eubine [france]
morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-
oxycontin
oxycodeinon
eucodalum
14-hydroxydihydrocodeinone
codeinone,8-dihydro-14-hydroxy-
dihydrone
nsc19043
nsc-19043
wln: t b6566 b6/co 4abbc r bx fv ho pn ght&&ttj cq jo1 p1
morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-
4ah-8,5-bcd]furan-5(6h)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-
diphydrone
dihydro-14-hydroxycodeinone
codeinone, dihydrohydroxy-
(-)-14-hydroxydihydrocodeinone
percobarb
(-)-oxycodone
morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-
dihydrohydroxycodeinone
dihydroxycodeinone
oxicon
oxycodeinone
oxycodon
codeinone, dihydro-14-hydroxy-
D05312
oxycodone (usan/inn)
C08018
oxycodone
76-42-6
4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
DB00497
4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
pavinal
CHEMBL656 ,
pf-00345439
xtampza
pti 821
remoxy
pti-821
ids-no-002
n02aa05
oxymorphone 3-methyl ether
oxycodone cii
dihydrohydroxycondeinone
supendol
apo-oxycodone cr
oxyneo
unii-cd35pmg570
oxyir
oxyfast
avridi
pancodone retard
ossicodone
xtampza er
cd35pmg570 ,
bdbm50370595
oxycodone [mi]
oxycodone cii [usp-rs]
oxycodone [mart.]
oxycodone [orange book]
(5.alpha.)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
oxycodone [hsdb]
hydrocodone hydrogen tartrate 2.5-hydrate impurity d [ep impurity]
oxycodone [who-dd]
oxycodone [vandf]
oxycodone [inn]
oxycodone [usan]
(4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
gtpl7093
BRUQQQPBMZOVGD-XFKAJCMBSA-N
SCHEMBL2737
(5-alpha)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
DTXSID5023407 ,
(1s,5r,13r,17s)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
oxycodone 0.1 mg/ml in methanol
oxycodone 1.0 mg/ml in methanol
pf06
(4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Q407535
oxicodone
dtxcid903407
oxycodone (mart.)
oxycodone cii (usp-rs)
hydrocodone hydrogen tartrate 2.5-hydrate impurity d (ep impurity)
supendol (canada)
xtampzaer
oxycodonum (latin)
eubine (france)
oxycodone sr
oxycodonum (inn-latin)
(5alpha)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
oxicodona (inn-spanish)
OOX ,
14-hydroxy-3-methoxy-17-methyl-5beta-4,5-epoxymorphinan-6-one

Excerpt	Reference	Relevance
"Approximately equianalgesic oral doses of codeine, an oxycodone compound resembling Percodan, and pentazocine were compared for adverse effects in a double-blind, randomized study of four doses of each drug given over two days to 247 postsurgical patients with pain."	( Adverse effects of commonly ordered oral narcotics. Hopper, M; Kantor, TG; Laska, E, 1981)	0.26
" The incidence of adverse effects was similar in all groups; serious adverse effects did not occur."	( The safety and efficacy of intrabursal oxycodone and bupivacaine in analgesia after shoulder surgery. Kirvelä, O; Muittari, P, )	0.13
" There were no significant differences in adverse effects (P=."	( Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Babul, N; Belzile, M; Bruera, E; Darke, A; Fainsinger, R; Ford, I; Harsanyi, Z; Pituskin, E, 1998)	0.3
"Controlled-release oxycodone is as safe and effective as controlled-release morphine in the treatment of cancer pain."	( Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Babul, N; Belzile, M; Bruera, E; Darke, A; Fainsinger, R; Ford, I; Harsanyi, Z; Pituskin, E, 1998)	0.3
"To assess the effect of opioid substitution (substituting one member of the opioid class for another) on the incidence and severity of adverse effects in palliative care patients who experience unacceptable, refractory adverse effects when taking an opioid drug."	( Opioid substitution to reduce adverse effects in cancer pain management. Ashby, MA; Jackson, KA; Martin, P, 1999)	0.3
" 49 substitutions were for adverse effects."	( Opioid substitution to reduce adverse effects in cancer pain management. Ashby, MA; Jackson, KA; Martin, P, 1999)	0.3
"We found that the incidence and severity of adverse effects differed between opioids in the same patient."	( Opioid substitution to reduce adverse effects in cancer pain management. Ashby, MA; Jackson, KA; Martin, P, 1999)	0.3
" The most common adverse events were constipation, nausea, pruritus, somnolence, and dizziness."	( Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Fleischmann, R; Hale, ME; Iwan, T; Kaiko, RF; Lacouture, PG; Salzman, R; Swanton, RE; Wild, J, 1999)	0.3
"To determine whether the use of diclofenac ophthalmic solution is a safe and effective analgesic in the treatment of traumatic corneal abrasions in the emergency department."	( Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions. Allegra, JR; Eskin, B; Nashed, AH; Szucs, PA, 2000)	0.31
" The outcome measurements were improvement in NPIS score 2 hours after treatment, use of oxycodone-acetaminophen, and occurrence of any adverse effects."	( Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions. Allegra, JR; Eskin, B; Nashed, AH; Szucs, PA, 2000)	0.31
"Diclofenac ophthalmic solution appears to be a safe and effective analgesic in the treatment of traumatic corneal abrasions in the ED."	( Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions. Allegra, JR; Eskin, B; Nashed, AH; Szucs, PA, 2000)	0.31
"Tramadol, a weak opioid mu-receptor agonist, may have a favourable potency and side effect profile for intravenous patient-controlled analgesia (PCA)."	( Efficacy and side effects of tramadol versus oxycodone for patient-controlled analgesia after maxillofacial surgery. Rosenberg, PH; Silvasti, M; Svartling, N; Tarkkila, P; Tuominen, M, 1999)	0.3
" The review suggested that immediate-release and controlled-release preparations of oxycodone have similar efficacy and comparable side effect profiles."	( Safety and efficacy of controlled-release oxycodone: a systematic literature review. Karbowicz, SH; Rischitelli, DG, 2002)	0.31
"In all, 28 of 33 patients (85%) completed the study; discontinuations were for adverse events (N=3), patient choice (N=1), and lack of effectiveness (N =1)."	( Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Domingos, J; Galer, BS; Gammaitoni, AR; Lacouture, P; Schlagheck, T, 2003)	0.32
" Opioid-related adverse events, similar among groups, were generally mild or moderate."	( The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Ahdieh, H; Gimbel, J, 2004)	0.32
" Adverse events for the active drugs were similar; the most frequent were constipation and sedation."	( Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. Dvergsten, C; Gimbel, J; Hale, ME, 2005)	0.33
" The occurrence of adverse events and changes in laboratory tests were evaluated as safety variables."	( Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008)	0.35
" A total of 316 adverse events occurred in 78 (90."	( Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008)	0.35
" The patch tested was well tolerated and its use did not result in any increased incidence of adverse drug reactions over those commonly found with opioid analgesics."	( Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008)	0.35
" One week later on administration, no significant adverse effects were found in the serology, conscious level, and subjective symptoms of nausea and vomiting."	( [Efficacy and safety of continuous subcutaneous injection of the compound oxycodone in cancer pain management: the first 4-year audit]. Hasegawa, T; Hisada, A; Matoba, M; Nozaki, Y; Yoshimoto, T, 2009)	0.35
" A data overview demonstrates the efficacy and tolerability of PR oxycodone/naloxone in the management of severe chronic pain without the burden of severe gastrointestinal adverse events."	( Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Clemens, KE; Mikus, G, 2010)	0.36
" Adverse events in both extension phases were consistent with those associated with opioid therapy; no additional safety concerns were observed."	( Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Dürr, H; Hakl, M; Hopp, M; Hrib, R; Lejcko, J; Leyendecker, P; Meissner, W; Reimer, K; Sandner-Kiesling, A; Sevcik, P; Tarau, L; Uhl, R, 2010)	0.36
" (1) The adverse effects caused by the prior opioids improved in more than half of the patients, and worsened in none."	( [Efficacy and safety of compound oxycodone injection for cancer pain relief-a multicenter survey of prescriptions]. Hasegawa, T; Hisada, A; Matoba, M; Murakami, S; Tomiyasu, S; Yomiya, K; Yoshimoto, T, 2010)	0.36
"4% (299/342) of patients reported at least one treatment-emergent adverse event (TEAE); incidences of gastrointestinal-related TEAEs were 26."	( Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III Afilalo, M; Etropolski, MS; Haeussler, J; Kelly, K; Kuperwasser, B; Lange, B; Okamoto, A; Rauschkolb, C; Steup, A; Van Hove, I, 2010)	0.36
" Safety evaluations included adverse events (AEs), vital signs, and clinical laboratory assessments."	( Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. Clark, FJ; Daniels, SE; Golf, M; Singla, S; Spivey, RJ, 2011)	0.37
" Adverse events were also recorded."	( The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Ashburn, MA; Messina, J; Slevin, KA; Xie, F, 2011)	0.37
" Adverse events with both study drugs were generally typical of opioids, and the majority occurred during titration."	( The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Ashburn, MA; Messina, J; Slevin, KA; Xie, F, 2011)	0.37
"Safety and tolerability assessments included adverse events (AEs), laboratory tests, vital signs, physical examinations, and electrocardiograms."	( Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Friedmann, N; Klutzaritz, V; Webster, L, 2011)	0.37
" Incidences of treatment-emergent adverse events were 56% during the open-label period, and 59, 77, and 73% for the BTDS 5, BTDS 20, and oxycodone 40 mg/day treatment groups, respectively, during the double-blind phase."	( Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011)	0.37
"Remoxy significantly improved analgesia among patients with moderate to severe chronic osteoarthritic pain with an adverse event profile similar to other opioids."	( Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. Friedmann, N; Klutzaritz, V; Webster, L, )	0.13
" The objective was to assess side effect frequency, degree of bother, and impact on health-related quality of life (HRQoL)."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" This raises a question about the unmet need for pain medications with improved side effect profiles."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" There was a 50-75 percent reduction in moderate to severe adverse events (AEs) commonly associated with opioids (ie, nausea, vomiting, and dizziness) in the MoxDuo 6 mg/4 mg group when compared with its morphine-equivalent dose groups."	( Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. Kelen, R; Richards, P; Riff, D; Stern, W, )	0.13
" No serious adverse effects associated with bowel stimulation were reported."	( Safety and efficacy of immediate postoperative feeding and bowel stimulation to prevent ileus after major gynecologic surgical procedures. Fanning, J; Hojat, R, 2011)	0.37
"Immediate postoperative feeding and bowel stimulation is a safe and effective approach to preventing ileus in patients who undergo major gynecologic surgical procedures."	( Safety and efficacy of immediate postoperative feeding and bowel stimulation to prevent ileus after major gynecologic surgical procedures. Fanning, J; Hojat, R, 2011)	0.37
" Overall, rates of adverse drug reactions were similar."	( A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Ahmedzai, SH; Bar-Sela, G; Bosse, B; Hopp, M; Leyendecker, P; Nauck, F, 2012)	0.38
"To provide family physicians with a practical clinical summary of the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain, developed by the National Opioid Use Guideline Group."	( Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Kahan, M; Mailis-Gagnon, A; Srivastava, A; Wilson, L, 2011)	0.37
"To determine the efficacy and adverse reactions of OxyContin® administered by rectal route in advanced cancer patients."	( Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Huang, XE; Li, CG; Li, Y; Lu, YY, 2011)	0.37
"OxyContin admistered by rectal route is safe for advanced cancer patients with satisfactory pain control effects, thus deserving further clinical observation."	( Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Huang, XE; Li, CG; Li, Y; Lu, YY, 2011)	0.37
" Pain intensity on a numeric rating scale, percentage of patients with each degree of pain, quality of life, adverse reactions, analgesic costs, and hospital stays were evaluated and compared among the three groups."	( Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. Kan, Z; Shi, P; Wang, J; Yan, Z; Zhou, B, 2012)	0.38
" No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group."	( Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. Kan, Z; Shi, P; Wang, J; Yan, Z; Zhou, B, 2012)	0.38
" The aim of the present study was to evaluate the results from randomized controlled trials investigating the relative amount of adverse effects using tapentadol or oxycodone for the treatment of pain."	( [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. Dinges, G; Koch, T; Kranke, P; Merker, M; Morin, AM, 2012)	0.38
" The incidences of typical adverse side effects of opioid-based analgesic therapy (e."	( [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. Dinges, G; Koch, T; Kranke, P; Merker, M; Morin, AM, 2012)	0.38
"The results show that using tapentadol significantly reduces the risk of the typical opioid-based adverse effects compared with oxycodone while providing equivalent analgesic treatment."	( [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. Dinges, G; Koch, T; Kranke, P; Merker, M; Morin, AM, 2012)	0.38
"Although opioids are widely accepted as standard therapy for treating acute postoperative pain, the frequent occurrence of adverse events (AEs) and the substantial burden on the patient and the costs of care are a barrier to optimal dosing and adherence to prescribed treatment."	( Efficacy and safety of dual-opioid therapy in acute pain. Webster, L, 2012)	0.38
"It has been confirmed by several clinical trials that the fentanyl patch causes less adverse events than sustained-release oral morphine, and after rotation."	( [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)	0.38
"We prospectively investigated the reduced effects of adverse events caused by sustained-release oral morphine and controlled-release oxycodone after rotating to the fentanyl patch in patients with metastatic breast cancer."	( [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)	0.38
" Those experiencing adverse events from oral morphine or oral oxycodone were administered a fentanyl patch."	( [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)	0.38
"This study suggested that the fentanyl patch can reduce adverse events caused by sustained-release oral morphine as well as controlled-release oral oxycodone."	( [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)	0.38
"5%) rated tolerability as "good" or "very good" at Week 52; few patients discontinued treatment because of an adverse event (1."	( Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Binsfeld, H; Richarz, U; Sabatowski, R; Szczepanski, L; Waechter, S, 2013)	0.39
"To understand the relationship between the risk of opioid-related gastrointestinal adverse effects (AEs) and exposure to tapentadol and oxycodone as well as its active metabolite, oxymorphone, using pharmacokinetic/pharmacodynamic models."	( Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR. Etropolski, M; Lin, R; Nandy, P; Okamoto, A; Upmalis, D; Xu, XS, 2012)	0.38
" Common adverse events, which occurred in 91."	( Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients. Bae, SH; Cho, YY; Hyun, MS; Kim, JY; Kim, MK; Lee, KH; Lee, SA; Lee, WS; Park, KU; Ryoo, HM; Song, HS, )	0.13
"4%) reported experiencing at least 1 side effect with 77."	( Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. Ackerman, SJ; Anastassopoulos, KP; Baik, R; Biondi, D; Chow, W; Kim, MS; Tapia, CI, 2012)	0.38
" Respondents who reported higher levels of side-effect bother also reported greater MRU, resulting in increased payer costs."	( Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. Ackerman, SJ; Anastassopoulos, KP; Baik, R; Biondi, D; Chow, W; Kim, MS; Tapia, CI, 2012)	0.38
" Moderate to severe gastrointestinal adverse events occurred in 50% of patients in the oxycodone/acetaminophen group compared with 15% of the equianalgesic morphine/oxycodone group."	( Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after total knee arthroplasty. Gimbel, JS; Kelen, R; Minkowitz, HS; Richards, P; Stern, W, 2013)	0.39
" The primary endpoint was a ≥1/3 reduction in pain (NRS); secondary endpoints included the time to analgesia and adverse effects."	( Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013)	0.39
" Given its tricyclic properties, serotonin syndrome is a potential side effect of this drug."	( Neuropsychiatric side effects of cyclobenzaprine. Sederholm, B; Shprecher, D; Sloan, CT, 2013)	0.39
" Safety assessments included adverse events, vital signs, pulse oximetry (SpO2), and electrocardiograms."	( Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Apseloff, G; Colucci, SV; Harris, SC; Perrino, PJ, 2013)	0.39
", adverse events, vital signs, laboratory tests) were assessed to 24 hours postdose."	( Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. Bartlett, C; Colucci, SV; Harris, SC; Perrino, PJ; Sellers, EM; Shram, MJ; Smith, I, 2014)	0.4
" Treatment-emergent adverse events were comparable between treatment groups."	( Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Han, J; Hou, Y; Richards, HM; Shen, W; Yu, L; Yu, S, 2014)	0.4
" Adverse events (AEs) and discontinuations were recorded in each study; pooled results were analyzed by treatment group."	( Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Etropolski, M; Flügel, M; Häufel, T; Kuperwasser, B; Lange, B; Laschewski, F; Rauschkolb, C, 2014)	0.4
" The difference in adverse events (AEs) between the two treatments did not reach significance, as 19."	( Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an establis Janecki, M; Lux, EA; Maritz, MA, 2014)	0.4
"Treatment-emergent adverse events, physical examinations, vital sign measurements, and clinical laboratory testing were assessed throughout the study."	( Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery. Barrett, T; Kostenbader, K; Singla, N; Sisk, L; Young, J, 2014)	0.4
" Adverse events occurred during the OLE in 64 patients (43."	( Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery. Barrett, T; Kostenbader, K; Singla, N; Sisk, L; Young, J, 2014)	0.4
"Number and type of adverse events (AEs) and drugrelated AEs, including assessments of withdrawal (Clinical Opiate Withdrawal Scale; COWS), pharmacokinetics, efficacy, and aberrant behaviors (Current Opioid Misuse Measure)."	( A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. Arora, S; Clemmer, R; Goli, V; Hudson, JD; Meisner, P; Michael, D; Pixton, GC; Setnik, B; Sommerville, KW, )	0.13
"Repeat dosing of ALO-02 for up to 12 months is safe and well tolerated in a CNCP population of both opioid-experienced and opioid-naïve patients."	( A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. Arora, S; Clemmer, R; Goli, V; Hudson, JD; Meisner, P; Michael, D; Pixton, GC; Setnik, B; Sommerville, KW, )	0.13
"Historically, chronic pain generally went under-treated for a variety of objective and subjective reasons, including difficulty to objectively diagnose and manage over a long period of time, potential serious adverse effects of commonly available medications, and patient, healthcare and societal concerns over opioid medications."	( Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Pergolizzi, JV; Raffa, RB; Taylor, R; Zampogna, G, 2015)	0.42
" We assessed the frequency and intensity of adverse effects, the intensity of postoperative pain by a verbal numeric scale and the use of rescue analgesia from 12 hours after administration of the drug and between 7 and 13 days after the last oxycodone dose."	( Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head and neck surgery. Carvalho, AC; Cavalcanti, IL; Figueiredo, NV; Migon, RN; Musauer, MG; Rodrigues, VS; Vane, LA, )	0.13
"The most common adverse events were nausea, vomiting, dizziness, pruritus, insomnia, constipation and urinary retention, most mild."	( Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head and neck surgery. Carvalho, AC; Cavalcanti, IL; Figueiredo, NV; Migon, RN; Musauer, MG; Rodrigues, VS; Vane, LA, )	0.13
"Controlled release oxycodone showed to be safe and well tolerated and caused a significant decrease in post-operative pain."	( Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head and neck surgery. Carvalho, AC; Cavalcanti, IL; Figueiredo, NV; Migon, RN; Musauer, MG; Rodrigues, VS; Vane, LA, )	0.13
" The primary outcome was the percentage of patients without adverse event-related study discontinuations who presented with a combination of a ≥50% improvement of pain intensity, disability and quality-of-life and a ≤50% worsening of bowel function at study end."	( Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. Mueller-Schwefe, GH; Ueberall, MA, 2015)	0.42
"0% of patients in the placebo group experienced a treatment-emergent adverse event (TEAE)."	( A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. Bass, A; Bramson, C; Hale, ME; Malhotra, BK; Meisner, P; Pixton, G; Rauck, RL; Setnik, B; Sommerville, KW; Wilson, JG; Wolfram, G, 2015)	0.42
" Xtampza ER had an adverse event profile consistent with other opioids and was well tolerated; no new safety concerns were identified."	( A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Brown, RH; Fleming, AB; Katz, N; Kopecky, EA; O'Connor, M, 2015)	0.42
" However, due to the concerns of adverse reactions, drug interactions, and addiction, clinicians frequently hesitate to prescribe opioids."	( Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report. Francis, M; Guerriero, F; Maurizi, N; Perna, S; Ricevuti, G; Rollone, M; Rondanelli, M; Sgarlata, C, 2015)	0.42
" The most common treatment-emergent adverse events (incidence ≥10%; n = 1154) were headache (13."	( Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. Arsenault, P; Buynak, R; Etropolski, M; Heisig, F; Rappaport, SA; Rauschkolb, C; Rod, K, 2015)	0.42
" Additionally, those patients administered epidural oxycodone had lower pain scores, needed less rescue analgesics and had fewer adverse effects compared with intravenous administration."	( Cytotoxicity of Oxycodone and Morphine in Human Neuroblastoma and Mouse Motoneuronal Cells: A Comparative Approach. Kokki, H; Kokki, M; Litmala, O; Pasanen, M; Pesonen, M; Vehviläinen, P, 2016)	0.43
" At each visit, pain intensity, modifications of therapy and adverse drug reactions (ADRs) were recorded."	( Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Apolone, G; Azzarello, G; Bandieri, E; Caraceni, A; Cavanna, L; Corli, O; Crispino, C; Di Gregorio, R; Dragani, TA; Floriani, I; Galli, F; Gamucci, T; Greco, MT; Iorno, V; Kaasa, S; Lipari, G; Luzzani, M; Montanari, M; Pacchioni, M; Pavesi, L; Reale, C; Roberto, A; Valenti, D, 2016)	0.43
"The main findings were the similarity in pain control, response rates and main adverse reactions among opioids."	( Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Apolone, G; Azzarello, G; Bandieri, E; Caraceni, A; Cavanna, L; Corli, O; Crispino, C; Di Gregorio, R; Dragani, TA; Floriani, I; Galli, F; Gamucci, T; Greco, MT; Iorno, V; Kaasa, S; Lipari, G; Luzzani, M; Montanari, M; Pacchioni, M; Pavesi, L; Reale, C; Roberto, A; Valenti, D, 2016)	0.43
" As cardiovascular safety data are lacking, we assessed disproportionate reporting of adverse cardiac events associated with naloxone across large, international pharmacovigilance systems."	( Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Haigney, MC; Kao, D; Krantz, MJ; Mehler, PS; Sandhu, A, 2016)	0.43
"Post-marketing data from the World Health Organization (WHO) and FDA Adverse Events Reporting System (FAERS) were evaluated for naloxone and the synthetic opioids oxycodone and tilidine."	( Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Haigney, MC; Kao, D; Krantz, MJ; Mehler, PS; Sandhu, A, 2016)	0.43
"In total, 14,827,374 million adverse drug event reports were reviewed."	( Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Haigney, MC; Kao, D; Krantz, MJ; Mehler, PS; Sandhu, A, 2016)	0.43
"Available pharmacovigilance data do not suggest disproportionate reporting of adverse cardiovascular events for opioid antagonists used to treat OIC."	( Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Haigney, MC; Kao, D; Krantz, MJ; Mehler, PS; Sandhu, A, 2016)	0.43
"The adverse events (AEs) of oxycodone in cancer-related pain were controversial, so we conducted a meta-analysis to determine it."	( The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Huang, L; Jin, SH; Liu, Y; Ma, H; Tian, X; Yue, GJ; Zeng, XT; Zhou, JG, 2016)	0.43
" HYD demonstrated a safety profile typical of µ opioids; nausea, constipation, vomiting, and dizziness were the most frequently reported opioid-related adverse events during the study."	( Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain. He, E; Kowalski, M; Pergolizzi, J, 2018)	0.48
" The safety profile was consistent with the application method and known side-effect profile of oxycodone and naltrexone."	( Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. Gavin, PD; Schlagheck, T; Shakib, S; Simon, LS; Smith, AJ, 2017)	0.46
" Adverse events were consistent with the known effects of OXN PR and no new safety concerns emerged."	( Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Bosse, B; Dupoiron, D; Ellery, A; Hopp, M; Kremers, W; Loewenstein, O; Stachowiak, A, 2017)	0.46
"2% for tapentadol PR); time to treatment discontinuation due to an adverse event was significantly shorter for oxycodone CR (p < 0."	( Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Dubois, C; Elling, C; Lange, B; von Zabern, D, 2017)	0.46
" Pain scores, adverse events, and length of stay were recorded."	( Intrathecal Morphine and Oral Analgesics Provide Safe and Effective Pain Control After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis. Abbott, MD; Burke, MC; Caird, MS; Farley, FA; Gibbons, KM; Holman, AE; Hong, RA; Li, Y; Robbins, CB, 2018)	0.48
" Adverse events occurred at similar rates in both groups."	( Intrathecal Morphine and Oral Analgesics Provide Safe and Effective Pain Control After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis. Abbott, MD; Burke, MC; Caird, MS; Farley, FA; Gibbons, KM; Holman, AE; Hong, RA; Li, Y; Robbins, CB, 2018)	0.48
"ITM and oral analgesics provide safe and effective pain control after PSF for AIS."	( Intrathecal Morphine and Oral Analgesics Provide Safe and Effective Pain Control After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis. Abbott, MD; Burke, MC; Caird, MS; Farley, FA; Gibbons, KM; Holman, AE; Hong, RA; Li, Y; Robbins, CB, 2018)	0.48
" Of the 26 patients ≥65 years old randomized to continue oxycodone DETERx during the double-blind maintenance phase, 18 (69%) completed the study; only two patients (8%) in the oxycodone DETERx group discontinued due to adverse events."	( Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial. Kopecky, EA; Lagasse, S; O'Connor, M; Vaughn, B, 2017)	0.46
" Thus, patients with cancer are commonly on medications, such as antifungals, that have the potential to interact with opioids, causing adverse effects."	( Oxycodone-induced neurotoxicity secondary to concurrent voriconazole use in a patient with cancer. Alghothani, L; Gustin, J, )	0.13
" 1) Opioid overdose is a common complication of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addictive effects of opioids."	( Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. Baruffaldi, F; Carroll, FI; Comer, SD; Langston, TL; Laudenbach, M; Navarro, HA; Pentel, PR; Peterson, SJ; Pravetoni, M; Raleigh, MD; Runyon, SP; Winston, S, 2017)	0.46
"3%) patients reported adverse events."	( Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. Jin, JY; Kang, JH; Kim, BS; Ko, YH; Kwon, JH; Park, HJ; Park, SY; Woo, IS, 2018)	0.48
" All adverse events during the hospital stay were recorded."	( A prospective, randomized, open label, controlled study investigating the efficiency and safety of 3 different methods of rectus sheath block analgesia following midline laparotomy. Anttila, M; Eskelinen, M; Hautajärvi, H; Kinnunen, M; Kokki, H; Kokki, M; Lehtonen, M; Purdy, M, 2018)	0.48
" No serious or unexpected adverse events were reported."	( A prospective, randomized, open label, controlled study investigating the efficiency and safety of 3 different methods of rectus sheath block analgesia following midline laparotomy. Anttila, M; Eskelinen, M; Hautajärvi, H; Kinnunen, M; Kokki, H; Kokki, M; Lehtonen, M; Purdy, M, 2018)	0.48
" The majority of adverse effects were moderate or mild and recovered with no sequelae."	( Efficacy and Safety of Oxycodone Injection for Relieving Cancer Pain: A Study in Japan Consisting of Two Open Trials for Intravenous and Subcutaneous Administration. Hojo, M; Kokubun, H; Matoba, M; Ryu, E; Tomiyasu, S; Yoshimoto, T, 2018)	0.48
"Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen."	( Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2018)	0.48
" The efficacy and safety of SFTs were evaluated, recording pain intensity (PI), onset of pain relief, and adverse events (AEs)."	( Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2018)	0.48
" Adverse events occurred in 83."	( A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Aruga, E; Inoue, S; Saito, Y; Takahashi, H; Tsuneto, S; Uemori, M, 2018)	0.48
" However, if the opioid analgesic could be limited to a single drug, we hypothesized that the risk of adverse drug interactions could be reduced, with fewer adverse effects."	( Oxycodone is safe and effective for general anesthesia. Ellerkmann, RK; Soehle, M; Wirtz, CD; Wirz, S, )	0.13
" Safety was evaluated by the measurement of hemodynamic changes (blood pressure, heart rate), the detection of pathologic changes in the electrocardiogram, changes of the peripheral oxygen saturation, and by the assessment of adverse effects."	( Oxycodone is safe and effective for general anesthesia. Ellerkmann, RK; Soehle, M; Wirtz, CD; Wirz, S, )	0.13
" No severe adverse events were recorded."	( Oxycodone is safe and effective for general anesthesia. Ellerkmann, RK; Soehle, M; Wirtz, CD; Wirz, S, )	0.13
" Our results in nonhuman primates suggest that bifunctional NOP/MOP agonists with the appropriate balance of NOP and MOP agonist activity may provide a dual therapeutic action for safe and effective pain relief and treating prescription opioid abuse."	( A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Czoty, PW; Daga, PR; Ding, H; Kiguchi, N; Kishioka, S; Ko, MC; Lu, JJ; Polgar, WE; Yasuda, D; Zaveri, NT, 2018)	0.48
" However, although opioids have been appropriately used in Japan, they rarely induce serious adverse events, such as respiratory depression."	( Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database. Futamura, A; Nakagawa, T; Suga, Y; Sugawara, H; Suzuki, S; Takase, H; Torigoe, K; Uchida, M; Uesawa, Y, 2019)	0.51
" The mild or moderate adverse effects were similar in 2 groups, while severe adverse effects were only identified in morphine group (P = ."	( Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL). Guo, Q; Han, F; Lu, L; Pan, H; Pan, J; Qian, S; Shen, P; Shu, Q; Wang, K; Xu, Q; Yang, Z; Zhang, P; Zhou, Y, 2019)	0.51
" There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by opioids compared to placebo."	( Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Häuser, W; Klose, P; Petzke, F; Sommer, C; Welsch, P, 2020)	0.56
" TAP IR was less likely to have gastrointestinal adverse effects such as nausea and constipation compared with other opioids."	( Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-Analysis. Narayan, SW; Patanwala, AE; Penm, J; Wang, X, 2020)	0.56
"TAP IR is as effective as other opioids at higher doses for acute pain and is associated with fewer gastrointestinal adverse effects."	( Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-Analysis. Narayan, SW; Patanwala, AE; Penm, J; Wang, X, 2020)	0.56
"With increased opioid use, drug-drug interactions (DDIs) and associated adverse events are growing among geriatric patients."	( The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients. Gwak, HS; Kim, JH; Kim, JY; Lee, N; Yee, J, 2020)	0.56
" Numerous tools and procedural practice guides are available to help facilitate safe prescribing."	( How I treat pain in hematologic malignancies safely with opioid therapy. Gazelka, H; Geyer, HL; Mesa, R, 2020)	0.56
"To perform the analysis, a comprehensive database consisting of pain relief compounds with information on summary-level of efficacy over time, adverse events and dropout rates was compiled from multiple sources."	( Model-based Meta-analysis to Compare Primary Efficacy-endpoint, Efficacy-time Course, Safety, and Tolerability of Opioids Used in the Management of Osteoarthritic Pain in Humans. Alhaj-Suliman, SO; Milavetz, G; Salem, AK, 2020)	0.56
" It was also found that gastrointestinal adverse events were the most opioid-associated and dosedependent adverse effects."	( Model-based Meta-analysis to Compare Primary Efficacy-endpoint, Efficacy-time Course, Safety, and Tolerability of Opioids Used in the Management of Osteoarthritic Pain in Humans. Alhaj-Suliman, SO; Milavetz, G; Salem, AK, 2020)	0.56
" To offer more effective medical interventions to treat or prevent OUD, antiopioid vaccines are in development that reduce the distribution of the targeted opioids to brain and subsequently reduce the associated behavioral and toxic effects."	( Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity. Accetturo, C; Pravetoni, M; Raleigh, MD, 2020)	0.56
" The purpose of this trial was to compare opioid-related adverse events (ORAES) of intravenous oxycodone and morphine after total hip arthroplasty."	( Post-operative opioid-related adverse events with intravenous oxycodone compared to morphine: A randomized controlled trial. Alonso, S; Boisson, C; Cuvillon, P; Kouyoumdjian, P; L'Hermite, J; Langeron, O; Luc Faillie, J; Raux, M; Reubrecht, V; Vialles, N; Zoric, L, 2021)	0.62
"Opioids are increasingly prescribed and frequently involved in adverse drug events (ADEs)."	( Nature of adverse events with opioids in hospitalised patients: a post-hoc analysis of three patient record review studies. de Bruijne, M; Jongerden, I; Klopotowska, JE; Langelaan, M; Moesker, M; Schutijser, BCFM; Wagner, C, 2020)	0.56
" Future interventions should focus on safe dosing of opioids when prescribing and administering, especially in elderly patients."	( Nature of adverse events with opioids in hospitalised patients: a post-hoc analysis of three patient record review studies. de Bruijne, M; Jongerden, I; Klopotowska, JE; Langelaan, M; Moesker, M; Schutijser, BCFM; Wagner, C, 2020)	0.56
"Opioids pose significant increased risk for serious adverse drug events (ADEs)."	( Predictors of serious adverse drug events from opioids: Results from the Food and Drug Administration Adverse Events Reporting System. McDonald, DD; Srisopa, P, 2021)	0.62
"A post hoc design was used to examine predictors of opioid analgesics ADEs with Food and Drug Administration Adverse Events Reporting System (FAERS) data."	( Predictors of serious adverse drug events from opioids: Results from the Food and Drug Administration Adverse Events Reporting System. McDonald, DD; Srisopa, P, 2021)	0.62
" The tool focused on pain expectations, multi-modal methods (both pharmacologic and non-pharmacologic) to manage pain, safe storage, and disposal of excess medication."	( A Quality Improvement Initiative Addressing Safe Opioid Prescribing and Disposal Postcesarean Delivery. Genord, C; Loomis, EA; McNaughton, D, 2022)	0.72
" Pain at rest/motion (based on pain visual analog scale (VAS) score), rescue analgesia consumption, satisfaction level and adverse events were assessed after AKS."	( Oxycodone-paracetamol tablet exhibits increased analgesic efficacy for acute postoperative pain, higher satisfaction and comparable safety profiles compared with celecoxib in patients underwent arthroscopic knee surgery. Di, J; Liu, J; Xing, E; Zhang, Y, 2021)	0.62
"Acute doses of diazepam or diclazepam result in the accumulation of oxycodone, whereas chronic administration induces the accumulation of oxymorphone, the toxic metabolite."	( Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model. Bazgier, V; Čechová, P; El Balkhi, S; Javellaud, J; Lawson, R; Marquet, P; Otyepka, M; Picard, N; Saint-Marcoux, F; Trouillas, P; Zarrouk, E, 2023)	0.91
"This cases series demonstrated that regional anesthesia using ultrasonography-guided indwelling popliteal catheters was safe and effective for pain control in CMT patients undergoing outpatient foot and ankle surgery."	( Safety and Efficacy of Postoperative Indwelling Popliteal Nerve Catheters for Outpatient Charcot-Marie-Tooth Surgery. An, T; Kissen, M; Pfeffer, G; Pollock, G; Schwartz, E, 2022)	0.72
" The incidence of adverse effects was monitored."	( Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study. Adamski, M; Bienert, A; Kowalski, G; Leppert, W; Olczak, B; Szkutnik-Fiedler, D; Teżyk, A; Wieczorowska-Tobis, K, 2022)	0.72
" Regarding adverse effects, one patient had hypotension, one had bradycardia, and one had pruritus."	( Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study. Adamski, M; Bienert, A; Kowalski, G; Leppert, W; Olczak, B; Szkutnik-Fiedler, D; Teżyk, A; Wieczorowska-Tobis, K, 2022)	0.72
"Oxycodone in spinal block prolongs analgesia period, does not cause serious adverse effects and seems to be safe and effective opioid for patients undergoing THA."	( Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study. Adamski, M; Bienert, A; Kowalski, G; Leppert, W; Olczak, B; Szkutnik-Fiedler, D; Teżyk, A; Wieczorowska-Tobis, K, 2022)	0.72
" There was no serious adverse event reported."	( Targin®: An effective opiate analgesia with minimal gastrointestinal side effects-An observational study. Jones, S; Rossaak, J; Smith, M, )	0.13
" At the same time, the incidence of adverse reactions in the rectal administration group was low."	( Meta-analysis of efficacy and safety of sustained release oxycodone hydrochloride rectal administration for moderate to severe pain. Chen, DD; Chen, HZ; Cheng, TF; Cui, BX; Dai, XJ; Hou, XB; Wang, D; Wang, Y; Wang, YY; Xu, H, 2022)	0.72
"To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture."	( Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study. Ali, S; Carleton, B; Drendel, AL; Gourlay, K; Johnson, DW; Le May, S; Ortiz, S; Rosychuk, RJ; Watts, R; Yukseloglu, A, 2022)	0.72
" However, the effect of pretreatment with oxycodone on recovery of cognitive function and adverse effects has rarely been studied."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
" Adverse events, including somatic motor reactions, hypotension, bradycardia, myocardial tremor, nausea and vomiting, and injection pain, were also recorded in both groups."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
" Fewer adverse events such as dynamic body reactions, cardiac tremor, nausea and vomiting, and injection pain occurred in the observation group than in the control group (P < ."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
"Etomidate in combination with oxycodone for painless gastroscopic operation in the elderly is a safe and effective anesthetic strategy."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
" The use of opioids is often associated with adverse effects or clinical issues."	( Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line. Almeida, W; da Costa, NS; Galiciolli, MEA; Irioda, AC; Lima, LS; Margarete Cestari, M; Nogara, PA; Oliveira, CS; Pereira, ME, 2023)	0.91
" We hypothesized that the preoperative administration of a liposomal bupivacaine (LB) supraclavicular nerve block would be safe and effective in controlling postoperative pain."	( Safety and Efficacy of Liposomal Bupivacaine Supraclavicular Nerve Blocks in Open Treatment of Distal Radius Fractures: A Perioperative Pain Management Protocol. Brown, CA; Ghanouni, A; Ghareeb, PA; Payne, SH; Williams, R, 2023)	0.91
"Liposomal bupivacaine supraclavicular nerve blocks are safe and effective in the treatment of postoperative pain after open reduction internal fixation of DRF."	( Safety and Efficacy of Liposomal Bupivacaine Supraclavicular Nerve Blocks in Open Treatment of Distal Radius Fractures: A Perioperative Pain Management Protocol. Brown, CA; Ghanouni, A; Ghareeb, PA; Payne, SH; Williams, R, 2023)	0.91
"Central nervous system adverse events (AEs) occur when oxycodone is used in combination with benzodiazepines, antidepressants and anticonvulsants."	( Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database. Huang, H; Huang, L; Lu, X; Wang, Z; Wu, X; Xiao, J; Zhang, L, 2023)	0.91
" Regarding adverse events, nausea occurred in 12."	( Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. Fujimoto, H; Funato, M; Kawana, M; Kiribayashi, M; Kokubun, H; Kondo, M; Kusakabe, A; Miyasato, A; Nagatani, K; Nakamura, K; Ohno, R; Okamoto, K; Onoda, C; Ozeki, A; Suzuki, N, 2023)	0.91
"Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs."	( Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021. Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B, 2023)	0.91
"Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common."	( Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study. Arakawa, S; Chiu, SW; Hiratsuka, Y; Hirayama, H; Inoue, A; Ishiki, H; Kosugi, K; Kubo, E; Matsuda, Y; Miyashita, M; Morita, T; Natsume, M; Nishijima, K; Ouchi, K; Sato, M; Satomi, E; Shigeno, T; Shimizu, M; Shimoda, M; Shimoi, T; Tagami, K; Yamaguchi, T; Yokomichi, N, 2023)	0.91

Excerpt	Reference	Relevance
" No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively."	( The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Kalso, E; Olkkola, KT; Pöyhiä, R; Seppälä, T, 1992)	0.28
" The mean +/- SD elimination half-life after single-dose administration of intravenous (4."	( Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Cramond, T; Leow, KP; Smith, MT; Williams, B, 1992)	0.28
" AUC values were also calculated for the pharmacodynamic variable "drug effect," scored on a 100 mm visual analog scale."	( Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Benziger, DP; Burke, BE; Fitzmartin, RD; Goldenheim, PD; Kaiko, RF; Reder, RF, 1996)	0.29
" Mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance."	( The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. Kirvela, M; Lindgren, L; Olkkola, KT; Seppala, T, 1996)	0.29
" The purpose of this investigation was to develop and validate a pharmacokinetic model for CR oxycodone tablets in comparison with IR oxycodone solution."	( Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Kaiko, RF; Mandema, JW; Oshlack, B; Reder, RF; Stanski, DR, 1996)	0.29
" Among the reasons for pursuing pharmacokinetic/ pharmacodynamic relationships is the prospect of predicting the time-action characteristics of new therapeutics on the basis of early studies in normals using pharmacodynamic surrogates for analgesia."	( Pharmacokinetics and pharmacodynamics of controlled-release opioids. Kaiko, RF, 1997)	0.3
"47 l/kg and the terminal elimination half-life 157 +/- 47 min."	( Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Kaasalainen, V; Kalso, E; Olkkola, KT; Seppälä, T; Takala, A, 1997)	0.3
" In addition, pharmacodynamic effects were assessed using both objective and subjective measures for up to 48 hr after dosing."	( A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. Benziger, DP; Fitzmartin, RD; Grandy, RP; Miotto, J; Swanton, RE; Thomas, GB, 1997)	0.3
" THe median elimination half-life of oxycodone was 13."	( Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Höckerstedt, K; Lindgren, L; Olkkola, KT; Seppälä, T; Tallgren, M, 1997)	0.3
" Plasma opioid concentrations, subjective pharmacodynamic ratings, and psychomotor function were assessed for 24 hours after drug administration."	( Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Heiskanen, T; Kalso, E; Olkkola, KT, 1998)	0.3
"A significant reduction in plasma oxymorphone levels did not substantially alter the pharmacodynamic effects of oxycodone."	( Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Heiskanen, T; Kalso, E; Olkkola, KT, 1998)	0.3
"93), Cmax (7."	( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001)	0.31
" Oxycodone AUC(0-t), AUC(0-infinity), and Cmax were dose dependent, whereas tma and t(1/2) were not."	( Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations. Davis, MW; Gammaitoni, AR, 2002)	0.31
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group."	( Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Kokki, H; Ojanperä, I; Rasanen, I; Reinikainen, M; Suhonen, P; Vanamo, K, 2004)	0.32
" Serum APAP concentrations (APAPs) were measured hourly from zero through eight hours and again at 24 hours, and basic noncompartmental pharmacokinetic parameters were compared."	( Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. Goklaney, A; Halcomb, SE; Mullins, ME; Sivilotti, ML, 2005)	0.33
" Special populations, including children and those with liver/renal failure, have a unique oxycodone pharmacokinetic profile that must be taken into account in order to maximize analgesic efficacy and reduce the risk of adverse events."	( The pharmacokinetics of oxycodone. Kern, SE; Lugo, RA, 2004)	0.32
"As part of ongoing studies to evaluate the analgesic efficacy and pharmacokinetic properties of combination oxycodone plus ibuprofen in the treatment of moderate to severe acute pain, 2 pharmacokinetic studies were conducted."	( Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Abramowitz, W; Benedek, I; Fiske, W; Kapil, R; Nolting, A; Roy, P, 2004)	0.32
"The goals of these studies were to compare the pharmacokinetic properties of monotherapy with oxycodone or ibuprofen with those of a tablet formulation of these 2 agents combined (study A), and to determine whether the absorption of the individual agents when given in the combination tablet was affected by the concomitant ingestion of food (study B)."	( Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Abramowitz, W; Benedek, I; Fiske, W; Kapil, R; Nolting, A; Roy, P, 2004)	0.32
" In both studies, the pharmacokinetic properties (C(max), T(max), t(1/2), AUC(0-4), AUC(0-1), and AUC(0-infinity)) of oxycodone and ibuprofen were derived from plasma drug concentrations."	( Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Abramowitz, W; Benedek, I; Fiske, W; Kapil, R; Nolting, A; Roy, P, 2004)	0.32
" The pharmacokinetic properties of ibuprofen and oxycodone were not statistically different when administered alone or combined."	( Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Abramowitz, W; Benedek, I; Fiske, W; Kapil, R; Nolting, A; Roy, P, 2004)	0.32
"The single-dose pharmacokinetic profiles of oxycodone and ibuprofen in these healthy volunteers were similar when these 2 drugs were given as monotherapy or in combination, suggesting bioequivalence."	( Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Abramowitz, W; Benedek, I; Fiske, W; Kapil, R; Nolting, A; Roy, P, 2004)	0.32
" One barrier to effective pain treatment is understanding the pharmacokinetic behavior of analgesics in this age group."	( Population pharmacokinetics of oxycodone in children 6 months to 7 years old. El-Tahtawy, A; Kokki, H; Reidenberg, BE, 2006)	0.33
" The samples were analyzed with a liquid chromatography-tandem mass spectrometry method and a population pharmacokinetic model was used to simultaneously fit all the data using NONMEM."	( In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Boström, E; Hammarlund-Udenaes, M; Simonsson, US, 2006)	0.33
" In the result, pharmacokinetic parameters calculated at CL/F were: 45."	( [Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. Hoka, S; Kokubun, H; Komatsu, T; Matoba, M; Nakamura, K; Yago, K, 2007)	0.34
" Oral administration of oxycodone to the SD rat is a poor model of the human for the study of the pharmacodynamic effects of oxycodone."	( Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Chan, S; Edwards, SR; Smith, MT; Wyse, BD, 2008)	0.35
" We used HPLC-electrochemical detector (ECD) to determine oxycodone and hydrocotarnine serum concentrations, and used the nonlinear least-squares method (MULTI) for calculation of the pharmacokinetic parameters."	( Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007)	0.34
" This study was carried out to assess the efficacy, safety and pharmacokinetic profiles of a 12."	( Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" This review highlights potential pharmacokinetic (changes in metabolite production, metabolizing enzyme expression, and transporter function) and pharmacodynamic (receptor type, location and functionality; alterations in signaling pathways and cross-tolerance) aspects of opioid tolerance development, and presents several pharmacodynamic modeling strategies that have been used to characterize time-dependent attenuation of opioid analgesia."	( Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. Dumas, EO; Pollack, GM, 2008)	0.35
"The aim of this paper was to report the pharmacokinetic results from a single-dose study and a multiple-dose bioequivalence study of OXN versus separate formulations of oxycodone PR and naloxone PR administered concurrently in healthy subjects."	( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008)	0.35
" The pharmacokinetic properties of the OXN FDC were similar to those of oxycodone PR + naloxone PR given as separate formulations, based on the regulatory definition."	( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008)	0.35
" Plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 hours, and pharmacodynamic effects were evaluated."	( Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. Grönlund, J; Hagelberg, N; Laine, K; Martikainen, IK; Neuvonen, PJ; Olkkola, KT; Saari, T, 2010)	0.36
" Plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 h, and pharmacodynamic effects were evaluated."	( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010)	0.36
" Most of the pharmacokinetic changes in oral oxycodone were seen in the elimination phase, with modest effects by itraconazole on its peak concentration, which was increased by 45% (P=0."	( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010)	0.36
" We performed a three-way, placebo-controlled, double-blind cross-over study to assess the pharmacokinetic and pharmacodynamic consequences of drug interactions with oxycodone."	( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011)	0.37
"Inhibition of CYP3A4 by ketoconazole increases the exposure and some pharmacodynamic effects of oxycodone."	( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011)	0.37
"Oxycodone blood concentrations could be described by a one-compartment model but, given the necessarily short timescale of the study, the concentrations were represented by linear interpolation for subsequent pharmacodynamic models."	( A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Olesen, AE; Staahl, C; Upton, R, 2010)	0.36
" Plasma concentrations of oxycodone and its oxidative metabolites were measured over 48 hours, and pharmacokinetic and pharmacodynamic parameters subsequently evaluated."	( Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2011)	0.37
" There were no significant sex-related differences in any of the pharmacokinetic parameters."	( Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Aantaa, R; Kuusniemi, K; Liukas, A; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Virolainen, P, 2011)	0.37
" The pharmacokinetic data of oxycodone available for elderly are limited, and there appear to be only little data on the population pharmacokinetics of oxycodone."	( Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Ihmsen, H; Neuvonen, PJ; Olkkola, KT; Saari, TI; Schwilden, H, 2012)	0.38
" The elimination half-life of oxycodone showed an age-dependent increase."	( Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Ihmsen, H; Neuvonen, PJ; Olkkola, KT; Saari, TI; Schwilden, H, 2012)	0.38
" The aim of this study was to evaluate the influence of cachexia on the pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients."	( Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Kagawa, Y; Kawakami, J; Naito, T; Ohnishi, K; Tashiro, M; Yamamoto, K, 2012)	0.38
" In the study group, maternal pharmacokinetics of oxycodone was measured from plasma concentrations during labour, and neonatal exposure was assessed from umbilical plasma samples using population pharmacokinetic methods."	( Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. Franco, MG; Heinonen, S; Kokki, H; Kokki, M; Neuvonen, PJ; Raatikainen, K; Sankilampi, U; Välitalo, P, 2012)	0.38
"A whole-body physiologically based pharmacokinetic (PBPK) model was developed for the prediction of unbound drug concentration-time profiles in the rat brain, in which drug transfer across the blood-brain barrier (BBB) was treated mechanistically by separating the parameters governing the rate (permeability) of BBB transfer from brain binding."	( Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. Ball, K; Bouzom, F; Declèves, X; Scherrmann, JM; Walther, B, 2012)	0.38
" Plasma drug concentration data were used to generate pharmacokinetic models, which were then used to fit the VPTT data using NONMEM(®) VI to generate population pharmacokinetic/pharmacodynamic models."	( A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone. Arendt-Nielsen, L; Drewes, AM; Kell, S; Kristensen, K; Olesen, AE; Staahl, C; Wong, GY, 2013)	0.39
" Mechanistic pharmacokinetic simulations suggested that the low metabolite ratio was the result of combined poor metabolizer (PM) status of cytochrome P450 (CYP) 2C19 and CYP2D6."	( A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Ahlner, J; Boel, LW; Brock, B; Jornil, J; Nielsen, TS; Rosendal, I; Zackrisson, AL, 2013)	0.39
" Crushed ORF administration yielded reduced oxycodone Cmax and increased Tmax versus crushed OC and Oxy API."	( Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. Bartlett, C; Colucci, SV; Harris, SC; Perrino, PJ; Sellers, EM; Shram, MJ; Smith, I, 2014)	0.4
"The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain."	( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014)	0.4
"Pharmacokinetic parameters showed that mean values of C(max), AUC(0-t) and AUC(0-∞) of oxycodone were dose dependent, whereas Tmax and t(1/2) were not."	( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014)	0.4
" Noncompartmental analysis and population pharmacokinetic analysis were performed."	( Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. Fukumura, K; Hojo, M; Kokubun, H; Matoba, M; Yoshimoto, T, 2014)	0.4
"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14."	( The pharmacokinetics of oral oxycodone in patients after total gastric resection. Biczysko-Murawa, A; Grabowski, T; Gracz, J; Grześkowiak, E; Karbownik, A; Murawa, D; Murawa, P; Połom, K; Szałek, E; Tezyk, A, 2014)	0.4
" The 90 % confidence intervals (CIs) for AUC∞ and Cmax ratios of ALO-02 with 20 % ethanol versus water were within 80-125 %; upper 90 % CIs were >125 % for ALO-02 with 40 % ethanol versus water."	( Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). Bramson, C; Malhotra, BK; Matschke, K; Salageanu, J; Wang, Q, 2015)	0.42
"Oxycodone exposures (Cmax) were unaffected when ALO-02 was administered with 20 % ethanol but Cmax increased by 37 % with 40 % ethanol versus water."	( Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). Bramson, C; Malhotra, BK; Matschke, K; Salageanu, J; Wang, Q, 2015)	0.42
"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17."	( The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. de Kater, AW; Friedmann, N; Malhotra, BK; Schoenhard, GL, )	0.13
"As renal or hepatic function decreased, oxycodone Cmax and AUC(0-t) were up to approximately twofold higher following single, oral doses of extended-release Remoxy."	( The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. de Kater, AW; Friedmann, N; Malhotra, BK; Schoenhard, GL, )	0.13
" Primary aims included examination of the plasma and urinary pharmacokinetic profile of once-daily quinine; secondary aims assessed pharmacokinetic/pharmacodynamic interactions with oxycodone (a CYP3A and CYP2D substrate)."	( Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. Babalonis, S; Hampson, AJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015)	0.42
" Crushed Oxycodone DETERx® was bioequivalent to intact Oxycodone DETERx® and exhibited a numerically lower Cmax ."	( Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Fleming, AB; Gudin, J; Kopecky, EA; Levy-Cooperman, N, 2015)	0.42
"These data demonstrate that when crushed and taken orally, Oxycodone DETERx® maintains its EXTENDED-release profile, while crushed OxyContin® shows a pharmacokinetic profile similar to an immediate-release product."	( Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Fleming, AB; Gudin, J; Kopecky, EA; Levy-Cooperman, N, 2015)	0.42
" In this review, comparative evidence on pharmacokinetic differences between abuse-deterrent and classical formulations of the same opioids is summarized; furthermore, pharmacodynamic differences, with a focus on analgesia and abuse-related symptoms, are addressed."	( Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations. Knothe, C; Lötsch, J; Walter, C, 2016)	0.43
"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6."	( A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Fleming, AB; Kopecky, EA; Smith, MD; Webster, LR, 2016)	0.43
"Pharmacokinetic and pharmacodynamic outcomes suggest that DETERx IN has relatively low HAP; continued research in larger populations is suggested."	( A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Fleming, AB; Kopecky, EA; Smith, MD; Webster, LR, 2016)	0.43
"The t1/2 and Tmax values for oxycodone were similar for all 3 treatments."	( Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. Bramson, C; Gandelman, K; Lamson, M; Malhotra, B; Matschke, K; Salageanu, J, 2015)	0.42
"5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24."	( A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. Babalonis, S; Hampson, AJ; Krieter, P; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2016)	0.43
"In the pharmacokinetic study, patients were administered intravenous oxycodone (0."	( Population pharmacokinetics and analgesic potency of oxycodone. An, SM; Choi, BM; Lee, EK; Lee, SH; Lee, YH; Noh, GJ, 2017)	0.46
"In the population pharmacokinetic study (n = 54), oxycodone plasma concentration over time was well described by a three-compartment mammillary model."	( Population pharmacokinetics and analgesic potency of oxycodone. An, SM; Choi, BM; Lee, EK; Lee, SH; Lee, YH; Noh, GJ, 2017)	0.46
" Preterm neonates were found to have the highest pharmacokinetic variability out of the study population."	( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017)	0.46
"Oxycodone elimination is slower and pharmacokinetic variability more pronounced in neonates when compared to older infants."	( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017)	0.46
"The aim of the current population pharmacokinetic study was to quantify oxycodone pharmacokinetics in children ranging from preterm neonates to children up to 7 years of age."	( Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials. Hooker, AC; Kokki, H; Kokki, M; Olkkola, KT; Ranta, VP; Välitalo, P, 2017)	0.46
" A population pharmacokinetic model was built using 781 measurements of oxycodone plasma concentration."	( Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials. Hooker, AC; Kokki, H; Kokki, M; Olkkola, KT; Ranta, VP; Välitalo, P, 2017)	0.46
" The pharmacokinetic model developed may be used to evaluate different multiple dosing regimens, but the safety of repeated doses should be ensured."	( Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials. Hooker, AC; Kokki, H; Kokki, M; Olkkola, KT; Ranta, VP; Välitalo, P, 2017)	0.46
"To characterize the pharmacokinetic profile and evaluate the safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM)."	( Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. Gavin, PD; Schlagheck, T; Shakib, S; Simon, LS; Smith, AJ, 2017)	0.46
" Two separate studies were conducted to assess the pharmacokinetic bioequivalence of a newly formulated oxycodone hydrochloride extended-release tablet to a marketed oxycodone product in Japan under fasting and fed conditions."	( Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist. Furuie, H; Ishizuka, H; Kuroda, K; Toyama, K, 2017)	0.46
" Our aim was to translate a recently published comprehensive CNS physiologically-based pharmacokinetic (PBPK) model from rat to human, and to predict drug concentration-time profiles in multiple CNS compartments on available human data of four drugs (acetaminophen, oxycodone, morphine and phenytoin)."	( Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. Beukers, MW; Danhof, M; de Lange, ECM; Huntjens, DR; Kokki, H; Kokki, M; Krauwinkel, W; Proost, JH; Välitalo, PA; van Hasselt, JGC; Vermeulen, A; Wong, YC; Yamamoto, Y, 2018)	0.48
"This second pharmacokinetic study demonstrated that Xtampza ER maintains its ER properties after crushing, unlike OxyContin, which failed to retain its ER properties after crushing."	( The comparative pharmacokinetics of physical manipulation by crushing of Xtampza Brennan, MJ; Fleming, AB; Kopecky, EA; Marseilles, A; O'Connor, M, 2017)	0.46
" The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis."	( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019)	0.51
" Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years."	( Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone. Kinnunen, M; Kokki, H; Kokki, M; Lammi, P; Piirainen, P, 2019)	0.51
"Physiologically-based pharmacokinetic (PBPK) modeling offers a unique modality to predict age-specific pharmacokinetics."	( Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization. Jiang, XH; Song, HX; Tang, SW; Wang, L; Xu, M; Zheng, L, 2019)	0.51
" This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and the original extended release (ER) formulation tablets administered with an opioid antagonist in patients with chronic pain."	( Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain. Hu, C; Luo, Z; Miao, J; Shen, Y; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" After a single dose of 40 mg tablets, pharmacokinetic results of the new OTR tablet were found to be similar to those of original extended-release oxycodone tablet."	( Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain. Hu, C; Luo, Z; Miao, J; Shen, Y; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" In this study, a physiologically based pharmacokinetic (PBPK) model was built using GastroPlus™ software for oxycodone, two primary metabolites (noroxycodone, oxymorphone) and one secondary metabolite (noroxymorphone)."	( Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. Hautajärvi, H; Heikkinen, AT; Kokki, H; Kokki, M; Ranta, VP; Rinne, V; Rytkönen, J, 2020)	0.56
" The latter was lower than in the MBMA and explained the slightly longer apparent half-life of oxycodone in the newly collected data."	( Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. Buller, S; Dari, A; Freijer, J; Gautrois, M; Rengelshausen, J; Stahlberg, HJ, 2021)	0.62
" Covariate influences such as age, size, and fat mass on oxycodone pharmacokinetic parameters over the human lifespan are poorly quantified."	( Population pharmacokinetics of oxycodone: Premature neonates to adults. Anderson, BJ; Hannam, JA; Kokki, H; Kokki, M; Morse, JD; Sundermann, M, 2021)	0.62
" Theory-based allometry was used to scale pharmacokinetic parameters to a 70 kg individual."	( Population pharmacokinetics of oxycodone: Premature neonates to adults. Anderson, BJ; Hannam, JA; Kokki, H; Kokki, M; Morse, JD; Sundermann, M, 2021)	0.62
" The limited studies that involve pharmacokinetics of the urinary excretion of OC metabolites leave a knowledge gap regarding the excretion of conjugated and minor metabolites, pharmacokinetic differences by formulation, and the impact of CYP2D6 activity on the metabolism and excretion of OC."	( Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC-MS-MS. Chermà, MD; Gréen, H; Jakobsson, G; Kronstrand, R; Swortwood, MJ; Truver, MT, 2023)	0.91
" This model-based pharmacokinetic (PK)-pharmacodynamic (PD) analysis quantified the impact of age and alcohol use on pupillometry and cold pressor test (CPT) PD based on data from an open-label study of a single, immediate-release 10-mg oral oxycodone in middle-age and older adults (aged 35-85) without severe functional limitations."	( Model-Based Analysis of the Influence of Alcohol Use and Age on Pharmacokinetics-Pharmacodynamics of Oral Oxycodone in Middle-Age and Older Community-Dwelling Adults. Cherrier, MM; Lalovic, BB; Shen, DD; Shireman, L, 2022)	0.72
" This study aims to characterize the pharmacokinetic profile of oxycodone after intravenous administration and to simulate an appropriate dosage for analgesic efficacy in obese patients."	( Population Pharmacokinetics and Dosing Simulations of Intravenous Oxycodone for Perioperative Pain Relief in Adult Surgical Patients with Obesity. Chaw, SH; Haron, DEBM; Lo, YL; Shariffuddin, II; Yeap, LL, 2023)	0.91

Excerpt	Reference	Relevance
" We evaluated 1014 fatality cases involving oxycodone (OXC) for evidence of enhanced toxicity associated with multiple drug-drug interactions."	( Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. Ballina, M; Caplan, YH; Cone, EJ; Fant, RV; Haddox, JD; Reder, RF; Rohay, JM, )	0.13
" We evaluated 1014 fatality cases involving oxycodone (OXC) for evidence of enhanced toxicity associated with multiple drug-drug interactions."	( Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. Ballina, M; Caplan, YH; Cone, EJ; Fant, RV; Haddox, JD; Reder, RF; Rohay, JM, 2004)	0.32
"This randomized, double-blind, placebo- and active-controlled, parallel-group study was designed to demonstrate the superiority of oxycodone in combination with naloxone in a prolonged release (PR) formulation over placebo with respect to analgesic efficacy."	( Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Fleischer, W; Grothe, B; Hermanns, K; Hopp, M; Leyendecker, P; Meissner, W; Reimer, K; Ruckes, C; Szombati, I; Vondrackova, D; Weber, S, 2008)	0.35
" Overall, the results suggest that several adjuvant analgesics may interact with the BBB transport of oxycodone at relatively high concentrations."	( Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect. Deguchi, Y; Nakazawa, Y; Okura, T; Shimomura, K; Terasaki, T, 2010)	0.36
"Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX) may have increased analgesic potency and have suggested reduced abuse or dependence liability."	( Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Bigelow, GE; Harrison, JA; Lanier, RK; Strain, EC; Tompkins, DA, 2010)	0.36
" A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug-drug interactions is well established."	( Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Daali, Y; Dayer, P; Desmeules, JA; Eap, CB; Hochstrasser, D; Hopfgartner, G; Rebsamen, MC; Rossier, MF; Samer, CF; Wagner, M, 2010)	0.36
"6 g/kg), and oxycodone combined with the lower dose and the higher dose of ethanol on separate sessions."	( Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Gutierrez, S; Zacny, JP, 2011)	0.37
"In this study, 10 mg of oral oxycodone combined with a low dose of ethanol generated abuse liability-related effects, but when tested separately, they did not."	( Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Gutierrez, S; Zacny, JP, 2011)	0.37
" Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone."	( Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Coalson, DW; Paice, JA; Zacny, JP, 2012)	0.38
"A mu receptor antagonist combined with oxycodone (OXY) may improve pain control, reduce physical tolerance and withdrawal, minimizing opioid-related bowel dysfunction and act as an abuse deterrent."	( Oxycodone combined with opioid receptor antagonists: efficacy and safety. Davis, M; Gamier, P; Goforth, HW, 2013)	0.39
" Prolonged-release (PR) naloxone combined with PR OXY demonstrates a consistent reduction in opioid-related bowel dysfunction in multiple randomized controlled trials."	( Oxycodone combined with opioid receptor antagonists: efficacy and safety. Davis, M; Gamier, P; Goforth, HW, 2013)	0.39
"CYP2D6 drug-drug interactions appear to change effectiveness of commonly prescribed drugs in the ED."	( The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Campbell, J; Hamamura, D; Heard, KJ; Monte, AA; Vasiliou, V; Weinshilboum, RM, 2014)	0.4
"To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain."	( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014)	0.4
"Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life."	( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014)	0.4
" The performance of the DRI oxycodone immunoassay was compared with liquid chromatography combined with tandem mass spectrometry (LC/MS/MS) assay."	( Comparison of Response of DRI Oxycodone Semiquantitative Immunoassay With True Oxycodone Values Determined by Liquid Chromatography Combined With Tandem Mass Spectrometry: Sensitivity of the DRI Assay at 100 ng/ml Cut-Off and Validity of Semiquantitative Dasgupta, A; Davis, B; Dixon, RB, 2016)	0.43
" Oxycodone and noroxycodone parameters (Tmax , Cmax , t1/2 ) were similar with or without quinine present, although drug exposure (AUC) was slightly greater when combined with quinine."	( Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. Babalonis, S; Hampson, AJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015)	0.42
" We evaluated the efficacy and the safety of a prolonged release oral formulation of oxycodone hydrochloride combined with naloxone hydrochloride dehydrate, in a fixed ratio of 2:1 (OXN PR)."	( Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. Dauri, M; Madeo, G; Natoli, S; Pierantozzi, M; Pisani, A; Schirinzi, T; Stefani, A, 2015)	0.42
" The primary outcome was reporting frequency of the MedDRA System Organ Class (SOC) 'Cardiac Disorders' for naloxone alone and in fixed-dose combination with opioids."	( Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Haigney, MC; Kao, D; Krantz, MJ; Mehler, PS; Sandhu, A, 2016)	0.43
"Determine the abuse potential of intravenous oxycodone combined with naltrexone, which represents simulated crushed ALO-02 in solution, compared with intravenous oxycodone in nondependent, recreational opioid users."	( Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. Backonja, M; Bass, A; Malhotra, BK; Matschke, K; Setnik, B; Sommerville, KW; Webster, LR; Wolfram, G, 2016)	0.43
"Low-dose ropivacaine combined with intrathecal fentanyl can provide adequate anaesthesia with minimal haemodynamic variation."	( EFFECT OF PREOPERATIVE INTRAVENOUS OXYCODONE ON LOW-DOSE ROPIVACAINE SPINAL ANESTHESIA COMBINED WITH INTRATHECAL FENTANYL. Fu, Y; Wang, J; Wang, N; Zhang, S, 2016)	0.43
"To assess the efficacy of preoperative intravenous oxycodone on transurethral resection of prostate (TURP) under 10 mg ropivacaine spinal anaesthesia combined with intrathecal 25 pg fentanyl."	( EFFECT OF PREOPERATIVE INTRAVENOUS OXYCODONE ON LOW-DOSE ROPIVACAINE SPINAL ANESTHESIA COMBINED WITH INTRATHECAL FENTANYL. Fu, Y; Wang, J; Wang, N; Zhang, S, 2016)	0.43
" Previous studies showed that opioids combined with gabapentin for management of cancer pain reduced the dosage of opioids."	( The research on long-term clinical effects and patients' satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Chen, DL; Li, YH; Wang, ZJ; Zhu, YK, 2016)	0.43
" Drug-drug interaction screening tools built into electronic health records and other services identify the interaction as risk of opioid withdrawal rather than hypersensitivity."	( Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use. Diaz, CJ; Goode, PA; Leonard, JB; Nair, V; Penoyar, JB, 2017)	0.46
" We hypothesize that different doses of oxycodone hydrochloride combined with flurbiprofen axetil would generate great results on postoperative intravenous analgesia in lower abdominal patients."	( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018)	0.48
"75 mg/kg oxycodone hydrochloride combined with flurbiprofen axetil can provide safe and effective postoperative analgesia for lower abdominal patients, with fewer adverse reactions."	( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018)	0.48
"DEX combined with oxycodone can improve sleep quality and provide good visceral analgesia."	( Effect of Intravenous Oxycodone in Combination With Different Doses of Dexmedetomdine on Sleep Quality and Visceral Pain in Patients After Abdominal Surgery: A Randomized Study. Bao, C; Chen, Z; Jiang, Z; Song, Q; Wang, H; Zhou, G, 2018)	0.48
"The primary purpose of this study was to identify the most common drug-drug interactions (DDI'S) in patients prescribed medications upon discharge from the emergency department."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
" The primary endpoint is the identification and characterization of drug-drug interactions caused by discharge prescriptions written by the treating physician."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
"This study was designed to discuss the clinical effects of dexmedetomidine combined with oxycodone patient-controlled intravenous analgesia for patients with laparoscopic radical resection of rectal cancer."	( Effect of dexmedetomidine combined with oxycodone patient-controlled intravenous analgesia on the levels of inflammatory cytokine in patients with rectal cancer. Song, J; Wang, G; Wei, N; Zhang, J, 2019)	0.51
" This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and the original extended release (ER) formulation tablets administered with an opioid antagonist in patients with chronic pain."	( Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain. Hu, C; Luo, Z; Miao, J; Shen, Y; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" The model was refined and verified against literature clinical data after oxycodone administration in the absence of drug-drug interactions (DDI)."	( Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. Hautajärvi, H; Heikkinen, AT; Kokki, H; Kokki, M; Ranta, VP; Rinne, V; Rytkönen, J, 2020)	0.56
"With increased opioid use, drug-drug interactions (DDIs) and associated adverse events are growing among geriatric patients."	( The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients. Gwak, HS; Kim, JH; Kim, JY; Lee, N; Yee, J, 2020)	0.56
"To compare the therapeutic effects of continuous epidural block combined with drugs and oral drugs alone on postherpetic neuralgia (PHN)."	( Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia. Dong, X; Liu, Y; Liu, Z; Yang, Q; Zhang, Z, 2021)	0.62
" Patients in group A had epidural block combined with oral administration of gabapentin and oxycodone-acetaminophen, and patients in group B received oral gabapentin and oxycodone-acetaminophen."	( Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia. Dong, X; Liu, Y; Liu, Z; Yang, Q; Zhang, Z, 2021)	0.62
"Both treatments have certain effects on PHN, but epidural block combined with drug therapy is more effective, especially for patients with severe pain, early use can quickly relieve pain."	( Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia. Dong, X; Liu, Y; Liu, Z; Yang, Q; Zhang, Z, 2021)	0.62
"In this preliminary study involving healthy participants, paroxetine combined with oxycodone, compared with oxycodone alone, significantly decreased the ventilatory response to hypercapnia on days 1 and 5, whereas quetiapine combined with oxycodone did not cause such an effect."	( Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial. Boughner, R; Burkhart, K; Dahan, A; Davis, MC; Florian, J; Ford, K; Gershuny, V; Han, X; Ismaiel, OA; Matta, M; Patel, V; Prentice, K; Racz, R; Rouse, R; Sanabria, C; Shah, A; Stone, M; Strauss, DG; van der Schrier, R; Wang, C; Weaver, J, 2022)	0.72
" Gabapentin significantly increased drug liking when given in combination with ALC and OXY + ALC (p < 0."	( Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Castillo, F; Comer, SD; Evans, SM; Foltin, RW; Jones, JD; Luba, RR; Mogali, S, 2022)	0.72
"The aim of this study is to investigate the safety and efficacy of different doses of oxycodone in combination with propofol during painless gastroscopy."	( Differential dosing of oxycodone in combination with propofol in diagnostic painless gastroscopy in elderly patients: A prospective randomized controlled trial. Li, YP; Zhou, Y, 2022)	0.72
"05 mg/kg oxycodone in combination with propofol can be used safely and effectively for painless gastroscopy, with the advantages of a low propofol dose, maintenance of hemodynamic stability and few adverse effects."	( Differential dosing of oxycodone in combination with propofol in diagnostic painless gastroscopy in elderly patients: A prospective randomized controlled trial. Li, YP; Zhou, Y, 2022)	0.72
" We conducted a prospective randomized controlled trial to compare etomidate alone with etomidate combined with oxycodone in elderly patients undergoing painless gastroscopy."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
"Etomidate in combination with oxycodone for painless gastroscopic operation in the elderly is a safe and effective anesthetic strategy."	( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study. Li, YP; Zhou, Y, 2023)	0.91
"To evaluate the adverse effects and particularly the anesthetic effect of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy."	( Application of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy. Cao, Y; Hao, S; Quan, Z; Yao, J; Zhou, C, 2023)	0.91
"Low-dose etomidate combined with oxycodone and midazolam for endoscopic injection sclerotherapy could reduce the incidence of hypoxia without increasing the incidence of complications."	( Application of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy. Cao, Y; Hao, S; Quan, Z; Yao, J; Zhou, C, 2023)	0.91
" More importantly, opioids are often prescribed in combination with multiple other drugs, especially in patient populations who typically are prescribed a large drug regimen."	( Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions. Coates, S; Lazarus, P, 2023)	0.91
" Potential drug-drug interactions (DDIs) were assessed by Lexi-Interact ver."	( Potential Drug Interactions in Terminally-Ill Cancer Patients, a Report from the Middle East. Mahzoni, H; Moghaddas, A; Momenzadeh, M; Naghsh, E; Sharifi, M, 2023)	0.91
" The objective is to investigate the optimal dose of oxycodone for PCIA combined with paravertebral nerve block, to achieve effective multimodal analgesia management in patients undergoing thoracoscopic lung cancer lobectomy."	( Effect of oxycodone combined with ultrasound-guided thoracic paravertebral nerve block on postoperative analgesia in patients with lung cancer undergoing thoracoscopic surgery: protocol for a randomised controlled study. Feng, H; Liu, Z; Shi, P; Su, J; Wang, Y; Wei, X; Wu, G, 2023)	0.91
" There is a risk of drug-drug interactions involving CYP450 in older adults due to the high prevalence of polypharmacy."	( Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study. Decaix, T; Gautier, S; Laprévote, O; Pépin, M; Royer, L; Sellier, C; Siguret, V; Teillet, L; Tritz, T, 2023)	0.91

Excerpt	Reference	Relevance
" intramuscular bioavailability of codeine in man."	( Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. Beaver, WT; Houde, RW; Rogers, A; Wallenstein, SL, 1978)	0.26
" The assay was developed for use in bioavailability studies of therapeutic doses of oxycodone."	( Quantitative GLC determination of oxycodone in human plasma. Renzi, NL; Tam, JN, 1979)	0.26
" The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249."	( Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Cramond, T; Leow, KP; Smith, MT; Williams, B, 1992)	0.28
" First-pass glucuronidation limits systemic bioavailability of oral naloxone."	( Treatment of opioid-induced constipation with oral naloxone: a pilot study. Culpepper-Morgan, JA; Foley, K; Houde, RW; Inturrisi, CE; Kreek, MJ; Marsh, F; Portenoy, RK, 1992)	0.28
" The assumed oral bioavailability ratios were 44% (group 1, first 10 patients) and 33% (group 2, last 10 patients) for morphine and 66% (group 1) and 50% (group 2) for oxycodone hydrochloride, respectively."	( Morphine and oxycodone hydrochloride in the management of cancer pain. Kalso, E; Vainio, A, 1990)	0.28
"29) and the mean (+/- SD) absolute bioavailability was 61."	( Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Cramond, T; Leow, KP; Smith, MT, 1995)	0.29
" It is suitable for oral administration due to high bioavailability (60%), and may also be given intramuscularly, intravenously, subcutaneously, and rectally; it is not recommended for spinal administration."	( A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. Kalso, E; Pöyhiä, R; Vainio, A, 1993)	0.29
"The steady-state bioavailability of a controlled-release (CR) oxycodone tablet was compared with that of an immediate-release (IR) oxycodone solution in a randomized, analytically masked, multiple-dose, crossover study in 24 normal subjects."	( Steady-state bioavailability of controlled-release oxycodone in normal subjects. Benziger, DD; Kaiko, RF; Miotto, JB; Oshlack, B; Reder, RF, )	0.13
"The effects of a high-fat meal on the bioavailability of oxycodone hydrochloride, administered as a recently developed 40 mg controlled-release (CR) tablet or a 20 mg immediate-release (IR) solution, were evaluated in a randomized crossover study in 22 normal male and female subjects."	( Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. Benziger, DP; Chasin, M; Fitzmartin, RD; Kaiko, RF; Miotto, JB; Reder, RF, 1996)	0.29
" Absorption rate of the IR solution was best described by a mono-exponential model with a lag time, whereas absorption rate of the CR tablet was best described using a bi-exponential model."	( Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Kaiko, RF; Mandema, JW; Oshlack, B; Reder, RF; Stanski, DR, 1996)	0.29
"A single-dose, analytically blinded, randomized, crossover study was conducted in 22 healthy male volunteers to compare the bioavailability of one 20 mg with two 10 mg controlled-release (CR) oxycodone tablets."	( A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. Benziger, DP; Fitzmartin, RD; Grandy, RP; Miotto, J; Swanton, RE; Thomas, GB, 1997)	0.3
" The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine."	( Morphine or oxycodone in cancer pain? Heiskanen, TE; Kalso, EA; Ruismäki, PM; Seppälä, TA, 2000)	0.31
"Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine."	( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001)	0.31
"Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate, such as morphine."	( Minimal interaction between gatifloxacin and oxycodone. Grant, EM; Nicolau, DR; Nightingale, C; Quintiliani, R, 2002)	0.31
" Compared with morphine, oxycodone has a higher oral bioavailability and is about twice as potent."	( Oxycodone. Pharmacological profile and clinical data in chronic pain management. Coluzzi, F; Mattia, C, )	0.13
" The following model adequately describes the population pharmacokinetic profile of oxycodone where absolute bioavailability (F) is estimated for each administration route: CL/F=55x(body weight/70)0."	( Population pharmacokinetics of oxycodone in children 6 months to 7 years old. El-Tahtawy, A; Kokki, H; Reidenberg, BE, 2006)	0.33
" Using a new, sensitive, and specific liquid chromatography/mass spectrometry (LC/MS) with electrospray ionization detector assay, the absorption bioavailability of sublingual oxycodone was determined in rabbits by comparing plasma concentration after sublingual spray delivery with equivalent intravenous dose."	( Effect of pH on sublingual absorption of oxycodone hydrochloride. Al-Ghananeem, AM; Crooks, PA; Malkawi, AH, 2006)	0.33
" Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%."	( Oxycodone: a pharmacological and clinical review. Espinosa Arranz, E; González Barón, M; Ordóñez Gallego, A, 2007)	0.34
" Treatments were considered bioequivalent if the 90% CIs for relative bioavailability calculations fell within a predetermined range of 80% to 125%."	( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008)	0.35
" These findings suggest that the coadministration of oxycodone PR and naloxone PR in an FDC would not significantly affect the bioavailability of either of its constituents in these subjects."	( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008)	0.35
" Oxycodone has good oral bioavailability and it produces more predictable plasma concentrations than morphine, which has a poor and more variable bioavailability."	( Oxycodone: new 'old' drug. Hagelberg, NM; Olkkola, KT, 2009)	0.35
" Oxycodone displays high bioavailability after oral administration and may be better than morphine in patients with renal impairment due to the decreased production of active metabolites."	( Role of oxycodone and oxycodone/naloxone in cancer pain management. Leppert, W, )	0.13
" The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets."	( Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Aaltomaa, S; Eskelinen, M; Kokki, H; Kokki, M; Ojanperä, I; Rasanen, I; Välitalo, P, 2012)	0.38
"Our results indicate that, in the elderly, the bioavailability of the three different oral dosage forms of oxycodone is fairly similar."	( Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Aaltomaa, S; Eskelinen, M; Kokki, H; Kokki, M; Ojanperä, I; Rasanen, I; Välitalo, P, 2012)	0.38
" Moreover, relatively high enteral bioavailability allows an easy switch from one drug formulation to another during the course of pain management."	( Oxycodone for the treatment of postoperative pain. Kokki, H; Kokki, M; Sjövall, S, 2012)	0.38
"To determine the absolute bioavailability of naloxone from oral doses ranging from 5 mg to 120 mg."	( Low absolute bioavailability of oral naloxone in healthy subjects. Bailey, P; Bell, D; Bond, S; Hopp, M; Mundin, G; Smith, K; Woodward, J, 2012)	0.38
"The mean oral absolute bioavailability of naloxone in this study was ≤ 2% at doses ranging from 5 mg to 120 mg."	( Low absolute bioavailability of oral naloxone in healthy subjects. Bailey, P; Bell, D; Bond, S; Hopp, M; Mundin, G; Smith, K; Woodward, J, 2012)	0.38
" Secondary objectives were to assess food effects on the pharmacokinetics of IRO-A tablets, to compare the relative bioavailability of oxycodone in IRO-A tablets versus marketed oxycodone hydrochloride (IRO) tablets under fed conditions and to evaluate the single-dose safety profile of the IRO-A tablets in healthy volunteers pretreated with naltrexone."	( Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA, 2012)	0.38
" Dose proportionality (IRO-A), food effects (IRO-A), and relative bioavailability in a fed state (IRO-A and IRO) were assessed by using bioequivalence criteria (90% CIs between 80% and 125% for C(max) and AUC)."	( Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA, 2012)	0.38
" The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16."	( Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA, 2012)	0.38
" Administration of IRO-A with food suggested increased overall bioavailability relative to fasting conditions and a reduction in peak systemic exposure of oxycodone that is not expected to be clinically significant."	( Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA, 2012)	0.38
" Their impact on oral pharmacotherapy, including their effect on the bioavailability of oral medications, is poorly understood."	( Unpredictable absorption of oral opioid medications in a quadriplegic patient with chronic enterocutaneous fistulas. Viswesh, VV, 2012)	0.38
"The rate of absorption of oxycodone from OXN PR tablets correlated well with the in vitro release rates, demonstrating that a Level A IVIVC with internal predictability has been successfully developed for OXN PR tablets."	( Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times. Hahn, U; Heun, G; Krämer, M; Leuner, C; Mundin, GE; Mysicka, J; Smith, KJ, 2012)	0.38
" The bioavailability is higher than for morphine and less variable."	( Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Andersson, ML; Gustafsson, LL; Söderberg Löfdal, KC, 2013)	0.39
"To assess relative bioavailability of a new generic (test) formulation of oxycodone hydrochloride (HCl) extended release (ER) tablets with that of marketed reference products, OxyContin®, in Canada and USA, in healthy adult subjects under fasting and fed conditions."	( Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US. Ducharme, MP; Freeman, JC; Godfrey, AR; Gosai, P; Katikaneni, P; Kumar, KS; Kumar, S; Monif, T; Mudnaik, R, 2013)	0.39
" Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31."	( Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? Anderson, H; Charles, B; George, R; Hardy, J; Norris, R; Tapuni, A, 2014)	0.4
" The aim of this formulation is to counteract opioid-induced constipation through the local antagonist effect of naloxone in the gut wall, while maintaining analgesia due to the low bioavailability of oral naloxone."	( Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Burness, CB; Keating, GM, 2014)	0.4
" To pilot test our hypothesis, we used a mathematical model which postulates that oxycodone's addictive potential is given by: LAP=E/(ka/ke), where LAP represents addictive potential, E represents euphoric potency, ka is the absorption rate constant of drug from the gastrointestinal tract, and ke is the systemic elimination rate constant of drug by all processes responsible for its removal from plasma."	( The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. Boston, RC; Daly, D; Linares, OA; Stefanovski, D, 2014)	0.4
" The low oral bioavailability (< 2%) of naloxone makes the precipitation of the acute opioid withdrawal symptoms unlikely following oral oxycodone/naloxone exposure."	( Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Graudins, A; Greene, SL; Koutsogiannis, Z; Macleod, D; Robinson, J; Wong, A, 2015)	0.42
" Under fed conditions, the absorption rate constant of OC and APAP decreased significantly, although there was no effect on CL/F and V/F."	( Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Devarakonda, K; Franke, RM; Morton, T, 2015)	0.42
"This study compared the development of tolerance to two orally bioavailable prescription opioids, oxycodone and hydrocodone, to that of morphine, and the reversal of this tolerance by ethanol."	( Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone. Akbarali, HI; Dewey, WL; Henderson, G; Jacob, JC; Poklis, JL, 2017)	0.46
" Bioavailability of OOD could be classified as comparable to the twice-daily administration of the OTD reference formulation."	( Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet . Gschwind, YJ; Guth, V; Kovacs, P; Maritz, MA; Rey, H; Scheidel, B; Steigerwald, K, 2017)	0.46
" As the bioavailability of each opioid has a certain extent of interindividual bioavailability this conversion represents an approximation."	( Oral oxycodone for pain after caesarean section: A randomized comparison with nurse-administered IV morphine in a pragmatic study. Arnelo, C; Blanck, A; Niklasson, B; Öhman, SG; Segerdahl, M, 2015)	0.42
" In this single-dose pharmacokinetic study, we assessed the relative bioavailability of oxycodone for Oxycodone ARIR and IR oxycodone, and the effect of food on Oxycodone ARIR following oral administration."	( Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Aigner, S; Iverson, M; Kinzler, ER; Pantaleon, C; Webster, LR, 2019)	0.51
"This open-label, randomized study in healthy adults compared the relative bioavailability of Oxycodone ARIR 30 mg to IR oxycodone 30 mg under fasted conditions, and Oxycodone ARIR under fed versus fasted conditions."	( Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Aigner, S; Iverson, M; Kinzler, ER; Pantaleon, C; Webster, LR, 2019)	0.51
"In this single-dose pharmacokinetic evaluation, fasted Oxycodone ARIR 30 mg had similar bioavailability to and is expected to have the same efficacy and safety profile as IR oxycodone."	( Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Aigner, S; Iverson, M; Kinzler, ER; Pantaleon, C; Webster, LR, 2019)	0.51
"Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to loss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life."	( [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review]. Brás, M; Fragoso, M; Vieira, C, 2019)	0.51
"The objective of this study was to determine the effect of concomitant alcohol intake on the bioavailability of oxycodone from an oxycodone once-daily (OOD) formulation and an oxycodone twice-daily (OTD) formulation."	( Once-Daily Oxycodone Prolonged-Release Tablets Are Resistant to Alcohol-Induced Dose Dumping: Results From a Randomized Trial in Healthy Volunteers. Burger, N; Faulkner, J; Fraser, D; Maritz, MA; Rey, H, 2020)	0.56
"The new data confirmed the PK profile and the PK/PD relationship identified using the MBMA, resulting in similar parameter estimates except for the intranasal absorption rate constant."	( Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. Buller, S; Dari, A; Freijer, J; Gautrois, M; Rengelshausen, J; Stahlberg, HJ, 2021)	0.62
" However, in patients with hepatic impairment, porto-systemic shunting can increase systemic bioavailability of naloxone, potentially compromising the analgesic efficacy of oral naloxone-oxycodone combinations."	( Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment. Aggarwal, G; Ahmedzai, S; Douglas, C; Green, M; Le, BH; Nicoll, A, 2022)	0.72
"Oxycodone is absorbed in a clinically relevant extent in patients with short bowel syndrome, but bioavailability varies greatly between patients, which shall be taken into consideration."	( Oral absorption of oxycodone in patients with short bowel syndrome. Christrup, LL; Drewes, AM; Hestvang, J; Ladebo, L; Mikkelsen, MS; Olesen, AE; Rasmussen, HH; Vinter-Jensen, L, 2021)	0.62
" Furthermore, oral bioavailability was 14."	( Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. Abuhelwa, AY; Christrup, LL; Drewes, AM; Foster, DJR; Kongstad, KT; Kroustrup, JP; Ladebo, L; Olesen, AE; Pacyk, GJ, 2021)	0.62

Excerpt	Relevance	Reference
" In the oxycodone group, only two patients (12%) needed maximal dosage (6 x 4 mg), one of them requiring 32 mg of oxycodone."	( Comparison of the analgesic dose-effect relationships of nefopam and oxycodone in postoperative pain. Leander, P; Tammisto, T; Tigerstedt, I, 1979)	0.26
" The marked interindividual variation observed in the pharmacokinetics and pharmacodynamics of oxycodone in this study supports the need for individualized dosing regimens."	( Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Cramond, T; Leow, KP; Smith, MT; Williams, B, 1992)	0.28
" The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48."	( Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Cramond, T; Leow, KP; Smith, MT; Watt, JA; Williams, BE, 1992)	0.28
"min/ml and with dosing intervals less than 3 hours."	( Treatment of opioid-induced constipation with oral naloxone: a pilot study. Culpepper-Morgan, JA; Foley, K; Houde, RW; Inturrisi, CE; Kreek, MJ; Marsh, F; Portenoy, RK, 1992)	0.28
" The dosing interval was 5 min, until the patient did not want any further analgesics."	( Intravenous morphine and oxycodone for pain after abdominal surgery. Kalso, E; Linko, K; Onnela, P; Pöyhiä, R; Tammisto, T; Tigerstedt, I, 1991)	0.28
" However, the effect of differences in dosing protocol on tolerance to opioid analgesics of high or low efficacy has not been addressed."	( The effect of intrinsic efficacy on opioid tolerance. Duttaroy, A; Yoburn, BC, 1995)	0.29
" At the end of treatment, the pumps and placebos were removed, and 4-24 h later, mice were tested in dose-response studies (tail flick) using the same drug that had been chronically administered."	( The effect of intrinsic efficacy on opioid tolerance. Duttaroy, A; Yoburn, BC, 1995)	0.29
" The marked interindividual variation observed in the pharmacokinetics and pharmacodynamics of oxycodone in this study emphasizes the need for individualized dosing regimens."	( Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Cramond, T; Leow, KP; Smith, MT, 1995)	0.29
" With the use of the tail flick model, dose-response curves were constructed to codeine, morphine, oxycodone and oxymorphone (the O-demethylated metabolite of oxycodone) in both rat strains."	( The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. Bochner, F; Cleary, J; Mikus, G; Somogyi, A, 1994)	0.29
" In conclusion, ondansetron given prior to anaesthesia in a dosage of 4 mg did not prevent postoperative nausea and vomiting after laparoscopic cholecystectomy."	( Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial. Koivuranta, MK; Läärä, E; Ryhänen, PT, 1996)	0.29
" Serial blood samples were collected for 36 h after dosing and analyzed for oxycodone by a validated method using gas chromatography/mass spectrometry."	( Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. Benziger, DP; Chasin, M; Fitzmartin, RD; Kaiko, RF; Miotto, JB; Reder, RF, 1996)	0.29
" Recently, controlled-release (CR) oxycodone tablets were developed to provide the benefits of twice-a-day dosing to patients treated with oxycodone."	( Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Kaiko, RF; Mandema, JW; Oshlack, B; Reder, RF; Stanski, DR, 1996)	0.29
" Medical records were reviewed to determine reasons for opioid dosage escalations."	( Codeine and oxycodone use in patients with chronic rheumatic disease pain. Mahowald, ML; Woods, SR; Ytterberg, SR, 1998)	0.3
" This patient's clinical course indicates that oral oxycodone can be used safely and to good effect at high dose, that the milligram relative potency ratio for oral oxycodone to parenteral morphine during repeated dosing is 3:1, and suggests that availability of multiple formulations of oxycodone may benefit cancer patients."	( The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration. Doona, M; Walsh, D; Zhukovsky, DS, 1999)	0.3
" Assessments were made at 30 min, 60 min, then hourly after dosing for 12 h or until remedication."	( Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Brown, J; Clark, P; Curtis, GB; Johnson, GH; Lacouture, PG; O'Callaghan, R; Shi, M; Taylor, R, 1999)	0.3
" Behaviourally, rats co-administered sub-antinociceptive doses of oxycodone and morphine were similar to control rats dosed with saline, whereas rats that received equi-potent doses of either opioid alone, were markedly sedated."	( Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Ross, FB; Smith, MT; Wallis, SC, 2000)	0.31
" A 34 year-old male patient experienced visual hallucinations and severe tremor after dramatically increasing his dosage of oxycodone while on stable amounts of sertraline and cyclosporin."	( Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. Flockhart, DA; Rosebraugh, CJ; Woosley, RL; Yasuda, SU, 2001)	0.31
"1 after titration with IR oxycodone dosed qid."	( Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. Davis, M; Reder, RF; Stambaugh, H; Stambaugh, JE; Stambaugh, MD, 2001)	0.31
" When initiating treatment, controlled-release preparations of opioids are generally favoured, and are combined with immediate release morphine to prevent or treat 'breakthrough' pain and to enable the optimum opioid dosage to be calculated."	( [Treatment of pain in cancer with systemically administered opioids]. de Wit, R; Enting, RH; Lieverse, PJ; Smitt, PA; van der Rijt, CC; Wilms, EB, 2001)	0.31
" This article will address the safety and efficacy of acetaminophen, aspirin, and ibuprofen independently and in combination with currently available prescription dosage forms with a focus on pharmacology, pharmacotherapeutics, pharmacodynamics, and pharmacokinetics, including drug interactions at the CYP450 system."	( Acetaminophen, aspirin, or Ibuprofen in combination analgesic products. Barkin, RL, )	0.13
" The reduced dosing frequency makes the oral medication more convenient for patients, making it easier for them to comply with the dosing regimen."	( Opioid formulations: tailoring to the needs in chronic pain. Reder, RF, 2001)	0.31
"Optimal pharmacologic management of pain requires selection of the appropriate analgesic drug, prescription of the appropriate dose, administration of the analgesic by the appropriate route, scheduling of the appropriate dosing interval, prevention of persistent pain and relief of breakthrough pain, aggressive titration of the dose of the analgesic, prevention, anticipation, and management of analgesic side-effects, use of appropriate co-analgesic drugs, and consideration of sequential trials of opioid analgesics."	( Advancement of opioid analgesia with controlled-release oxycodone. Levy, MH, 2001)	0.31
" The recommended dosing of the study medications was 1 tablet every 4 to 6 hours, not to exceed 5 tablets per day."	( Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Dornseif, BE; Doyle, RT; Morris, E; Palangio, M; Valente, TJ, 2002)	0.31
" Controlled-release oxycodone has the advantage of less frequent dosing than immediate-release oxycodone; however, other agents may be dosed infrequently at much lower costs."	( Safety and efficacy of controlled-release oxycodone: a systematic literature review. Karbowicz, SH; Rischitelli, DG, 2002)	0.31
" The new difference CD spectroscopic method can be applied to the selective determination of 6-oxo-morphinans in bulk and dosage forms."	( Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy. Gergely, A; Horváth, P; Hosztafi, S; Szász, G; Szentesi, A, 2002)	0.31
"All prior analgesics were discontinued, and oxycodone/acetaminophen was dosed three times a day (TID), titrated to clinically meaningful pain relief."	( Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Domingos, J; Galer, BS; Gammaitoni, AR; Lacouture, P; Schlagheck, T, 2003)	0.32
"2, on average, provided adequate pain control during the subsequent 12-hour dosing interval and for a maximum of 7 days."	( Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. Adler, LJ; Ashburn, MA; Crews, JC; Ginsberg, B; Hord, AH; Laurito, CE; Sinatra, RS, 2003)	0.32
" The median daily dosage strength of transdermal fentanyl was 75."	( Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. Ackerman, SJ; Brennan, M; Mordin, M; Reblando, J; Schein, J; Vallow, S; Xu, X, )	0.13
"To assess clinical efficacy of controlled-release oxycodone (CRO) 20 mg on a 12-h dosing schedule in this prospective, randomised, placebo-controlled, double-blinded study of 40 ASA physical status I-III women undergoing breast surgery for cancer."	( Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Hundegger, S; Kampe, S; Kaufmann, J; Kiencke, P; Mellinghoff, H; Warm, M, 2004)	0.32
"The administration of CRO 20 mg on a 12-h dosing schedule halves postoperative IV PCA opioid consumption."	( Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Hundegger, S; Kampe, S; Kaufmann, J; Kiencke, P; Mellinghoff, H; Warm, M, 2004)	0.32
" The mean daily dosage of oxycodone CR (91."	( Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Ahdieh, H; Dvergsten, C; Gabrail, NY, 2004)	0.32
"To determine the dosing of sustained-release oxycodone that is typically prescribed to achieve pain relief in a mixed group of chronic pain patients."	( Sustained-release oxycodone dosing survey of chronic pain patients. Glick, RM; Marcus, DA, )	0.13
" Total daily dosing for both long- and short-acting opioids were recorded for each patient."	( Sustained-release oxycodone dosing survey of chronic pain patients. Glick, RM; Marcus, DA, )	0.13
"The prescribed frequency of dosing sustained-release oxycodone determined through clinical practice was twice daily for 33% of patients, with 67% requiring greater than twice daily dosing."	( Sustained-release oxycodone dosing survey of chronic pain patients. Glick, RM; Marcus, DA, )	0.13
" Patients maintained on every-12-hour dosing were twice as likely to use regularly scheduled, daily, short-acting opioids to achieve pain relief."	( Sustained-release oxycodone dosing survey of chronic pain patients. Glick, RM; Marcus, DA, )	0.13
" Postoperatively the propacetamol dosage was repeated twice and diclofenac once on the ward."	( Propacetamol and diclofenac alone and in combination for analgesia after elective tonsillectomy. Hiller, A; Savolainen, S; Silvanto, M; Tarkkila, P, 2004)	0.32
" The median dosing interval was >9."	( The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Ahdieh, H; Gimbel, J, 2004)	0.32
" Long-acting oral opioids supply satisfactory analgesia at more convenient dosing intervals."	( Advances in opioid therapy and formulations. Walsh, D, 2005)	0.33
" With stable dosing throughout the treatment phase, oxymorphone ER (79."	( Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. Dvergsten, C; Gimbel, J; Hale, ME, 2005)	0.33
" Oxycodone is available in the United States in oral dosage forms and controlled-release tablets."	( The pharmacokinetics of oxycodone. Kern, SE; Lugo, RA, 2004)	0.32
" Based on these data, the following primary efficacy end points were determined: total pain relief 6 hours after dosing (TOTPAR6) and sum of pain intensity differences 6 hours after dosing (SPID6)."	( Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study. Newman, K; Pong, A; Singla, N, 2005)	0.33
" The onset of pain relief occurred within 15 minutes of dosing with all 4 regimens."	( Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study. Newman, K; Pong, A; Singla, N, 2005)	0.33
" The primary outcome measures were total pain relief through 6 hours after dosing (TOTPAR6), sum of pain intensity differences through 6 hours (SPID6), and adverse events."	( Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blin Adamson, DN; Christensen, SE; Han, SH; Litkowski, LJ; Newman, KB; Van Dyke, T, 2005)	0.33
" In this Phase II dose-ranging study, Oxytrex bid demonstrated greater pain relief with a more convenient dosing schedule compared to oxycodone qid."	( Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. Burns, LH; Butera, PG; Chindalore, VL; Craven, RA; Friedmann, N; Yu, KP, 2005)	0.33
" Routine dosing of oxycodone in young infants may be dangerous."	( Marked variation in oxycodone pharmacokinetics in infants. Anttila, E; Olkkola, KT; Pokela, ML; Seppälä, T, 2005)	0.33
" Along these trials, mean daily dosage of oxycodone was approximately 40 mg, with a low incidence of intolerable typical opiate side effects."	( Oxycodone. Pharmacological profile and clinical data in chronic pain management. Coluzzi, F; Mattia, C, )	0.13
"When opioids are used for postoperative pain control, it is useful to define the dose-response relationship for analgesia and respiratory depression."	( Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. Davis, JJ; Dillon, JD; Egan, TD; Hall, RH; Johnson, KB; Niu, SY; Pace, NL; Swenson, JD, 2005)	0.33
" This model confirms using a weight-based dose for oxycodone without adjustment for age between 6 months and 7 years and is valuable for evaluating dosing schedules and dosing routes."	( Population pharmacokinetics of oxycodone in children 6 months to 7 years old. El-Tahtawy, A; Kokki, H; Reidenberg, BE, 2006)	0.33
" A sublingual spray dosage form of oxycodone hydrochloride would be a good alternative for fast onset pain management, especially in children."	( Effect of pH on sublingual absorption of oxycodone hydrochloride. Al-Ghananeem, AM; Crooks, PA; Malkawi, AH, 2006)	0.33
" l-methadone, racemic methadone, and oxycodone had a similar dose-dependent antinociceptive effect, whereas the dose-response curve of morphine was shallower."	( Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Kalso, E; Kontinen, VK; Kylänlahti, I; Lemberg, K; Viljakka, K; Yli-Kauhaluoma, J, 2006)	0.33
"Patients were randomized to receive either P-ERMS once-daily (QD) dosing or CRO twice-daily (BID) dosing for a 24-week treatment period."	( Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Nicholson, B; Ross, E; Sasaki, J; Weil, A, 2006)	0.33
" After 24 weeks, all patients on P-ERMS were dosing within the FDA-approved frequencies (65% QD, 35% BID); 56% of patients on CRO dosed BID, but 38% dosed TID and 6% dosed four times daily (QID)."	( Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Nicholson, B; Ross, E; Sasaki, J; Weil, A, 2006)	0.33
"P-ERMS and CRO both relieved chronic nonmalignant pain in this community-based population; however, patients taking P-ERMS dosed in accordance with FDA-approved frequencies (QD/BID); 44% of those taking CRO dosed more frequently (TID/QID)."	( Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Nicholson, B; Ross, E; Sasaki, J; Weil, A, 2006)	0.33
" The shift to the right of the dose-response curves was greater for morphine and oxycodone compared to etorphine and the highest dose of clocinnamox reduced the maximal effect of morphine and oxycodone, but not etorphine."	( Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Kumar, P; Pawar, M; Sirohi, S; Sunkaraneni, S; Walker, EA; Yoburn, BC, 2007)	0.34
" They received oral OCRT at an initial dosage of 5mg every 12 hours for patients scoring 4-6 and 10mg every 12 hours for patients scoring > or =7."	( Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Dai, Y; Dou, C; Guo, Y; Lu, L; Pan, H; Wu, D; Wu, S; Xu, N; Yue, J; Zhang, Y; Zhang, Z, 2007)	0.34
" The total mean OCRT dosage was 445."	( Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Dai, Y; Dou, C; Guo, Y; Lu, L; Pan, H; Wu, D; Wu, S; Xu, N; Yue, J; Zhang, Y; Zhang, Z, 2007)	0.34
" Oral controlled-release opioid products enable patients to better maintain pain control due to convenient dosing intervals and sustained blood concentration."	( [Oxycodone: a strong opioid in the treatment of patients with arthritis]. Anić, B; Bilusić, M; Grazio, S, 2006)	0.33
" The average wholesale price per dosing unit of each drug during each period studied was obtained from internal databases."	( Prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital. Arbuckle, R; Bruera, E; Curry, EA; Hung, F; Palla, S, 2007)	0.34
"Lacking enough knowledge of pediatric cancer pain and pediatric dosage form of analgesics, current treatment of pediatric cancer pain in China is unsatisfactory."	( [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy]. Lin, H; Ling, JY; Luo, WB; Sun, XF; Xia, Y; Zhen, ZJ; Zheng, L, 2007)	0.34
"Basing on the components and the endurable dosage of each component for children, we formulated the appropriate dosage and usage of a few analgesics (including sustained release tablets of morphine, oxycodone and transdermal fantanyl) available in China, most of which were used in adults."	( [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy]. Lin, H; Ling, JY; Luo, WB; Sun, XF; Xia, Y; Zhen, ZJ; Zheng, L, 2007)	0.34
" Dosage was individualized for each patient and up-titrated until effective pain control was achieved."	( Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Aitini, E; Bandieri, E; Calorio, A; Dambrosio, M; Del Prete, S; Endrizzi, L; Garetto, F; Ianniello, GP; Marra, A; Micheletto, G; Nastasi, G; Piantedosi, F; Sabbatini, G; Sidoti, V; Silvestri, B; Spanu, P, 2008)	0.35
" A dosage increase of oxycodone from 20 to 40 mg bid was required in only one patient with a clavicle fracture."	( Use of oxycodone in polytrauma patients: the "Gemelli" experience. Barbaro, F; Buccelletti, F; Candelli, M; Carbone, L; De Marco, G; Fiore, V; Franceschi, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Gigante, G; Giupponi, B; Mancini, F; Marini, M; Ojetti, V; Pignataro, G; Roccarina, D; Santarelli, L; Silveri, NG; Ursella, S, )	0.13
" Opioids are often reduced in dosage or even discontinued as a result of impaired bowel function, leading to insufficient pain treatment."	( Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Fleischer, W; Grothe, B; Hermanns, K; Hopp, M; Leyendecker, P; Meissner, W; Reimer, K; Ruckes, C; Szombati, I; Vondrackova, D; Weber, S, 2008)	0.35
" Conclusions This case suggests that, in some circumstances, the opioid blockade may be overcome when naltrexone levels drop towards the end of the dosing interval, producing vulnerability to subsequent naltrexone-induced withdrawal."	( Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Fishman, M, 2008)	0.35
" This phase III, randomized, double-blind, active-controlled study evaluated the tolerability of tapentadol immediate release (IR) and oxycodone IR for low back pain or osteoarthritis pain (hip or knee), using flexible dosing over 90 days."	( Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Hale, M; Lange, C; Okamoto, A; Rauschkolb, C; Upmalis, D, 2009)	0.35
" Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period."	( Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009)	0.35
" Measurements were performed before dosing and at 30, 60, and 90 min after dosing."	( Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Arendt-Nielsen, L; Drewes, AM; Kell, S; Menzaghi, F; Olesen, AE; Staahl, C; Wong, GY, 2009)	0.35
"To assess clinical equivalence of 20 mg controlled-release oxycodone (Oxygesic; Mundipharma, Limburg, Germany) and 200 mg controlled-release tramadol (Tramal long; Grunenthal, Aachen, Germany) on a 12-hour dosing schedule in a randomized, double-blinded study of 54 ASA I-III physical status (American Society of Anesthesiologists classification of physical status) patients undergoing surgery for breast cancer."	( Clinical equivalence of controlled-release oxycodone 20 mg and controlled-release tramadol 200 mg after surgery for breast cancer. Dagtekin, O; Kampe, S; Landwehr, S; Shaheen, S; Warm, M; Wolter, K, 2009)	0.35
"Analgesic efficacy of opioids and dosing protocol have been shown to influence analgesic tolerance."	( Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Dighe, SV; Madia, PA; Sirohi, S; Walker, EA; Yoburn, BC, 2009)	0.35
" Dose-response studies were conducted using morphine following treatment."	( Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Dighe, SV; Madia, PA; Sirohi, S; Walker, EA; Yoburn, BC, 2009)	0.35
" These results suggest that opioid analgesic tolerance may be increased when sustained release dosing formulations or continuous infusions are employed clinically."	( Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Dighe, SV; Madia, PA; Sirohi, S; Walker, EA; Yoburn, BC, 2009)	0.35
" Most patients had a clear indication for use of oxycodone and appropriate dosing regimes."	( Oxycodone--an audit of its prescription in a local hospital. Chan, SY; Choo, CY; Ong, CY, 2009)	0.35
" Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks."	( A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010)	0.36
" Also, an analysis of medians was calculated for each of the dosage groupings using Bonett-Price confidence intervals for both raw and adjusted LC-MS-MS values."	( Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. Couto, JE; Leider, HL; Linden, A; Romney, MC; Webster, L, )	0.13
" At the scene were numerous bottles of methadone, with the chronic dosage of 240 mg 3 times a day."	( Cause of death conundrum with methadone use: a case report. Benson, BE; Letsky, MC; Seifert, SA; Zumwalt, RE, 2011)	0.37
" To determine the dosing frequency of sustained-release opioids (morphine, oxycodone, and transdermal fentanyl) and the prevalence of end-of-dose failure in clinical practice, a patient-reported survey was performed."	( The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Ahn, JS; Kim, DY; Kim, SY; Ryoo, BY; Shin, DB; Song, HS; Yim, CY, 2010)	0.36
"8% of these patients took medication earlier than the prescribed dosing schedule."	( The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Ahn, JS; Kim, DY; Kim, SY; Ryoo, BY; Shin, DB; Song, HS; Yim, CY, 2010)	0.36
" End-of-dose failure is suggested to explain increased dosing frequency, and patients reported that adequate pain relief lasted for less time than was stated in the manufacturers' prescription recommendation."	( The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Ahn, JS; Kim, DY; Kim, SY; Ryoo, BY; Shin, DB; Song, HS; Yim, CY, 2010)	0.36
" The treatment started with oxycodone/acetaminophen at the dosage of 5 mg/325 mg, and then the dosage was titrated until the attainment of good pain relief."	( Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis. Biasi, G; Corvetta, A; Di Sabatino, V; Galeazzi, M; Pari, C; Raffaeli, W; Sarti, D, )	0.13
" Dosage was individualized for each patient and up-titrated over the first week of treatment."	( Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control. Bandieri, E; Costa, G; Fornasier, G; Iorno, V; Micheletto, G; Pastacaldi, G; Pizza, C; Tessaro, L, 2010)	0.36
" These parameters further improved after 3 months of therapy and remained stable during the follow-up; moreover, an increase of daily dosage of oxycodone was never required."	( Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers. Colaci, M; Ferri, C; Giuggioli, D; Manfredi, A, 2010)	0.36
" The aim of this review is to outline the pharmacodynamic and pharmacokinetic properties, drug interactions, dosing rules, adverse effects, equianalgesic dose ratio with other opioids and clinical studies of oxycodone in patients with cancer pain."	( Role of oxycodone and oxycodone/naloxone in cancer pain management. Leppert, W, )	0.13
"randomized, double-blind, placebo-controlled, ascending-dose cohort, dose-response study with flexible dosing."	( A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. Kelen, R; Richards, P; Stern, W; Webster, L, )	0.13
" There was a poor correlation between concentrations of both oxycodone and noroxycodone in plasma and saliva over a range of times following dosing (r (2) = 0."	( Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? Anderson, H; Charles, B; Hardy, J; Norris, R; O'Shea, A, 2012)	0.38
"8 percent vomiting, which affected adherence to prescribed dosing regimens and, thus, is inversely associated with the level of pain relief."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" Simulations of repetitive bolus dosing showed a 20% increase in oxycodone concentration in the elderly."	( Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Ihmsen, H; Neuvonen, PJ; Olkkola, KT; Saari, TI; Schwilden, H, 2012)	0.38
" In elderly patients, dosing should therefore be reduced and carefully titrated to avoid considerable accumulation of oxycodone and potentially hazardous side-effects."	( Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Ihmsen, H; Neuvonen, PJ; Olkkola, KT; Saari, TI; Schwilden, H, 2012)	0.38
"Although opioids are widely accepted as standard therapy for treating acute postoperative pain, the frequent occurrence of adverse events (AEs) and the substantial burden on the patient and the costs of care are a barrier to optimal dosing and adherence to prescribed treatment."	( Efficacy and safety of dual-opioid therapy in acute pain. Webster, L, 2012)	0.38
"The optimal dosage of the 3-day-type transdermal fentanyl patch was determined by titration of short-acting oral oxycodone."	( [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. Fujio, N; Ishikawa, N; Kameyama, M; Watanabe, H; Yamazaki, K, 2012)	0.38
"To characterize the pharmacokinetics (PK) of oxycodone following intravenous injection and administration of three oral dosage forms (solution, capsule, and controlled-release tablet) in elderly patients (age 76-89 years) undergoing cystoscopy."	( Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Aaltomaa, S; Eskelinen, M; Kokki, H; Kokki, M; Ojanperä, I; Rasanen, I; Välitalo, P, 2012)	0.38
" For intravenous injection we calculated clearance, volume of distribution at steady state, and the half-life of elimination, and for oral dosage forms also the absolute bioavailability."	( Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Aaltomaa, S; Eskelinen, M; Kokki, H; Kokki, M; Ojanperä, I; Rasanen, I; Välitalo, P, 2012)	0.38
"Our results indicate that, in the elderly, the bioavailability of the three different oral dosage forms of oxycodone is fairly similar."	( Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Aaltomaa, S; Eskelinen, M; Kokki, H; Kokki, M; Ojanperä, I; Rasanen, I; Välitalo, P, 2012)	0.38
" The effects of oxycodone (0, 5, and 20 mg/70 kg, orally) were compared, using a within-session cumulative dosing procedure, on the first and fifth days of the 'daily' dosing phase to assess for tolerance; active oxycodone was administered on the second and fourth days of the daily dosing phase."	( Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers. Comer, SD; Cooper, ZD; Evans, SM; Foltin, RW; Haney, M; Kowalczyk, WJ; Manubay, JM; Saccone, PA; Sullivan, MA; Vosburg, SK, 2012)	0.38
"" Global assessments of efficacy, dosing convenience, and tolerability were secondary endpoints."	( Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Binsfeld, H; Richarz, U; Sabatowski, R; Szczepanski, L; Waechter, S, 2013)	0.39
"Pharmacokinetic parameters were determined over a 12-hour dosing interval."	( Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Bath, B; Marmon, T; Medve, RA; Stoddard, GJ; Webster, LR, 2012)	0.38
"We investigated the safety and efficacy of the bilateral periarticular multimodal drug injection (PMDI) at a reduced dosage in patients undergoing simultaneous bilateral total knee arthroplasty (SBTKA)."	( Use of reduced-dose periarticular injection for pain management in simultaneous bilateral total knee arthroplasty. Chang, CB; Jeon, YT; Kang, YG; Kim, TK; Koh, IJ; Song, J, 2012)	0.38
"The aim of the study was to evaluate the analgesic/antihyperalgesic efficacy and to establish the dose-response relationship of morphine immediate release (IR) and oxycodone IR in a human experimental algesimetric model."	( Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects. Hoeben, E; Mangold, B; Reitmeir, P; Rusch, S; Schaffler, K; Smit, JW; Upmalis, D, 2012)	0.38
"Of the 35 adults enrolled in the study, 33 completed at least 1 dosing period."	( Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA, 2012)	0.38
" In part 1 of the study, patients were dosed every 5 minutes for the first 65 minutes (up to 13 doses) with study drug, provided that vital signs criteria were met."	( Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement. Bäthis, H; Böhmer, A; Joppich, R; Kelen, R; Lefering, R; Neugebauer, E; Otto, C; Petzke, F; Richards, P; Stern, W; Treptau, T; Zarghooni, K, 2012)	0.38
" Two chronic pain patients with loss of pain control following dosage increase in levothyroxine supplementation are presented."	( Loss of antinociceptive effectiveness of morphine and oxycodone following titration of levothyroxine: case reports and a brief review of published literature. Herndon, CM; Kearney, TC; Lindsay, TJ; Matoushek, TA, )	0.13
" It has also been reported that pregabalin used with oxycodine reveals analgesic effect with smaller dosage than pregabalin alone."	( [Case of acute exacerbation of neuropathic cancer pain rapidly relieved by simultaneous oral intake of immediate release oxycodone and pregabalin]. Baba, M; Gomwo, I, 2012)	0.38
" Sensitivity analyses consider the impact of real-world dosing patterns for LAO on treatment costs."	( Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. Merchant, S; Mody, SH; Neil, N; Ogden, K; Provenzano, D, 2013)	0.39
" In sensitivity analyses, tapentadol ER becomes a dominant strategy when real-world dosing patterns are considered."	( Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. Merchant, S; Mody, SH; Neil, N; Ogden, K; Provenzano, D, 2013)	0.39
" When the dosage of morphine may result in unpredictable bioavailability, like in patients with severe hepatic cirrhosis, oxycodone might be beneficial because it has higher and less variability in bioavailability between patients than morphine."	( Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Andersson, ML; Gustafsson, LL; Söderberg Löfdal, KC, 2013)	0.39
" The abuse quotient (AQ), calculated as C(max)/t(max), served as an index of the average rate of increase in drug concentration from dosing to t max."	( Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Apseloff, G; Colucci, SV; Harris, SC; Perrino, PJ, 2013)	0.39
"In a head-to-head study of up to 10 days in duration, the analgesic efficacy and tolerability of tapentadol immediate release (IR) versus oxycodone IR using a flexible dosing regimen were compared in patients with acute low back pain (LBP) and associated radicular leg pain."	( Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Benson, C; Biondi, D; Etropolski, M; Moskovitz, B; Rauschkolb, C; Xiang, J, )	0.13
"This head-to-head study demonstrated that tapentadol IR had comparable analgesic efficacy and overall safety to that of oxycodone IR for the relief of moderate to severe, acute LBP and associated radicular leg pain when using flexible dosing regimens that reflect typical use in clinical practice; however, tapentadol IR demonstrated a better gastrointestinal tolerability profile, particularly for the common opioid-related TEAEs of vomiting and constipation."	( Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Benson, C; Biondi, D; Etropolski, M; Moskovitz, B; Rauschkolb, C; Xiang, J, )	0.13
"We conducted a prospective, randomized, cross-sectional study to develop and validate a new model to predict oxycodone in urine that can be used to help evaluate whether patients are complying with their oxycodone dosing regimens."	( A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. Boston, RC; Daly, D; Linares, OA; Stefanovski, D, 2013)	0.39
" The questions asked were related to whether a narcotic was routinely prescribed for patients who have had impacted teeth removed, the most common drug used, and the dosage and number of tablets prescribed."	( Narcotic prescribing habits and other methods of pain control by oral and maxillofacial surgeons after impacted third molar removal. Abubaker, AO; Laskin, DM; Mutlu, I, 2013)	0.39
"Most oral and maxillofacial surgeons prescribe analgesic drugs of an appropriate type and dosage and use proper adjunctive pain control measures to supplement these drugs."	( Narcotic prescribing habits and other methods of pain control by oral and maxillofacial surgeons after impacted third molar removal. Abubaker, AO; Laskin, DM; Mutlu, I, 2013)	0.39
" Dosage of CR oxycodone increased from a mean of 130."	( Noninterventional observational study using high-dose controlled-release oxycodone (CR oxycodone) for cancer pain management in outpatient clinics. Baek, JH; Baek, SK; Cho, DY; Choi, YJ; Kim, SY; Ryoo, HM; Shin, HW; Song, HS; Zang, DY, 2013)	0.39
" Despite reports that patient characteristics significantly affect oxycodone pharmacokinetics, our results do not support alteration of current prescribing practices for maintenance dosing of Oxycontin® in most patients with advanced cancer."	( Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? Anderson, H; Charles, B; George, R; Hardy, J; Norris, R; Tapuni, A, 2014)	0.4
" This approach is intended to reduce the opioid subjective rewarding effects such as euphoria which are prominent following swallowing the dosage form without tampering."	( Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use? Pergolizzi, JV; Raffa, RB; Taylor, R, 2014)	0.4
" Secondary endpoints included SPIDs and total pain relief (TOTPAR) over the dosing intervals; time to perceptible, meaningful, and confirmed pain relief; and the proportion of patients with ≥30% reduction in pain intensity scores."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain. Barrett, T; Giuliani, M; Kostenbader, K; Singla, N; Sisk, L; Young, J, 2014)	0.4
"OC/APAP ER was efficacious and generally well tolerated in an established model of moderate to severe acute pain, providing an onset of analgesia in approximately 30 minutes and sustained pain relief over the 12 hour dosing period."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain. Barrett, T; Giuliani, M; Kostenbader, K; Singla, N; Sisk, L; Young, J, 2014)	0.4
" Our hypothesis about oxycodone's addictive potential may provide a unifying approach useful for both personalized medicine dosing and predicting addictive potential of oral drugs in humans, since it is based on both oxycodone's pharmacogenetics and pharmacokinetics."	( The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. Boston, RC; Daly, D; Linares, OA; Stefanovski, D, 2014)	0.4
"To develop a framework for integrating pharmacogenetics with clinical pharmacokinetics for personalized oxycodone dosing based on a patient's CYP2D6 phenotype."	( Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Boston, RC; Daly, D; Linares, AD; Linares, OA; Stefanovski, D, 2014)	0.4
"Our study shows how clinicians can reduce risk and increase effectiveness for oxycodone dosing by (1) determining the patient's likely metabolic response through testing a patient's CYP2D6 phenotype, and (2) calculating clinical pharmacokinetics specific to the patient's CYP2D6 phenotype to design a personalized oxycodone dosing regimen."	( Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Boston, RC; Daly, D; Linares, AD; Linares, OA; Stefanovski, D, 2014)	0.4
"Personalized oxycodone dosing is a new tool for a clinician treating chronic pain patients requiring oxycodone."	( Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Boston, RC; Daly, D; Linares, AD; Linares, OA; Stefanovski, D, 2014)	0.4
" For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive."	( In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. Kuo, A; Meutermans, W; Smith, MT; Wyse, BD, 2015)	0.42
"Organ-specific OC mass transport kinetics provide new information for OC dosing in pain management."	( Organ-specific microcirculatory mass transport of oxycodone in humans: clinical implications for therapeutic use. Daly, A; Linares, OA; Schiesser, WE, 2015)	0.42
" Thus, a treatment option with the potential for a reduced dosing frequency exists for health care providers and patients."	( Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Han, J; Hou, Y; Richards, HM; Shen, W; Yu, L; Yu, S, 2014)	0.4
" In addition, the dynamic changes accompanying repetitive OC dosing suggested that local unbound OC gave rise to both higher extravascular OC content and increased OC spillover."	( Oxycodone recycling: a novel hypothesis of opioid tolerance development in humans. Boston, RC; Fudin, J; Linares, AD; Linares, OA; Schiesser, WE, 2014)	0.4
" Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning)."	( Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. Chayahara, N; Fujiwara, Y; Imamura, Y; Kiyota, N; Minami, H; Mukohara, T; Shimada, T; Toyoda, M, 2014)	0.4
"In vitro: Mechanical manipulation of dosage forms using common household utensils."	( Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. Fleming, AB; Grima, M; Kopecky, EA; Mayock, SP; Noonan, PK; Saim, S; Varanasi, RK, )	0.13
" Manipulation of DETERx by crushing (using the most effective method established in vitro) or chewing resulted in bioequivalent plasma concentration-time profiles to the intact dosage form."	( Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. Fleming, AB; Grima, M; Kopecky, EA; Mayock, SP; Noonan, PK; Saim, S; Varanasi, RK, )	0.13
" In a within-subjects, randomized, double-blind, placebo-controlled, dose-response design, 14 healthy subjects completed a resting-state scan following ingestion of placebo, 10 mg, or 20 mg of oxycodone."	( Opioid modulation of resting-state anterior cingulate cortex functional connectivity. Angstadt, M; de Wit, H; Fitzgerald, DA; Gorka, SM; Phan, KL, 2014)	0.4
"001; n = 373), using a final average daily dosage of 252."	( [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone]. Kern, KU; Krings, D; Waldmann-Rex, S, 2014)	0.4
"Repeat dosing of ALO-02 for up to 12 months is safe and well tolerated in a CNCP population of both opioid-experienced and opioid-naïve patients."	( A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. Arora, S; Clemmer, R; Goli, V; Hudson, JD; Meisner, P; Michael, D; Pixton, GC; Setnik, B; Sommerville, KW, )	0.13
"Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life."	( Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Ca, LH; Chang, J; Huang, XE; Huang, XH; Liu, J; Ma, YM; Wei, W; Wu, YJ; Xiao, Y; Zhang, RX, 2014)	0.4
" However, in clinical sites, a higher dosage may be needed due to characteristics of cancer pain."	( [Switching from oral oxycodone to oxycodone injection - an investigation into the dosage amount ratio]. Goda, Y; Kamiyama, H; Oda, K, 2015)	0.42
" The findings of the present study emphasize the potential of oxycodone once-a-day CR tablets for improved patient compliance, safety, and efficacy, which could help researchers to develop new CR dosage forms of oxycodone."	( Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. Kim, DW; Kim, JY; Lee, M; Lee, SH; Park, CW; Park, ES; Park, J; Rhee, YS; Seo, JW, 2015)	0.42
" It also allows for convenient dosing before or during surgery, permitting the initiation of effective analgesia in the early phase of the postoperative period."	( Perspectives on Intravenous Oxycodone for Control of Postoperative Pain. Pergolizzi, JV; Raffa, RB; Seow-Choen, F; Taylor, R; Wexner, SD; Zampogna, G, 2016)	0.43
"During this investigation, nondependent prescription opioid abusers (N=17 completers) were maintained for 2-3weeks on ascending daily doses of PIO (0mg, 15mg, 45mg) prior to completing a laboratory session assessing the aforementioned effects of OXY [using a within-session cumulative dosing procedure (0, 10, and 20mg, cumulative dose=30mg)]."	( The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Ciccocioppo, R; Comer, SD; Jones, JD; Manubay, JM; Metz, VE; Mogali, S; Sullivan, MA, 2016)	0.43
" These results have important implications for future dosing strategies and may limit the utility of dronabinol as a treatment for opioid withdrawal."	( Safety of oral dronabinol during opioid withdrawal in humans. Babalonis, S; Elayi, SC; Jicha, CJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015)	0.42
" Subsequently, the dosing regimen was increased to 3 mg/kg twice a day over 10 days, although further marked tolerance did not develop."	( Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats. Beardsley, PM; Walentiny, DM; Wiebelhaus, JM, 2016)	0.43
" Because of a previously reported 82% error rate in handwritten discharge narcotic prescriptions, we developed a computerized, web-based, controlled substance prescription writer that includes weight-based dosing logic and alerts to reduce the error rate to (virtually) zero."	( An Analysis of 34,218 Pediatric Outpatient Controlled Substance Prescriptions. George, JA; Hunsberger, J; Lee, BH; Lehmann, CU; Park, PS; Shay, JE; White, ED; Yaster, M, 2016)	0.43
" The primary outcome will be oxycodone dosage needed to achieve satisfactory analgaesia on day 14."	( MAGnesium-oral supplementation to reduce PAin in patients with severe PERipheral arterial occlusive disease: the MAG-PAPER randomised clinical trial protocol. Bisighini, L; Bonardelli, S; Lamberti, L; Latronico, N; Minelli, C; Rizzo, F; Rizzolo, A; Turin, M; Venturini, MA; Zangrandi, M; Zappa, S, 2015)	0.42
" The present case indicates that unless opioid side effects improve after dosage reduction, the possibility that they may be withdrawal symptoms should also be considered."	( Opioid withdrawal presenting only nausea during tapering of oxycodone after celiac plexus block: a case report. Koizumi, T; Mamiya, K; Sakamoto, A; Takayama, H, 2016)	0.43
" The prevalence of opioid abuse via intravenous (IV) injection has led to the development of dosage forms designed to deter abuse using different inactive ingredients and formulation strategies."	( In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. Fleming, AB; Grima, MP; Mayock, SP; Scungio, TA, )	0.13
"The extraction of oxycodone DETERx and two comparators, extended-release oxycodone (oxycodone ER) and immediate-release oxycodone (oxycodone IR), was evaluated in small volumes (5 and 10 mL) of water after manipulation of the dosage forms."	( In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. Fleming, AB; Grima, MP; Mayock, SP; Scungio, TA, )	0.13
" ADFs, therefore, are particularly useful with ER opioid agents, which are designed to produce consistent analgesia over prolonged dosing intervals."	( Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone. Kopecky, EA; Nalamachu, S; O'Connor, M; Taylor, R; Vaughn, B, 2016)	0.43
"To evaluate the durability of pain relief of a novel formulation of oxycodone throughout the 12 hour dosing interval."	( Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone. Kopecky, EA; Nalamachu, S; O'Connor, M; Taylor, R; Vaughn, B, 2016)	0.43
"The evaluation of dosing patterns indicates that this ER oxycodone capsule formulation has durability of effect over the entire 12-hour dosing interval."	( Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone. Kopecky, EA; Nalamachu, S; O'Connor, M; Taylor, R; Vaughn, B, 2016)	0.43
" Analysis was based on 748 Numerical Rating Scale (NRS) scores of pain intensity and 51 observed morphine and oxycodone dosing events."	( A Model-Based Approach for Joint Analysis of Pain Intensity and Opioid Consumption in Postoperative Pain. Christrup, LL; Drewes, AM; Juul, RV; Knøsgaard, KR; Kreilgaard, M; Lund, TM; Olesen, AE; Osther, PJ; Pedersen, KV, 2016)	0.43
" Plasma samples were analyzed just before dosing through 48 hours postdose for oxycodone, and through 120 hours postdose for naltrexone and its major metabolite, 6-ß-naltrexol."	( Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. Bramson, C; Gandelman, K; Lamson, M; Malhotra, B; Matschke, K; Salageanu, J, 2015)	0.42
" Use of conversion tables to guide selection of opioid agonist dosage may compromise patient safety."	( Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. Bruno, R; Degenhardt, L; Demirkol, A; Lintzeris, N; Nielsen, S, 2017)	0.46
" The rate of acetazolamide elimination into urine was followed for several days after dosing cessation."	( A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. Babalonis, S; Hampson, AJ; Krieter, P; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2016)	0.43
" For each of 4 consecutive mornings after dosing cessation, the rates of urinary acetazolamide elimination remained quantifiable."	( A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. Babalonis, S; Hampson, AJ; Krieter, P; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2016)	0.43
" Patients or caregivers may manipulate extended-release (ER) opioid formulations to facilitate oral dosing due to a lack of therapeutic options that allow for sprinkle or enteral feeding tube administration."	( An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Fleming, AB; Kopecky, EA; Marseilles, A; McCarberg, BH; O'Connor, M; Thompson, C; Varanasi, RK, 2016)	0.43
" This study investigated the patterns of opioid prescribing and characterized the dosing and duration of opioid use in patients with noncancer and cancer pain."	( Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia. Choy, LW; Ismail, CR; Rahman, NA; Zin, CS, 2017)	0.46
" Previous studies showed that opioids combined with gabapentin for management of cancer pain reduced the dosage of opioids."	( The research on long-term clinical effects and patients' satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Chen, DL; Li, YH; Wang, ZJ; Zhu, YK, 2016)	0.43
" Fentanyl and ketorolac dose-response relationships were evaluated for selected outcome variables."	( Intramuscular Fentanyl and Ketorolac Associated with Superior Pain Control After Pediatric Bilateral Myringotomy and Tube Placement Surgery: A Retrospective Cohort Study. Cook-Sather, SD; Jantzen, EC; Jawad, AF; Li, Y; Long, AS; Muhly, WT; Polansky, M; Stricker, PA, 2017)	0.46
"03 mg/kg/infusion) under fixed ratio 1 (FR1), FR2, and FR5 schedules of reinforcement followed by a dose-response study to assess sensitivity to the reinforcing effects of oxycodone."	( Oxycodone self-administration in male and female rats. Chartoff, E; Mavrikaki, M; Page, S; Potter, D; Pravetoni, M, 2017)	0.46
"Burn victim patients are frequently prescribed opioids at doses that are significantly higher than standard analgesic dosing guidelines, and, even despite an escalation in opioid dosing, many continue to experience pain."	( Burn injury decreases the antinociceptive effects of opioids. Bates, MLS; Eitan, S; Emery, MA; Wellman, PJ, 2017)	0.46
" The pharmacokinetic model developed may be used to evaluate different multiple dosing regimens, but the safety of repeated doses should be ensured."	( Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials. Hooker, AC; Kokki, H; Kokki, M; Olkkola, KT; Ranta, VP; Välitalo, P, 2017)	0.46
" Physiologic and opioid agonist effects were assessed during chronic dosing sessions."	( Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers. Coe, MA; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2017)	0.46
" The merits of adopting a different dosage form were also noted."	( [Outcomes of an Independent Clinical Study to Compare Branded and Generic Formulations of Sustained-Release Oxycodone]. Aoyama, Y; Nawa, T; Okawa, M; Onodera, Y; Saito, Y; Shimizu, K; Yamamoto, M; Yamamoto, Y, 2017)	0.46
"159 mg/kg, can be useful to adjust the dosage of IV oxycodone for maintain stable BP during induction of general anesthesia."	( Optimal dose of intravenous oxycodone for attenuating hemodynamic changes after endotracheal intubation in healthy patients: A randomized controlled trial. Baek, CW; Jung, YH; Kang, H; Lee, OH; Lee, SH; Park, YH; Shin, HY; Woo, YC, 2017)	0.46
" This literature review reveals that variants in ABCB1, OPRM1, and COMT have been replicated for opioid dosing and variants in ABCB1 have been replicated for both treatment response and adverse effects."	( Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl. Hall, C; Hotham, E; Lloyd, RA; Suppiah, V; Williams, M, 2017)	0.46
" Additional endpoints assessed at every visit were the impact of pain on quality of life (QoL), breakthrough cancer pain (BTCP) episodes, opioid dosage escalation index, bowel dysfunction, safety, and other side effects."	( High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. Amato, F; Ceniti, S; Consoletti, L; Magaldi, D; Mameli, S; Marcassa, C; Notaro, P; Palmieri, V; Pisanu, GM; Vellucci, R, 2017)	0.46
" Daily dosage of OXN-PR slightly increased (T0: 81."	( High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. Amato, F; Ceniti, S; Consoletti, L; Magaldi, D; Mameli, S; Marcassa, C; Notaro, P; Palmieri, V; Pisanu, GM; Vellucci, R, 2017)	0.46
") dose-dependently decreased oxycodone self-administration, and shifted the oxycodone dose-response curve downward."	( The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats. Bi, GH; Boateng, C; Cao, J; Gao, JT; Gardner, EL; He, Y; Newman, AH; Xi, ZX; You, ZB, 2017)	0.46
"Plasma profiles of OOD reveal sustained concentrations of oxycodone over the complete dosing interval of 24 hours."	( Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet . Gschwind, YJ; Guth, V; Kovacs, P; Maritz, MA; Rey, H; Scheidel, B; Steigerwald, K, 2017)	0.46
"The new 10-mg OOD formulation provides sustained oxycodone plasma concentrations over the dosing interval of 24 hours and is suitable for once-daily administration."	( Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet . Gschwind, YJ; Guth, V; Kovacs, P; Maritz, MA; Rey, H; Scheidel, B; Steigerwald, K, 2017)	0.46
" Dissolution was assessed for intact and crushed dosage forms."	( In Vitro Drug Release After Crushing: Evaluation of Xtampza Fleming, AB; Mayock, SP; Saim, S, 2017)	0.46
"Intact formulations exhibited drug release rates characteristic of 12- or 24-h dosage forms."	( In Vitro Drug Release After Crushing: Evaluation of Xtampza Fleming, AB; Mayock, SP; Saim, S, 2017)	0.46
" As such, Xtampza ER may be less appealing to abusers and offer a margin of safety for patients who manipulate dosage forms to facilitate swallowing."	( In Vitro Drug Release After Crushing: Evaluation of Xtampza Fleming, AB; Mayock, SP; Saim, S, 2017)	0.46
" Further research to assess adverse events and other dosing may be warranted."	( Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial. Baer, J; Barnaby, DP; Bijur, PE; Chang, AK; Esses, D, 2017)	0.46
" Vaccination shifted the dose-response curves to the right, representing protection, for each of these endpoints."	( Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. Baruffaldi, F; Carroll, FI; Comer, SD; Langston, TL; Laudenbach, M; Navarro, HA; Pentel, PR; Peterson, SJ; Pravetoni, M; Raleigh, MD; Runyon, SP; Winston, S, 2017)	0.46
" Univariate and multivariable regressions were used to examine the influence of dosage strength, drug formulation, and bulk purchasing on street price."	( Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Bau, GE; Dart, RC; Dasgupta, N; Lebin, JA; Murphy, DL; Severtson, SG, 2019)	0.51
" For a 2-fold increase in dosage strength, there is a 24."	( Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Bau, GE; Dart, RC; Dasgupta, N; Lebin, JA; Murphy, DL; Severtson, SG, 2019)	0.51
"Haemodialysis performed 6-10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone."	( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019)	0.51
" Because of its strong analgesic activity and dosage form, fentanyl has become one of the first choices for severe and moderate pain in clinical practice."	( Comparison of the use of different analgesics in the course of anesthesia care based on pharmacoeconomics. Jing, C; Ping, Y; Qing, J, 2018)	0.48
" The dosage of oxycodone in GG genotype was significantly higher than that in AA genotype and AG genotype (15."	( [Relationship of OPRM1 118A/G gene polymorphism and oxycodone analygesic dose in paitents with cancer pain]. Bie, M; Li, X; Lin, T; Song, J; Zhang, C, 2018)	0.48
" VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior."	( Dopamine D Bi, GH; Cao, J; Gadiano, A; Galaj, E; Gardner, EL; Kumar, V; Newman, AH; Rais, R; Slusher, BS; Xi, ZX; You, ZB, 2019)	0.51
"001) and significantly decreased sufentanil dosage within 6h ( P= ."	( Intra-operative Oxycodone Reduced Postoperative Catheter-Related Bladder Discomfort Undergoing Transurethral Resection Prostate. A Prospective, Double Blind Randomized Study. Chen, X; Li, J; Liu, S; Weng, C; Xiong, J, 2019)	0.51
" A strong consensus was achieved regarding which pharmacological treatment (transmucosal fentanyl) and dosing method (start low and go slow) are the most suitable for the older population."	( Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. Alarcón, MDL; Cabezón-Gutiérrez, L; Estévez, FV; Jiménez-López, AJ; Martín-Arroyo, JMT; Padrós, MC; Rebollo, MA; Sanz-Yagüe, A, 2019)	0.51
" A dose-response trend was observed for constipation but not for the other side effects."	( Side effects from opioids used for acute pain after emergency department discharge. Castonguay, V; Chauny, JM; Cournoyer, A; Daoust, R; Lessard, J; Morris, J; Paquet, J; Piette, É; Williamson, D, 2020)	0.56
" Furthermore, enduring exacerbation of nociceptive hypersensitivity is also observed when the same dosing regimen for either morphine, fentanyl, or oxycodone begins 1 month after nerve injury."	( Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats. Ball, JB; Fabisiak, T; Grace, PM; Green-Fulgham, SM; Kwilasz, AJ; Maier, SF; Watkins, LR, 2019)	0.51
" CYP3A4*1G polymorphism related to postoperative VAS score, medication dosage and prevalence of adverse reactions in sufentanil group (p<0."	( Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer. He, XY; Huang, ZK; Pu, J; Wang, N; Yuan, HB, 2019)	0.51
" All 9 interventions significantly reduced at least one of the following: high-risk agent use including meperidine use by up to 71%; total or daily dosage of opioids at discharge, including median morphine milligram equivalence (MME) from 90 mg to 45 mg per patient; and quantity of medications such as oxycodone supplied to patients, halved in one study from 6,170 expected to 2,932 supplied tablets."	( Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review. Arnold, C; Bui, T; Dooley, M; Hopkins, RE; Magliano, D, 2019)	0.51
" We sought to evaluate the effectiveness and safety of over the counter dosing of ibuprofen on pain and bleeding rates following ESS."	( Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. Davis, GE; Humphreys, IM; Miller, C, 2020)	0.56
"Over the counter dosing of ibuprofen along with acetaminophen may yield better pain control after sinus surgery compared to acetaminophen alone."	( Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. Davis, GE; Humphreys, IM; Miller, C, 2020)	0.56
" Moreover, there is scant literature on the efficacy of around-the-clock (ATC) scheduled dosing of opioid analgesia compared to pro re nata (PRN; as-needed) dosing for postpartum pain management."	( Scheduled versus as-needed postpartum analgesia and oxycodone utilization. Blitz, MJ; Marchbein, H; Palleschi, GT; Pappas, K; Prasannan, L; Rochelson, B; Stoffels, GJ, 2022)	0.72
"Our aim was to determine how inpatient oxycodone use is affected by as-needed compared to ATC scheduled dosing of acetaminophen, ibuprofen, and low-dose oxycodone, with the option to decline any of these medications."	( Scheduled versus as-needed postpartum analgesia and oxycodone utilization. Blitz, MJ; Marchbein, H; Palleschi, GT; Pappas, K; Prasannan, L; Rochelson, B; Stoffels, GJ, 2022)	0.72
" In month 21 of the 48-month study period, a new institutional protocol for postpartum pain management was implemented which consisted of scheduled dosing of a multimodal analgesic regimen."	( Scheduled versus as-needed postpartum analgesia and oxycodone utilization. Blitz, MJ; Marchbein, H; Palleschi, GT; Pappas, K; Prasannan, L; Rochelson, B; Stoffels, GJ, 2022)	0.72
"After cesarean delivery, scheduled multimodal analgesia that includes ATC dosing of acetaminophen, ibuprofen, and low-dose oxycodone, with the option to decline any of these medications, does not increase the percentage of women who receive oxycodone or mean oxycodone consumption per inpatient day compared to as-needed analgesia."	( Scheduled versus as-needed postpartum analgesia and oxycodone utilization. Blitz, MJ; Marchbein, H; Palleschi, GT; Pappas, K; Prasannan, L; Rochelson, B; Stoffels, GJ, 2022)	0.72
" Fast and accurate determination of oxycodone blood concentration would enable personalized dosing and monitoring of the analgesic as well as quick diagnostics of possible overdose in emergency care."	( Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes. Jiang, H; Kalso, E; Kauppinen, EI; Koskinen, J; Laurila, T; Lilius, T; Mikladal, B; Mynttinen, E; Sainio, S; Varjos, I; Wester, N, 2020)	0.56
" An efficient and sensitive method to measure multiple serum drugs and metabolites could inform drug dosing in polypharmacy."	( Quantification of serum levels in mice of seven drugs (and six metabolites) commonly taken by older people with polypharmacy. Hilmer, SN; Mach, J; Wang, X, 2021)	0.62
" Of these, 10 were caused by dosing errors and 4 probably contributed to patients' death."	( Nature of adverse events with opioids in hospitalised patients: a post-hoc analysis of three patient record review studies. de Bruijne, M; Jongerden, I; Klopotowska, JE; Langelaan, M; Moesker, M; Schutijser, BCFM; Wagner, C, 2020)	0.56
" Future interventions should focus on safe dosing of opioids when prescribing and administering, especially in elderly patients."	( Nature of adverse events with opioids in hospitalised patients: a post-hoc analysis of three patient record review studies. de Bruijne, M; Jongerden, I; Klopotowska, JE; Langelaan, M; Moesker, M; Schutijser, BCFM; Wagner, C, 2020)	0.56
"This nationwide study aimed to compare use of oxycodone and doctor shopping for oxycodone in 2010 and 2016, and to quantify doctor shopping for oxycodone by sex, age, formulation, and dosage in 2010 and 2016."	( Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Lapeyre-Mestre, M; Micallef, J; Pradel, V; Soeiro, T, 2021)	0.62
" Herein we evaluate the effects of acute and repeated dosing of SR-17018, oxycodone and morphine in additional models of pain-related behaviors."	( Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain. Acevedo-Canabal, A; Bannister, TD; Bohn, LM; Cameron, MD; Grim, TW; Kennedy, NM; Pantouli, F; Schmid, CL, 2021)	0.62
"Proportions of BZD coprescribing, BZD dosing patterns in matched patients, and the esti-mated number of lives potentially saved by the opioid treatment switch."	( Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment-A retrospective claims analysis. DeGeorge, M; Imro, M; Passik, SD; Tatovic, S; Vukicevic, D; Zah, V, )	0.13
"032 mg/kg/inf) on a fixed ratio 1 (FR1) schedule of reinforcement and (2) compare full dose-response curves for MDPV and oxycodone self-administration under an FR5 schedule of reinforcement."	( MDPV "high-responder" rats also self-administer more oxycodone than their "low-responder" counterparts under a fixed ratio schedule of reinforcement. Gannon, BM; Murnane, KS; Rice, KC, 2021)	0.62
" High levels of timeout responding were noted in a subset of rats that acquired MDPV self-administration ("high-responders", n = 5), and the FR5 dose-response curve for MDPV was shifted upward for these rats relative to their "low-responder" (n = 6) counterparts."	( MDPV "high-responder" rats also self-administer more oxycodone than their "low-responder" counterparts under a fixed ratio schedule of reinforcement. Gannon, BM; Murnane, KS; Rice, KC, 2021)	0.62
" The primary endpoint was the total dosage of oxycodone."	( Changes of Opioid Consumption After Lumbar Fusion Using Ultrasound-Guided Lumbar Erector Spinae Plane Block: A Randomized Controlled Trial. Chen, L; Li, J; Wang, M; Wang, X; Wang, Y; Zhu, L, 2021)	0.62
"In Japan, 14 opioids with a variety of dosage forms, such as oral preparation, injection, transdermal patch, transmucosal and suppository are clinically available as analgesics, and their use properly depends on the type and degree of pain and patient condition."	( [Current status and issues in clinical use of opioids]. Nakagawa, T, 2021)	0.62
" This study was designed to simulate dosing and stock check procedures for oxycodone oral solution, as a sample CD solution, and evaluate where the volume losses that cause discrepancies could arise from."	( Reduction of oral liquid controlled drugs discrepancy in day-to-day practice. Fox, A; Mohanasundaram, S; Roldo, M; Rutter, P; Wood, K, 2021)	0.62
" These were used to simulate dosing and stock check practices."	( Reduction of oral liquid controlled drugs discrepancy in day-to-day practice. Fox, A; Mohanasundaram, S; Roldo, M; Rutter, P; Wood, K, 2021)	0.62
"During dosing with tapentadol, gastrointestinal side effects and motility parameters were on placebo level."	( Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers. Drewes, AM; Frøkjaer, JB; Hansen, TM; Krogh, K; Mark, EB; Nedergaard, RB; Nissen, TD; Scott, SM, 2021)	0.62
" However, optimal dosing is a difficult task as current guidelines are based on an intact gastrointestinal tract."	( Oral absorption of oxycodone in patients with short bowel syndrome. Christrup, LL; Drewes, AM; Hestvang, J; Ladebo, L; Mikkelsen, MS; Olesen, AE; Rasmussen, HH; Vinter-Jensen, L, 2021)	0.62
" Still, optimal therapeutic dosing must be individualized, and other factors such as those related to malnutrition and motility shall also be taken into consideration."	( Oral absorption of oxycodone in patients with short bowel syndrome. Christrup, LL; Drewes, AM; Hestvang, J; Ladebo, L; Mikkelsen, MS; Olesen, AE; Rasmussen, HH; Vinter-Jensen, L, 2021)	0.62
" Prescriptions for OC vary based on the dosage and formulation, immediate release (IR) and controlled release (CR)."	( Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC-MS-MS. Chermà, MD; Gréen, H; Jakobsson, G; Kronstrand, R; Swortwood, MJ; Truver, MT, 2023)	0.91
" During the transition, she experienced some withdrawal in the setting of swallowed buprenorphine/naloxone tablets, which were intended to be dosed sublingually."	( Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report. DeFries, T; Leyde, S; Pratt, L; Suen, L, 2022)	0.72
" Thus, in order to adjust the dosage of OXY for well-managed pain relief with less toxicity, we tried establishing and validating a system for measuring plasma concentrations of OXY using liquid chromatography-tandem mass spectrometry (LC-MS/MS)."	( Establishment to measure oxycodone in plasma with liquid chromatography-tandem mass spectrometry. Ito, S; Kitaichi, K; Matsuo, M; Mori, M; Oida, Y; Soda, M; Yamasaki, R, 2022)	0.72
"En absence de changements cliniques ou biochimiques suggérant une aggravation de la fonction rénale, la cystatine C sérique a été mesurée par dosage immunoturbidimétrique."	( Abbasi, BA; Amaro-Estrada, I; Andreas, NS; Ariga, K; Bedrov, D; Bello, AK; Bouganim, N; Braam, B; Cao, Y; Capasso, R; Caro, AL; Chen, G; Chen, Y; Clark, MK; Cossio-Bayugar, R; Dong, D; Gao, D; Gao, T; Ghimire, A; Gul, F; Hamonic, LN; He, Y; Hill, JP; Hollebeek, LD; Hu, B; Iqbal, J; Jardan, YAB; Jiang, M; Jindal, K; John, B; Khan, I; Khan, M; Klarenbach, S; Kumar, V; Li, J; Li, L; Li, Z; Lin, H; Liu, C; Liu, HF; Liu, J; Liu, L; Liu, Z; Ma, R; Mach, T; Mahmood, T; Marath, U; Mathew, D; Mei, C; Muneer, S; Nakamura, J; Ni, H; Okpechi, IG; Padwal, R; Qi, A; Qin, Y; Renjitha, M; Ringrose, J; Scott-Douglas, N; Shahbaz, A; Shi, L; Shojai, S; Singh, SK; Slabu, D; Song, Y; Srivastava, RK; Sultana, N; Takeyasu, K; Tang, SS; Thompson, S; Tinwala, MM; Trinh, E; Valappil, SP; Wang, L; Wang, T; Wang, Y; Wu, W; Xi, H; Yang, M; Yang, Y; Ye, F; Yin, G; Yin, M; Yin, X; Yuan, XS; Zaidi, D; Zeng, L; Zhang, L; Zhang, Z; Zhang, ZC; Zheng, D, 2022)	0.72
" The other aim included the average blood pressure, heart rate, surgical pleth index, and bispectral index values fluctuation during the intraoperative period of expanding the medullary cavity, the sufentanil, and remifentanil consumption during the operation, the amount of time the patients stayed in the Postanesthesia Care Unit, the 8 hours, 16 hours, and 24 hours total dosage of oxycodone, the resting and exercise Visual Analog Scale (VAS) pain scores at 8 hours, 16 hours, and 24 hours after surgery, postoperative adverse events, and safety."	( Ultrasound-Guided Oblique Sagittal Anterior Quadratus Lumborum Block in Total Hip Arthroplasty: A Randomized Controlled Trial. Chen, L; Li, H; Ruan, B; Wang, M; Wang, N; Ye, W; Ying, T, 2022)	0.72
" The trials were short in duration (maximum length was 24 days) and only assessed safety and efficacy of a 12-h dosing interval."	( On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data. Bavli, I; Herder, M; Pappin, J, 2022)	0.72
" OPRM1 and COMT are receiving increasing attention and have implications for all opioids, with changes in opioid dosage requirements observed but they have not yet been studied widely enough to be considered clinically actionable."	( The Role of Pharmacogenomics in Opioid Prescribing. Philip, J; Rubio, J; Somogyi, AA; Wong, AK, 2022)	0.72
" This study aims to characterize the pharmacokinetic profile of oxycodone after intravenous administration and to simulate an appropriate dosage for analgesic efficacy in obese patients."	( Population Pharmacokinetics and Dosing Simulations of Intravenous Oxycodone for Perioperative Pain Relief in Adult Surgical Patients with Obesity. Chaw, SH; Haron, DEBM; Lo, YL; Shariffuddin, II; Yeap, LL, 2023)	0.91
" The intraoperative propofol dosage and the operative time of gastroscopy were recorded."	( Differential dosing of oxycodone in combination with propofol in diagnostic painless gastroscopy in elderly patients: A prospective randomized controlled trial. Li, YP; Zhou, Y, 2022)	0.72
" ITS analyses showed that immediately postrescheduling, quarterly hydrocodone dispensing decreased by 177M dosage units while codeine, oxycodone, and morphine dispensing increased by 49M, 62M, and 4M dosage units, respectively."	( The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths. Ajao, A; Chai, GP; Ding, Y; Gill, R; Karami, S; Major, JM; McAninch, J; Meyer, T; Secora, A; Wong, J; Zhang, D; Zhao, Y, 2023)	0.91
" Oxycodone increased as first prescribed opioid (from 44% to 85%) whereas tramadol decreased (64-11%), but their dosage remained stable (stronger opioids were preferred by prescribers)."	( Out-of-hospital opioid prescriptions after knee and hip arthroplasty: prescribers and the first prescribed opioid. Bouvy, ML; Dahan, A; Gademan, MGJ; Nelissen, RGHH; Rosendaal, FR; van Brug, HE; van Dorp, ELA; van Steenbergen, LN, 2023)	0.91
"0-10 mg/kg) were studied in combination with the peak oxycodone dose and a dose on the descending limb of the dose-effect curve; NTX and (±)VK4-40 were also studied at the peak of the PR dose-response curve (N = 4)."	( Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys. Allen, MI; Banks, ML; Cornelissen, JC; Nader, MA; Newman, AH; Woodlief, K, 2023)	0.91
" The index of consciousness 2 was utilized to titrate the remifentanil dosage in all patients to ensure sufficient analgesia."	( Pre-incisional Preventive Precise Multimodal Analgesia May Enhance the Rehabilitation Process of Acute Postoperative Pain Following Total Laparoscopic Hysterectomy: A Randomized Controlled Trial. Feng, S; Qi, M; Wan, A; Wang, C; Wang, S; Wang, T; Xiao, W; Yang, S; Yao, D; Zhou, L, 2023)	0.91
" By combining with clinical data such as age, sex, dosage and duration of medication, the effect of gene polymorphism on the ADR of patients after taking opioid drugs was statistically analysed."	( Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study. Fu, Z; Guan, YY; Li, QF; Song, C; Sun, YZ; Yang, J; Zheng, L, 2023)	0.91

Role	Description
opioid analgesic	A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonist	A compound that exhibits agonist activity at the mu-opioid receptor.
antitussive	An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organic heteropentacyclic compound
semisynthetic derivative	Any organic molecular entity derived from a natural product by partial chemical synthesis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Oxycodone Action Pathway	31	11

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	2,003.7800	0.2100	5.5537	10.0000	AID1526751
Acetylcholinesterase	Electrophorus electricus (electric eel)	IC50 (µMol)	76.2000	0.0000	0.9453	9.9400	AID514203
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	1.0870	0.0000	0.6068	9.2330	AID239360
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0436	0.0000	0.3845	8.6000	AID239089
Kappa-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	2.6580	0.0000	0.1868	3.9500	AID239148
Mu-type opioid receptor	Homo sapiens (human)	Ki	0.0120	0.0000	0.4197	10.0000	AID1558955; AID1681778; AID1811101
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	76.2000	0.0003	0.7123	7.0700	AID514203
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0009	1.9014	10.0000	AID1681774
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	10.0000	0.0000	0.4901	10.0000	AID1558961; AID1681775; AID1811100
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Kappa-type opioid receptor	Mus musculus (house mouse)	EC50 (µMol)	16.0000	0.0008	0.8056	4.8860	AID765837
Mu-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.1378	0.0000	0.3263	9.4000	AID1558957; AID1681777; AID1811102; AID765841
Delta-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	4.0000	0.0000	0.4332	8.3000	AID765842
Kappa-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	16.0000	0.0000	0.2244	8.9900	AID765840
Mu-type opioid receptor	Mus musculus (house mouse)	EC50 (µMol)	0.1600	0.0002	0.0393	0.2030	AID765836
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
immune response	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Delta-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
adult locomotory behavior	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Delta-type opioid receptor	Homo sapiens (human)
response to nicotine	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
eating behavior	Delta-type opioid receptor	Homo sapiens (human)
regulation of mitochondrial membrane potential	Delta-type opioid receptor	Homo sapiens (human)
regulation of calcium ion transport	Delta-type opioid receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Delta-type opioid receptor	Homo sapiens (human)
cellular response to hypoxia	Delta-type opioid receptor	Homo sapiens (human)
cellular response to toxic substance	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)
eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
response to estrogen	Kappa-type opioid receptor	Homo sapiens (human)
estrous cycle	Kappa-type opioid receptor	Homo sapiens (human)
response to ethanol	Kappa-type opioid receptor	Homo sapiens (human)
regulation of saliva secretion	Kappa-type opioid receptor	Homo sapiens (human)
behavioral response to cocaine	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of temperature stimulus	Kappa-type opioid receptor	Homo sapiens (human)
defense response to virus	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to glucose stimulus	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of p38MAPK cascade	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Kappa-type opioid receptor	Homo sapiens (human)
response to acrylamide	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
conditioned place preference	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Mus musculus (house mouse)
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Mus musculus (house mouse)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1526832	Ratio of unbound Cmax in human at 5 mg, po dosed as immediate release formulation to inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1681777	Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1681778	Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1558982	Antinociceptive activity in orally dosed mouse assessed as reduction in mechanical nociception measured after 30 mins post dose by paw pressure pain test	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID514209	Inhibition of electric eel AChE at 500 uM by Ellman's method	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID604021	Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604024	Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1195147	Analgesic activity in Swiss albino mouse assessed as latancy of withdrawing tail at 100 mg/kg, po measured after 2 hrs by tail flick test relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1562939	Agonist activity at MOR in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1526826	Unbound maximal portal vein concentration of in human at 10 mg, po dosed as controlled release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID604023	Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1558955	Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1195156	Gastrointestinal toxicity in Swiss albino mouse assessed as ulcer index at 100 mg/kg, po measured after 2 hrs	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1562911	Displacement of [3H]WIN-55,212-2 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID514204	Displacement of [3H]DAMGO from mu opioid receptor in rat brain membrane	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1562923	Effect on nociception of the contralateral paw in rat model of sodium iodoacetate-induced osteoarthritis paw withdrawal threshold in early phase at 20 ug administered as intrathecal injection measured up to 45 mins by Von Frey test (Rvb = 44 +/- 2.4 g)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1526824	Cmax in human at 10 mg, po dosed as controlled release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID178325	Compound was tested for antinociceptive activity in heat stimulus rat tail flick assay after subcutaneous administration of the drug	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Analgesic narcotic antagonists. 8. 7 alpha-Alkyl-4,5 alpha-epoxymorphinan-6-ones.
AID128214	Narcotic agonistic activity in acetic acid mouse writhing assay after subcutaneous administration of the drug	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Analgesic narcotic antagonists. 8. 7 alpha-Alkyl-4,5 alpha-epoxymorphinan-6-ones.
AID1526733	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.5 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID765838	Selectivity ratio of EC50 for human KOR to EC50 for human DOR	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1811103	Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay relative to DAMGO	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1811139	Antinociceptive activity in CD-1 mouse at 10 mg/kg, ip	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1526830	Unbound Cmax in human at 5 mg, po dosed as immediate release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1562903	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1211698	Transactivation of human CAR1 transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1558961	Displacement of [3H]-(+)-pentazocine from human sigma-1 receptor expressed in HEK293 membranes incubated for 120 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID239360	Displacement of [3H[Ile5,6]-deltorphin II from delta opioid receptor of rat brain membranes	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID246957	In vivo analgesic effect (sc) assessed as antinociceptive potency by hot plate test in mice	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID1216211	Unbound brain to plasma concentration ratio in rat	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1562931	Agonist activity at MOR/CB1R/CB2R receptor in Wistar rat brain membranes at 10 uM after 60 mins by [35S]-GTPgammaS binding assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1681774	Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1211701	Transactivation of human CAR1 Ala retention mutant transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID765833	Activation of human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay relative to DAMGO	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1195148	Analgesic activity in Swiss albino mouse assessed as time of licking paws at 50 mg/kg, po measured after 2 hrs by tail flick test relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID765840	Agonist activity at human KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1681776	Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay relative to DAMGO	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID765837	Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1681746	Antinociceptive activity in CD1 mouse PSNL model assessed as reduction in mechanical allodynia by measuring decrease in the pressure required to elicit withdrawal of the ipsilateral paw after von Frey filament stimulation at 1.25 mg/kg, ip BID for 11 days	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID765842	Agonist activity at human DOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID514205	Displacement of [3H][Ile5,6]deltorphin2 from delta opioid receptor in rat brain membrane	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1211703	Transactivation of human CAR1 transfected in human primary hepatocytes assessed as nuclear translocation at 30 uM by confocal laser scanning microscopy	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1195151	Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID765828	Activation of mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay relative to U69593	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID604025	Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1209582	Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1526827	Ratio of unbound Cmax in human at 10 mg, po dosed as controlled release formulation to inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1562937	Agonist activity at MOR in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1526829	Cmax in human at 5 mg, po dosed as immediate release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1562927	Antiallodynic activity in sodium iodoacetate-induced rat model of osteoarthritis assessed as increase in maximum effect in early phase at 20 ug administered as intrathecal injection measured up to 45 mins by Von Frey test	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID514203	Inhibition of electric eel AChE by Ellman's method	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1558984	Induction of constipation in mouse assessed as effect on intestinal transit at 10 mg/kg, po dosed 30 mins before charcoal suspension dosing and measured after 30 mins	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1811134	Antinociceptive activity in CD-1 mouse model of partial sciatic nerve ligation-induced neuropathic pain assessed as reduction in allodynia by measuring maximum efficacy at 1.25 mg/kg, ip administered for 10 days	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1562929	Antiallodynic activity in sodium iodoacetate-induced rat model of osteoarthritis assessed as reduction in maximum effect in late phase at 20 ug administered as intrathecal injection measured up to 60 to 90 mins by Von Frey test	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID247014	In vivo analgesic effect (sc) assessed as antinociceptive potency by p-phenylquinone writhing test in mice	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID765830	Activation of mouse MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay relative to DAMGO	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1811100	Displacement of [3H]-(+)-pentazocine from human sigma-1 receptor transfected in HEK293 membranes incubated for 120 mins measured by microBeta scintillation counter method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1526833	Ratio of unbound maximal portal vein concentration in human at 5 mg, po dosed as immediate release formulation to inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1149090	Analgesic activity in po dosed mouse by Nilsen assay	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Optical resolution of (+/-)-2,5-dimethyl-2'-hydroxy-9alpha- and -9beta-propyl-6,7-benzomorphans and their pharmacological properties.
AID1209581	Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1211697	Transactivation of human AhR at 0.1 to 30 uM after 24 to 48 hrs by cell-based luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID624608	Specific activity of expressed human recombinant UGT1A4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID239148	Displacement of [3H]U-69593 from kappa opioid receptor of rat brain membranes	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID1526831	Unbound maximal portal vein concentration of in human at 5 mg, po dosed as immediate release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1195149	Analgesic activity in Swiss albino mouse assessed as time of licking paws at 100 mg/kg, po measured after 2 hrs by tail flick test relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1681775	Displacement of 3H](+)-pentazocine from human sigma1 receptor expressed in HEK293 cell membranes incubated for 120 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1195155	Gastrointestinal toxicity in Swiss albino mouse assessed as ulcer index at 50 mg/kg, po measured after 2 hrs	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1526828	Ratio of unbound maximal portal vein concentration in human at 10 mg, po dosed as controlled release formulation to inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1558960	Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay relative to DAMGO	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1562910	Selectivity ratio of Ki for displacement of [3H]HS-665 from KOR in guinea pig brain membranes to Ki for displacement of [3H]DAMGO from MOR in Wistar rat brain membranes	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562906	Displacement of [3H]DAMGO from MOR in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562908	Displacement of [3H]HS-665 from KOR in guinea pig brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1526731	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1562909	Selectivity ratio, ratio of Ki for displacement of [3H]Ile5,6-deltorphin-2 from DOR in Wistar rat brain membranes to Ki for displacement of [3H]DAMGO from MOR in Wistar rat brain membranes	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1681742	Toxicity in CD1 mouse assessed as inhibition of intestinal transit by measuring percentage of distance traveled by charcoal meal at 20 mg/kg, po	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID765839	Selectivity ratio of EC50 for human KOR to EC50 for human MOR	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1558957	Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID246962	In vivo analgesic effect (sc) assessed as antinociceptive potency by tail flick test in mice	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID1681767	Displacement of 3H](+)-pentazocine from human sigma1 receptor expressed in HEK293 cell membranes at 10 uM incubated for 120 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1209583	Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1562907	Displacement of [3H]Ile5,6-deltorphin-2 from DOR in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1558962	Displacement of [3H]-(+)-pentazocine from human sigma-1 receptor expressed in HEK293 membranes at 10 uM incubated for 120 mins by liquid scintillation counting method relative to control	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1195150	Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1681772	Inhibition of human ERG expressed in CHO cells at 10 uM at -80 mV holding potential by whole cell patch clamp assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1211696	Transactivation of rat PXR at 0.1 to 30 uM after 24 to 48 hrs by cell-based luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1562912	Agonist activity at MOR/CB1R/CB2R receptor in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID244397	Selectivity ratio of binding affinities for kappa versus mu opioid receptors	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1562924	Effect on nociception of the contralateral paw in rat model of sodium iodoacetate-induced osteoarthritis paw withdrawal threshold in late phase at 20 ug administered as intrathecal injection measured after 60 to 90 mins by Von Frey test (Rvb = 43 +/- 3.4	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID514206	Displacement of [3H]U69593 from kappa opioid receptor in guinea pig brain membrane	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID765832	Activation of human DOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay relative to DPDPE	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID624616	Specific activity of expressed human recombinant UGT2B15	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID604020	Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID765836	Agonist activity at mouse MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID1209593	Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID244396	Selectivity ratio of binding affinities for delta versus mu opioid receptors	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID514207	Selectivity ratio of Ki for delta opioid receptor in rat brain to mu opioid receptor in rat brain	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1811137	Toxicity in CD-1 mouse assessed as intestinal transit reduction at 10 mg/kg, ip by measuring charcoal distance travel by charcoal meal test	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1195146	Analgesic activity in Swiss albino mouse assessed as latancy of withdrawing tail at 50 mg/kg, po measured after 2 hrs by tail flick test relative to control	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID1811131	Analgesic activity in ip dosed CD-1 mouse acute pain model by paw pressure test	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1526732	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.1 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1811101	Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1211695	Transactivation of human PXR transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM by luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID239089	Displacement of [3H]DAMGO from mu opioid receptor of rat brain membranes	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID765831	Activation of human KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay relative to U69593	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID604022	Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1526751	Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1526752	Passive membrane permeability by LC-MS/MS analysis based PAMPA	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1811102	Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID765841	Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID514208	Selectivity ratio of Ki for kappa opioid receptor in guinea pig brain to mu opioid receptor in rat brain	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1811132	Analgesic activity in CD-1 mouse acute pain model assessed as maximum efficacy at 2.5 to 20 mg/kg, ip by paw pressure test	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1211699	Transactivation of mouse CAR1 transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1526825	Unbound Cmax in human at 10 mg, po dosed as controlled release formulation	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	98 (3.67)	18.7374
1990's	119 (4.46)	18.2507
2000's	542 (20.32)	29.6817
2010's	1331 (49.91)	24.3611
2020's	577 (21.63)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	744 (25.73%)	5.53%
Reviews	215 (7.43%)	6.00%
Case Studies	282 (9.75%)	4.05%
Observational	67 (2.32%)	0.25%
Other	1,584 (54.77%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (436)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo-and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared With Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users [NCT05567354]	Phase 1	27 participants (Actual)	Interventional	2022-06-10	Completed
Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery [NCT02238340]	Phase 4	40 participants (Actual)	Interventional	2012-03-31	Completed
Phase I Study Assessing Safety of Intraperitoneal Chemotherapy in Neoadjuvant Treatment of Peritoneal Carcinomatosis of Colorectal Origin [NCT03253133]	Phase 1	19 participants (Actual)	Interventional	2016-05-10	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo And Active Comparator Controlled 4-Period Cross-Over Study To Assess The Effect Of PF-04531083 On Heat Pain In The UVB-Induced Pain Model In Healthy Volunteers [NCT01127906]	Phase 1	36 participants (Actual)	Interventional	2010-06-30	Completed
Neurobehavioral Mechanisms of Choice in Opioid Use Disorder [NCT03958474]	Early Phase 1	31 participants (Anticipated)	Interventional	2019-08-16	Recruiting
Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain [NCT00312221]	Phase 3	418 participants (Actual)	Interventional	2004-04-30	Terminated(stopped due to terminated early for administrative reasons unrelated to safety or efficacy)
Comparison of Analgesic Efficacy of Morphine Sulfate Immediate Release (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet) for Acute Pain in Emergency Department Patients [NCT03088826]	Phase 2	80 participants (Actual)	Interventional	2017-08-18	Completed
Opioid Analgesia for MAB: A Randomized Controlled Trial [NCT03139240]	Phase 4	172 participants (Actual)	Interventional	2017-05-01	Completed
Multi-institutional, Randomized Controlled Trial Assessing Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery [NCT03783702]	Phase 4	118 participants (Actual)	Interventional	2019-04-04	Completed
A Clinical, Multicenter, Randomized, Parallel-group, Double-dummy, Comparative Study of Non-inferiority of the Fixed-dose Combination of Oxycodone 5 mg/Ibuprofen 400 mg From Eurofarma Versus Tylex® (Codeine 30 mg/Paracetamol 500 mg) in the Treatment of Mo [NCT05081102]	Phase 3	288 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery: a Randomized Control, Double-blinded, Factorial Design Trial [NCT05795478]		264 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
Effect of Ketorolac Administration on Post-operative Narcotic Utilization and Union Rates in Great Toe Arthrodesis [NCT05054868]	Phase 1	40 participants (Anticipated)	Interventional	2020-04-14	Recruiting
Study of Ketorolac Versus Opioid for Pain After Endoscopy (SKOPE): A Double-blinded Randomized Control Trial Comparing Outpatient Analgesic Efficacy of NSAIDs and Opioids in Patients Undergoing Ureteroscopy for Kidney Stones [NCT03888144]	Phase 4	81 participants (Actual)	Interventional	2017-10-13	Completed
Adjunctive Oral Analgesia for Laceration Repair: Assessing Pain in a Pediatric Emergency Department [NCT01268670]		150 participants (Anticipated)	Interventional	2012-07-31	Suspended(stopped due to This study is currently suspended due to transition of the investigator.)
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain [NCT01179828]	Phase 3	150 participants (Actual)	Interventional	2010-07-31	Completed
Post-operative Pain Control After Photorefractive Keratectomy Comparing Acetaminophen/Codeine vs Acetaminophen/Oxycodone [NCT04399122]	Phase 4	200 participants (Actual)	Interventional	2017-03-21	Completed
Population Pharmacokinetic-Pharmacodynamic Study of Intravenous Oxycodone in Malaysian Population [NCT02728648]	Phase 4	33 participants (Actual)	Interventional	2016-04-30	Completed
Post Operative Analgesia After Pediatric Hip Surgery - PCA, Epidural or Lumbar Plexus Catheter: A Prospective Randomized Control Trial [NCT03435692]		42 participants (Actual)	Interventional	2011-07-15	Terminated(stopped due to Funding was exhausted prior to enrolling intended number of patients.)
Pre vs. Postoperative Adductor Canal Block for Total Knee Arthroplasty: Prospective Randomized Trial [NCT05974501]	Phase 4	84 participants (Anticipated)	Interventional	2023-09-29	Recruiting
[NCT01109511]	Phase 4	85 participants (Actual)	Interventional	2010-03-01	Completed
An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain [NCT01167699]	Phase 3	174 participants (Actual)	Interventional	2009-06-30	Completed
An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due [NCT01197261]	Phase 2	120 participants (Actual)	Interventional	2010-09-30	Completed
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets [NCT01100086]	Phase 1	84 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin® [NCT02454712]	Phase 1	64 participants (Actual)	Interventional	2016-11-16	Completed
Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial [NCT02455726]		150 participants (Anticipated)	Interventional	2015-09-30	Not yet recruiting
A Study Examining the Pharmacodynamics Interaction Between Buprenorphine and Fentanyl [NCT03747341]	Phase 1	22 participants (Actual)	Interventional	2018-03-22	Completed
A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 in Subjects Undergoing Complete Abdominoplasty [NCT03789318]	Phase 2	54 participants (Actual)	Interventional	2018-12-03	Completed
Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing: an Exploratory Study in Healthy Volunteers (The Polo Study) [NCT05598905]	Phase 4	24 participants (Anticipated)	Interventional	2022-10-10	Recruiting
Open-Label Parallel Group Flexible Dosing & Titration Study to Evaluate the Efficacy, Safety of Oxycodone/APAP Extended Release Formulation Xartemisxr® in the Management of Post-Operative Pain Following Outpatient Arthroscopic Knee Surgery [NCT02391844]	Phase 4	50 participants (Actual)	Interventional	2014-05-31	Completed
A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment of Dose of Tapentadol Extended-Release (ER) and Oxycodone Controlled-Release (CR) in Subjects With Chronic, Painful Diabetic Peripheral Neu [NCT01063868]	Phase 3	47 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to Business decision)
Avoiding Adverse Opioid Outcomes With Proactive Precision Care Following Cesarean Delivery [NCT05280743]		341 participants (Actual)	Observational	2022-03-28	Active, not recruiting
Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes [NCT02932579]	Phase 4	59 participants (Actual)	Interventional	2017-07-01	Terminated(stopped due to Study was halted permanently due to enrollment and logistic issues.)
A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain [NCT03254459]	Phase 2	100 participants (Actual)	Interventional	2017-09-12	Completed
Multimodal Anesthesia and Analgesia for Total Shoulder and Reverse Total Shoulder Arthroplasty: A Randomized Controlled Trial [NCT03586934]	Phase 3	0 participants (Actual)	Interventional	2018-06-01	Withdrawn(stopped due to Difficult to enroll patients for the study)
Abuse Liability of Controlled-Release Oxycodone Formulations [NCT02101840]	Phase 4	11 participants (Actual)	Interventional	2014-02-28	Completed
Efficacy of Erector Spinae Plane (ESP) Blockade in Patients Scheduled for Minimally Invasively Mitral Valve Replacement [NCT03415555]	Phase 4	19 participants (Actual)	Interventional	2018-02-07	Completed
Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals [NCT02136784]		12 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Prospective Controlled Study of Surgical Management of Unstable Thoracic Cage Injuries and Chest Wall Deformity in Trauma [NCT02132416]		92 participants (Actual)	Interventional	2014-05-31	Completed
Inhaled PPP001 Versus Immediate-release Oral Opioids for the Management of Breakthrough Pain in Cancer Subjects: a Randomized, Open Label, Crossover, Comparison Study [NCT03564548]	Phase 2	20 participants (Anticipated)	Interventional	2021-05-26	Recruiting
A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery [NCT01374763]	Phase 4	165 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Se [NCT01358526]	Phase 3	1,095 participants (Actual)	Interventional	2011-05-31	Completed
Influence of Medication on Functional Connectivity [NCT03612713]	Early Phase 1	21 participants (Actual)	Interventional	2018-10-30	Completed
An Open Label, Single Dose, Randomized, Two Way Crossover Study to Estimate Oxycodone Relative Bioavailability in Healthy Volunteers Following Administration of PF 00345439 Formulation K 40 Mg Under Fasting Conditions With 40% Ethanol Compared With Water [NCT02165930]	Phase 1	17 participants (Actual)	Interventional	2014-07-31	Completed
A Prospective, Randomized, Blind, Multicentre, Parallel Group Study to Investigate the Efficacy and Safety of Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment [NCT01304134]	Phase 3	240 participants (Actual)	Interventional	2010-03-31	Completed
Factors Affecting the Speed of Recovery After Anterior Cruciate Ligament Reconstruction [NCT03770806]		48 participants (Actual)	Interventional	2017-03-24	Completed
A Single-site, Randomized, Double-blind, Double-dummy, Active-comparator, Placebo-controlled, 3-way Crossover Trial in Adult Non-dependent Recreational Opioid Users to Compare the Intranasal Abuse Potential of Immediate Release Abuse-deterrent and Standar [NCT03765346]	Phase 1	123 participants (Actual)	Interventional	2018-07-24	Completed
A Randomized, Double-Blind, Double Dummy, 6-Period, Placebo-Controlled, Crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH), of Belbuca, Oxycodone Hydrochloride (HCl) and Placebo in Recreational Opioid Users [NCT03996694]	Phase 1	19 participants (Actual)	Interventional	2019-07-23	Completed
Ambulatory Gynecologic Surgery: Finding the Optimal Postoperative Opioid Prescription [NCT03588910]	Phase 2	120 participants (Actual)	Interventional	2018-08-08	Completed
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture [NCT01583660]		800 participants (Anticipated)	Observational	2012-01-31	Recruiting
Use of Oxycodone in Multimodel Perioperative Analgesia of Bariatric Surgery and Its Effect on Inflammatory Factors [NCT05515822]	Phase 4	90 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
The Effect of Oxycodone Hydrochloride on Catheter-related Bladder Discomfort After TURBT Under General Anesthesia [NCT05510986]		196 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia [NCT03120962]		140 participants (Anticipated)	Interventional	2017-05-31	Not yet recruiting
A Comparison of Analgesic and Respiratory Effects From Tapentadol Versus Oxycodone After Laparoscopic Hysterectomy. [NCT03314792]	Phase 4	86 participants (Actual)	Interventional	2017-12-04	Completed
Multimodal Nonopioid Pain Protocol Following Shoulder Arthroplasty Surgery [NCT05488847]	Phase 4	80 participants (Anticipated)	Interventional	2022-06-25	Recruiting
Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone in Female Patients Before Anesthesia Induction [NCT04396587]	Phase 4	80 participants (Actual)	Interventional	2020-05-20	Completed
A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Effects of Q8003 to the Morphine-Equivalent Doses of Oxycodone and of Morphine on the Opioid-Related Adverse Events of Moderate to Severe Nausea, Emesis, and Dizziness in Subjects Wi [NCT01280331]	Phase 3	375 participants (Actual)	Interventional	2011-01-31	Completed
An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty [NCT00818493]	Phase 2	44 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in SubjectsTreated With Tapentadol IR and Oxycodone IR Using a Bowel Fun [NCT00784277]	Phase 3	597 participants (Actual)	Interventional	2008-10-31	Completed
A Double-Blind, Randomized, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of the Opioid Combination Q8003 to Each of the Individual Milligram Components (Oxycodone and Morphine) in the Management of Acute Moderate to Severe Pa [NCT00831051]	Phase 2	197 participants (Actual)	Interventional	2008-12-31	Completed
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Pr [NCT00853216]	Phase 1	38 participants (Actual)	Interventional	2003-01-31	Completed
"GREAT (Good Response With Appropriate Treatment) Factors Influencing the Analgesic Response Over Time of the Oxycodone-Naloxone Association in Painful Cancer Patients" [NCT02293785]		200 participants (Actual)	Observational	2014-11-30	Completed
Randomised, Double-blind, Double-dummy, Cross-over Multicenter Study to Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Taking Oxycodone Equivalents of 120 & 160 mg Per Day as Achieved With the Higher OXN PR Tablet Strengths (OXN60/30 mg PR [NCT02321397]	Phase 2/Phase 3	155 participants (Actual)	Interventional	2014-11-30	Completed
Use of a Non-Opioid Pain Regimen for Post-Operative Analgesia Following Intracapsular Adenotonsillectomy [NCT04791761]	Phase 1/Phase 2	300 participants (Anticipated)	Interventional	2021-04-13	Recruiting
An Open-label, Single Centre Prospective Cohort Study to Determine the Effectiveness and Safety of Targin® for Pain Management and Opioid-induced Constipation in Patients With Spinal Cord Injury: Can we Improve Pain and Ameliorate Secondary Complications [NCT03179475]	Phase 4	1 participants (Actual)	Interventional	2019-09-05	Completed
A Phase 1b, Randomized 2-Part Single-Center Study to Evaluate the PK and Safety of Multiple Ascending Oral Doses of PF614 and the Food Effect and BA/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects [NCT05043766]	Phase 1	84 participants (Actual)	Interventional	2021-09-08	Completed
Adductor Canal Block With Liposomal Bupivacaine (Exparel) Versus Femoral Nerve Catheter for Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Trial [NCT05161221]	Phase 3	154 participants (Anticipated)	Interventional	2021-12-06	Enrolling by invitation
Sufentanil Sublingual Tablet System For Management Of Postoperative Pain In Enhanced Recovery After Surgery Pathway For Total Knee Arthroplasty: A Randomized Controlled Study [NCT04448457]		72 participants (Actual)	Interventional	2017-09-01	Completed
Neurotoxic Adverse Effects of Morphine and Oxycodone in Continuous Subcutaneous Infusion for Treatment of Pain in Terminal Patients With Diminished Renal Function: a Randomized Controlled Trial [NCT03616639]	Phase 4	8 participants (Actual)	Interventional	2018-06-04	Terminated(stopped due to Insufficient inclusion of subjects)
Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy [NCT03640247]	Phase 1	126 participants (Actual)	Interventional	2018-11-15	Completed
A COMPARATIVE STUDY BETWEEN TWO PHARMACOLOGICAL ASSOCIATIONS OXYCODONE/NALOXONE AND CODEINE / PARACETAMOL IN TREATMENT OF MODERATE-SEVERE CHRONIC PAIN DUE TO OSTEOARTHRITIS OF KNEE AND/OR HIP [NCT02032927]	Phase 4	0 participants (Actual)	Interventional	2013-06-30	Withdrawn
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population: A Randomized Controlled Trial [NCT06042426]	Phase 4	100 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
The Effects of Single Dose Oxycodone Versus Sufentanil on Pain and Inflammatory Response After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Randomized Controlled Study [NCT06041425]	Phase 4	40 participants (Anticipated)	Interventional	2023-08-07	Recruiting
Understanding Opioid Use Before and After Surgery in Norway: A Prospective Multicenter Study and Randomized Double-blind Controlled Study [NCT05639712]	Phase 4	1,000 participants (Anticipated)	Interventional	2022-12-13	Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
A Randomized, Open Label,Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP (Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain [NCT02101476]	Phase 4	114 participants (Actual)	Interventional	2014-05-31	Completed
Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints [NCT05846451]	Early Phase 1	16 participants (Anticipated)	Interventional	2023-06-01	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Single-Dose,4-Way Crossover Study With Exploratory Fifth Treatment to Determine the Relative Nasal Abuse Potential of PTI-821 (Oxycodone Extended-Release Capsules) [NCT03475862]	Phase 1	38 participants (Actual)	Interventional	2017-05-15	Completed
Comparison of Controlled-release Oxycodone to Control Chemoradiotherapy-induced Moderate or Severe Oral Mucositis Pain in Nasopharyngeal Carcinoma Patients [NCT03045484]		70 participants (Anticipated)	Interventional	2016-05-31	Recruiting
[NCT01366014]	Phase 2	157 participants (Actual)	Interventional	2011-06-30	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis [NCT01094262]	Phase 2	196 participants (Actual)	Interventional	2010-04-20	Terminated(stopped due to Logistic reasons associated with the FDA-imposed clinical hold.)
A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of Q8003 With Oxycodone and Morphine for the Management of Acute Moderate to Severe Postoperative Pain Following Bunionectomy Surgery [NCT01016808]	Phase 3	522 participants (Actual)	Interventional	2009-12-31	Completed
Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study [NCT02084355]	Phase 3	136 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
A Prospective Randomized Controlled Trial of Pain as Indication for Operative Treatment of Traumatic Rib Fractures. [NCT02094807]		0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to Slow inclusion rate. Awaiting results from NCT02132416.)
Decreasing Narcotics in Advanced Pelvic Surgery: A Randomized Study [NCT02110719]	Phase 4	138 participants (Actual)	Interventional	2014-03-31	Completed
An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study To Estimate The Effects Of Food On Oxycodone Pharmacokinetics Following Oral Administration Of 40 Mg Doses Of Pf 00345439 Formulation K Taken Whole Or After Chewing In Healthy Volunteers [NCT02117583]	Phase 1	34 participants (Actual)	Interventional	2014-04-30	Completed
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. [NCT02741076]	Phase 4	44 participants (Actual)	Interventional	2016-09-14	Terminated(stopped due to Inability to recruit sufficient no. of subjects over an acceptable time period)
Oxycodone Concentration in the Blood After Oral Premedication [NCT03386318]		20 participants (Actual)	Observational	2019-01-01	Completed
Prospective Randomized Trial of Narcotic vs Non-Narcotic Pain Modulation Following a Labrum Repair [NCT05974423]	Phase 4	60 participants (Anticipated)	Interventional	2022-12-16	Enrolling by invitation
Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia, a Randomized Controlled Trial [NCT03364088]		402 participants (Actual)	Interventional	2016-10-03	Completed
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (P [NCT01112644]	Phase 3	205 participants (Actual)	Interventional	2010-04-30	Completed
Comparison of Oxycodone and Sufentanil for Analgesic Efficacy After Hip Surgery: a Prospective, Multicenter Randomized Controlled Trial [NCT03685188]	Phase 4	570 participants (Anticipated)	Interventional	2018-12-01	Enrolling by invitation
Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery [NCT02295124]	Phase 4	200 participants (Actual)	Interventional	2012-08-31	Completed
Oxycodone (10, 20 mg) in a Postoperative Dressing in Patients After Surgical Debridement of Burn Wounds. A Prospective, Double-blinded, Randomized, Controlled Trial. [NCT06142591]	Phase 4	20 participants (Actual)	Interventional	2016-01-01	Completed
A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer [NCT03574792]		62 participants (Actual)	Interventional	2018-05-03	Completed
An Open Study to Observe OXN Treatment for Patients With Moderate to Severe Non-malignant Pain [NCT01167127]	Phase 3	113 participants (Actual)	Interventional	2009-06-30	Completed
Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion: a Randomized Controlled Trial [NCT03480009]	Phase 3	156 participants (Actual)	Interventional	2018-07-28	Completed
Multi-Modal Pain Management After Outpatient Orthopaedic Surgery: A Prospective Randomized Trial [NCT05154682]	Phase 3	200 participants (Anticipated)	Interventional	2021-11-30	Enrolling by invitation
A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty [NCT03845881]	Early Phase 1	45 participants (Actual)	Interventional	2019-04-10	Completed
An Exploratory, Single-Dose, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Evaluate The Subjective and Objective Effects of Extended-Release Oxymorphone Compared to Controlled-Release Oxycodone in Healthy Non-Dependent Recreational Opioi [NCT00955110]	Phase 4	78 participants (Actual)	Interventional	2009-06-30	Completed
The Effect of Multimodal Pain Therapy After Hernia Repair [NCT03792295]	Phase 2	0 participants (Actual)	Interventional	2021-07-01	Withdrawn(stopped due to no enrollment, reallocation of resources)
A Randomized, Open-label, Single-dose, Crossover Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers [NCT01568450]	Phase 1	24 participants (Actual)	Interventional	2012-03-31	Completed
Pain Management in Outpatient Urologic Procedures [NCT03393364]	Early Phase 1	150 participants (Actual)	Interventional	2018-04-01	Completed
A Randomized, Placebo- and Active-Controlled, Double-Blind, Single and Multiple Ascending Dose Study in Healthy Adults to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KP-1199 [NCT03880487]	Phase 1	26 participants (Actual)	Interventional	2019-03-12	Terminated(stopped due to The Study was terminated early by sponsor)
Randomized Clinical Trial of Non-Opioid Pain Medications After Adenotonsillectomy [NCT03618823]	Phase 1/Phase 2	268 participants (Actual)	Interventional	2018-10-25	Terminated(stopped due to Early termination due to COVID-19 cases and cancelled surgeries.)
Comparing the Efficacy of Five Oral Analgesics for Treatment of Acute Musculoskeletal Extremity Pain in the Emergency Department [NCT03173456]	Phase 2	600 participants (Actual)	Interventional	2017-11-28	Completed
A Phase 2, Randomized, Double-blind, Placebo-controlled Safety, Pharmacokinetics and Efficacy Study of CA-008 in Subjects Undergoing Bunionectomy [NCT03599089]	Phase 2	147 participants (Actual)	Interventional	2018-07-09	Completed
Phase II Study of Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain [NCT03639415]	Phase 4	0 participants (Actual)	Interventional	2018-10-30	Withdrawn(stopped due to There is no fund to support)
The Effect of General Anesthesia on Pharmacokinetics and Pharmacogenomics of Liquid Oxycodone in Pediatric Surgical Patients [NCT03054831]	Phase 4	40 participants (Anticipated)	Interventional	2019-07-08	Recruiting
Optimal Dose of Intravenous Oxycodone for Attenuation of Hemodynamic [NCT02484352]	Phase 4	95 participants (Actual)	Interventional	2015-07-31	Completed
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Pr [NCT00853736]	Phase 1	23 participants (Actual)	Interventional	2003-02-28	Completed
Efficacy of Oxycodone-propofol Combination Compared With a Fentanyl-propofol Combination on Conscious Sedation Effect and Early Cognitive Function During Therapeutic Endoscopic Retrograde Cholangio-pancreatography:a Prospective,Randomized, Single- Blinded [NCT03755609]		100 participants (Anticipated)	Interventional	2018-06-01	Recruiting
Prescription After Cesarean Trial [NCT04296396]	Phase 3	5,521 participants (Actual)	Interventional	2020-09-21	Completed
Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain [NCT01344720]	Phase 4	250 participants (Anticipated)	Interventional	2011-05-31	Not yet recruiting
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets [NCT01101178]	Phase 1	79 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets [NCT01100320]	Phase 1	88 participants (Actual)	Interventional	2007-01-31	Completed
Opioids Versus Extra Strength Acetaminophen for the Management of Moderate Persistent Non-cancer Pain [NCT01264965]	Phase 4	25 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to recruitment problems)
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO AND OXYCODONE CONTROLLED MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP [NCT00985621]	Phase 3	614 participants (Actual)	Interventional	2009-10-30	Terminated(stopped due to See termination reason in detailed description.)
[NCT02536209]	Phase 1	20 participants (Actual)	Interventional	2015-08-31	Completed
Evaluation of Fentalogs and Their Metabolites in Hair of Patients in a Monitored Clinical Context by Means of Hair Analysis [NCT05740657]		225 participants (Anticipated)	Observational [Patient Registry]	2022-12-06	Recruiting
A Randomized, Double-Blind, Placebo And Active Controlled Methodology Study Investigating The Effects Of Tramadol And Naproxen On The Pain Thresholds Of Patients With Severe Pain Due To Osteoarthritis Of The Thumb [NCT00743587]	Phase 1	36 participants (Actual)	Interventional	2008-09-30	Completed
A Single-Center, Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse [NCT00734461]	Phase 2	14 participants (Actual)	Interventional	2007-08-31	Completed
Cognitive Function and Addiction in Patients With Chronic Pain Under Opioid Tapering in a Multidisciplinary Pain Treatment [NCT03365817]	Phase 3	75 participants (Actual)	Interventional	2009-02-02	Completed
A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain. [NCT01675622]	Phase 3	242 participants (Actual)	Interventional	2011-01-31	Completed
Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty. A Double Blinded Randomized Controlled Study. Tapentadol vs Oxycodone vs Placebo [NCT02604446]	Phase 3	134 participants (Actual)	Interventional	2015-09-30	Completed
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures [NCT05076110]	Phase 4	188 participants (Anticipated)	Interventional	2022-04-07	Recruiting
Efficacy of the Anterior Quadratus Lumborum Block Versus the Transversus Abdominis Plane Block for Elective Laparoscopic Inguinal Hernia Repair: A Randomized Controlled Trial [NCT03023462]		60 participants (Actual)	Interventional	2019-09-05	Completed
An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study Of 40 Mg Doses Of Pf-00345439 To Evaluate The Bioequivalence Of Modified Formulation K Vs. Original Formulation X Under Intermediate-Fat Fed Conditions And To Estimate Relative Bioavailabil [NCT02059915]	Phase 1	134 participants (Actual)	Interventional	2014-04-30	Completed
An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study [NCT01369615]	Phase 3	23 participants (Actual)	Interventional	2011-10-31	Completed
Influence of Oxycodone on Individuals Taking an SSRI [NCT05730062]	Phase 1	55 participants (Anticipated)	Interventional	2023-03-15	Not yet recruiting
Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease [NCT02452437]	Phase 4	20 participants (Anticipated)	Interventional	2015-05-31	Recruiting
Comparison of the Effects of Oxycodone Versus Fentanyl on Airway Reflex to Tracheal Extubation and Postoperative Pain During Recovery of Anesthesia After Laparoscopic Cholecystectomy [NCT03204045]		90 participants (Actual)	Interventional	2017-02-01	Completed
An Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Dose Proportionality of 5 Mg, 20 Mg and 40 Mg of PF-00345439 Formulation K Under Intermediate-fat Fed Conditions in Healthy Volunteers [NCT02089295]	Phase 1	18 participants (Actual)	Interventional	2014-04-30	Completed
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain [NCT05265052]	Phase 2	177 participants (Anticipated)	Interventional	2024-09-30	Not yet recruiting
Individualising Drug Therapy in Neonates Using Pharmacogenomic Profiling, Population Based Modeling and Simulations [NCT02426463]	Phase 4	80 participants (Anticipated)	Interventional	2015-04-20	Completed
Randomized Comparison of Two Pre-induction Analgesia Regimens: Multimodal vs Acetaminophen in the Reduction of Post-operative Pain Following Ureteroscopy With Lithotripsy for Kidney Stones Evaluated With Text Messaging [NCT03549611]	Phase 4	0 participants (Actual)	Interventional	2018-08-01	Withdrawn(stopped due to elected not to proceed with the study)
Analysis of Analgesia Regimens During Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study [NCT02531906]	Phase 1	60 participants (Actual)	Interventional	2015-04-24	Completed
Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients [NCT02160301]	Phase 4	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to Insufficient infrastructure/funding for enrollment)
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain [NCT03176121]	Phase 4	73 participants (Actual)	Interventional	2016-10-31	Completed
An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain [NCT03176199]	Phase 4	30 participants (Actual)	Interventional	2016-09-01	Completed
Assessing the Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control: A Randomized Controlled Trial [NCT03175653]		0 participants (Actual)	Interventional	2017-06-16	Withdrawn(stopped due to Feasibility - could not operationalize prior to PI leaving the institution.)
A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users With Moderate-to-Severe Opioid Use Disorder [NCT03389750]	Phase 2	16 participants (Actual)	Interventional	2018-03-15	Completed
"ICE-T Postoperative Multimodal Pain Regimen Compared to the Standard Regimen in Laparoscopic Gynecologic Surgery: a Randomized Controlled Trial" [NCT03987022]	Phase 4	66 participants (Actual)	Interventional	2019-08-01	Completed
A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects With Moderate to Severe Chronic Low Back Pain [NCT00449176]	Phase 3	981 participants (Actual)	Interventional	2007-02-28	Completed
Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study [NCT06003218]		88 participants (Anticipated)	Interventional	2023-10-16	Recruiting
The Effect of NSAIDs After a Rotator Cuff Repair Surgery. A Prospective Randomized Controlled Trial [NCT02153177]	Phase 4	0 participants (Actual)	Interventional	2015-01-31	Withdrawn(stopped due to The study was withdrawn prior to any participants being enrolled.)
Oxycodone Pharmacokinetics in Preterms, Infants and Children [NCT02564003]		79 participants (Actual)	Observational	2012-06-30	Completed
Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur [NCT00964808]	Phase 4	76 participants (Actual)	Interventional	2009-09-30	Completed
The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty [NCT04003350]		216 participants (Actual)	Interventional	2017-12-21	Completed
A Randomized, Double-Blind, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Compared With Immediate-release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patient With Chronic Pain [NCT00463047]	Phase 3	323 participants (Actual)	Interventional	2007-07-31	Completed
A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain [NCT00361504]	Phase 3	1,123 participants (Actual)	Interventional	2006-11-30	Completed
Toward Zero Prescribed Opioids for Outpatient General Surgery Procedures: a Prospective Cohort Trial [NCT05327777]	Phase 4	129 participants (Actual)	Interventional	2019-11-01	Completed
Comparison of Tramacet Versus Percocet in Post Surgical Patients [NCT02361567]	Phase 4	160 participants (Actual)	Interventional	2015-04-30	Completed
The Safety and Efficacy of Epidural Oxycodone [NCT02573909]	Phase 4	100 participants (Anticipated)	Interventional	2015-01-01	Active, not recruiting
A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 10-mg [NCT01101308]	Phase 1	55 participants (Actual)	Interventional	2008-07-31	Completed
Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery [NCT02732262]	Phase 3	134 participants (Actual)	Interventional	2016-04-30	Completed
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients [NCT02044497]	Phase 4	68 participants (Anticipated)	Interventional	2014-05-31	Recruiting
Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient : A Randomized, Controlled, Double-Blind Trial [NCT02600247]		100 participants (Anticipated)	Interventional	2015-11-30	Not yet recruiting
Preoperative Controlled-Release Oxycodone or Intraoperative Morphine As Transition Opioid After Intravenous Anesthesia For Video-Assisted Thoracic Surgery: a Randomized, Double-blind, Controlled Trial. [NCT00681174]	Phase 4	22 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Failure to enroll sufficient patients by expected deadline.)
Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery - AGE AWARE II [NCT04696445]		34 participants (Actual)	Observational	2020-10-01	Completed
A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Solution is Co-Administered With Nafamostat, as an Immediate Release Solution and/or Extended Release (ER) Capsule Formulations in Healthy Subjects [NCT05090280]	Phase 1	111 participants (Actual)	Interventional	2021-12-01	Active, not recruiting
Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain [NCT02824276]	Phase 1	35 participants (Actual)	Interventional	2017-01-06	Active, not recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]		5,000 participants (Anticipated)	Observational	2020-03-05	Recruiting
Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee [NCT00902837]	Phase 3	181 participants (Actual)	Interventional	2009-05-31	Completed
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS) [NCT00414453]	Phase 4	19 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Did not reach enrollment goals)
Modulation of Opioid Effects by Garlic Supplements [NCT00499460]	Phase 4	15 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery F [NCT00364533]	Phase 3	367 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Slow enrollment)
Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions: A Randomized, Double-blinded, Controlled Trial [NCT04112550]	Phase 1	150 participants (Anticipated)	Interventional	2020-02-11	Not yet recruiting
A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain [NCT00813488]	Phase 3	213 participants (Actual)	Interventional	2008-12-31	Completed
NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial [NCT04808531]	Phase 3	360 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
The Efficacy and Safety of Intravenous Oxycodone and Plasma Oxycodone Concentrations in Labour Pain [NCT01016821]		15 participants (Anticipated)	Interventional	2009-11-30	Completed
Study of Efficacy of OXN PR, Compared to Oxy PR, for Reduction of Intensity of Opioid-induced Constipation Symptoms in Pts Treated for Cancer or Non-cancer Pain: A Randomised, Double-blind, Controlled, Multicentre Study [NCT01014559]	Phase 3	225 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Lack of recruitment)
A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarth [NCT00486811]	Phase 3	990 participants (Actual)	Interventional	2007-06-30	Completed
Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety and Pharmacogenetic Factors Influence. [NCT00916890]	Phase 4	320 participants (Anticipated)	Interventional	2009-02-28	Suspended(stopped due to difficulties in patients enrolment)
A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacodynamics And Pharmacokinetics of TRV734 in Healthy Adult Male and Female Subjects [NCT02211625]	Phase 1	75 participants (Actual)	Interventional	2014-07-31	Completed
A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery [NCT04015908]	Phase 4	100 participants (Actual)	Interventional	2019-08-01	Completed
A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis [NCT00771758]	Phase 3	108 participants (Actual)	Interventional	2008-09-30	Completed
A Comparative Study With Pre-Emptive Parenteral Oxycodone, Morphine and Dexamethasone in the Treatment of Postoperative Pain in Paediatric Patients 4 to 12 Years of Age [NCT00733083]		100 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain [NCT02603705]	Phase 3	281 participants (Actual)	Interventional	2016-03-07	Completed
A Randomized, Double-Blind, Multi-Center, Parallel-Group Study of Tapentadol Immediate Release (IR) Versus Oxycodone IR for the Treatment of Subjects With Acute Post-Operative Pain Following Elective Arthroscopic Shoulder Surgery [NCT00814580]	Phase 3	382 participants (Actual)	Interventional	2008-12-31	Completed
An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Op [NCT01192295]	Phase 3	155 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee [NCT00979953]	Phase 2	408 participants (Actual)	Interventional	2009-10-31	Completed
Multimodal Analgesia With NSAID vs. Narcotics Alone After Shoulder Instability Surgery [NCT04018768]		80 participants (Actual)	Observational	2017-12-01	Completed
Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery [NCT02573922]	Phase 4	180 participants (Actual)	Interventional	2012-05-31	Completed
Effectiveness of Quadratus Lumborum Block After Nephrectomy [NCT03529201]		105 participants (Actual)	Interventional	2018-05-07	Completed
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions [NCT00864526]	Phase 1	40 participants (Actual)	Interventional	2006-10-31	Completed
Effect of Default Electronic Health Record Settings on Clinician Opioid Prescribing Patterns in Emergency Departments [NCT04155229]		104 participants (Actual)	Interventional	2016-10-03	Completed
A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain [NCT01205126]	Phase 3	260 participants (Actual)	Interventional	2009-12-31	Completed
An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve S [NCT00944697]	Phase 2	98 participants (Actual)	Interventional	2009-07-31	Completed
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation [NCT04310579]	Phase 1	55 participants (Actual)	Interventional	2020-06-15	Completed
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets [NCT01101191]	Phase 1	84 participants (Actual)	Interventional	2007-08-31	Completed
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-Fasting Conditions [NCT00864357]	Phase 1	40 participants (Actual)	Interventional	2006-10-31	Completed
Towards Enhanced Recovery After Cesarean: Scheduled Post-operative Medication: a Randomized Controlled Trial [NCT04612920]	Early Phase 1	33 participants (Actual)	Interventional	2020-12-12	Completed
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled Trial [NCT05597878]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2023-04-18	Recruiting
Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia for Postoperative Pain Control, Placebo-controlled RCT, 2021 [NCT05389813]	Phase 2/Phase 3	150 participants (Anticipated)	Interventional	2021-08-15	Enrolling by invitation
A Prospective, Multi-center, Observational Registry of Patients Using Prescription Medications Containing Oxycodone Immediate Release for the Treatment of Pain [NCT00978328]		827 participants (Actual)	Observational	2009-06-30	Completed
A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction [NCT00941304]	Phase 2	153 participants (Actual)	Interventional	2009-08-31	Completed
An Open, Multi-centre, Non-comparative Observational Study to Assess the Safety and Tolerability of Oxycodone Injection 50 mg/mL as a Subcutaneous Infusion in Patients With Severe Cancer Pain. [NCT00626600]	Phase 3	33 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Lack of recruitment)
Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction [NCT03893175]	Phase 1	86 participants (Actual)	Interventional	2019-05-10	Completed
Visceral Pain Originating From the Upper Urinary Tract - a Randomized Controlled Trial on the Effect of Morphine and Oxycodone in Patients Undergoing Percutaneous Nephrolithotomy (PCNL) [NCT00784472]	Phase 3	55 participants (Actual)	Interventional	2008-12-31	Completed
A Comparative Study of Buprenorphine TDS, Oxycodone/ Acetaminophen Tablets Qid and Placebo in Patients With Chronic Back Pain [NCT00315445]	Phase 3	134 participants (Actual)	Interventional	1997-12-31	Completed
A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet® Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain [NCT02716857]	Phase 3	549 participants (Actual)	Interventional	2016-03-31	Completed
A Randomized, Double-blind, Triple-dummy, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Pf-00345439 (Oxycodone Extended Release Capsules) Compared To Immediate-release Oxycodone And Placebo When Admini [NCT01986283]	Phase 1	67 participants (Actual)	Interventional	2013-11-30	Completed
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (15 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Pr [NCT00853320]	Phase 1	38 participants (Actual)	Interventional	2003-02-28	Completed
A Phase IV Study to Evaluate the Pharmacokinetics and Safety of Oxycodone Oral Solution in Pediatric and Adolescent Subjects [NCT01959204]	Phase 4	97 participants (Actual)	Interventional	2013-10-14	Completed
The Utilization of Opioid Medication Following ACL Reconstruction [NCT04278703]		192 participants (Anticipated)	Interventional	2019-02-15	Enrolling by invitation
[NCT00801788]	Phase 1	16 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy [NCT00613938]	Phase 3	901 participants (Actual)	Interventional	2008-02-29	Completed
A Pilot Study Of The Efficacy Of WafermineTM Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy [NCT02541396]	Phase 2	72 participants (Actual)	Interventional	2015-10-31	Completed
The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients [NCT00822614]	Phase 3	500 participants (Anticipated)	Interventional	2008-12-31	Recruiting
A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthr [NCT00421928]	Phase 3	1,030 participants (Actual)	Interventional	2007-01-31	Completed
Randomized, Open-Label, Comparative Parallel Group Study to Assess Efficacy and Safety on Flexible Dosages of OROS Hydromorphone Once-Daily Compared to Sustained Release Oxycodone Twice Daily in Subjects With Chronic Non-malignant Pain Requiring Continuou [NCT00261495]	Phase 3	504 participants (Actual)	Interventional	2006-03-31	Completed
A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain [NCT00313014]	Phase 3	660 participants (Actual)	Interventional	2004-02-29	Terminated(stopped due to Terminated early due to administrative reasons unrelated to efficacy or safety.)
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets [NCT01099709]	Phase 1	85 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Double-blind, Double-dummy, Parallel-group, Multicenter Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Non-malignant Pain Taking Oxycodone Equivalent of ≥10 mg/Day and ≤50 mg/Day as Oxycodone [NCT01918098]	Phase 3	230 participants (Actual)	Interventional	2013-09-01	Completed
An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Food on Oxycodone Pharmacokinetics Following Oral 40 Mg Doses of PF-00345439 Formulation K and to Estimate Its Relative Bioavailability of Oxycodone Compared to P [NCT01924676]	Phase 1	18 participants (Actual)	Interventional	2013-08-31	Completed
Adductor Canal Nerve Block Following Total Knee Arthroplasty: A Randomized, Prospective Study Comparing High vs. Low Volume Bolus of 0.33% Ropivacaine [NCT01939379]		0 participants (Actual)	Interventional	2013-09-30	Withdrawn(stopped due to PI left institution. Efforts made to contact PI unsuccessful. No study data available.)
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain [NCT01946555]		150 participants (Actual)	Observational	2013-09-30	Completed
A Randomsied, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of 60-80 mg/Day as Oxycodone/Naloxone Prolonged Release Compa [NCT00412100]	Phase 3	0 participants	Interventional	2006-04-30	Completed
[NCT01971632]	Phase 3	463 participants (Actual)	Interventional	2005-01-31	Completed
The Efficacy, With Regard to Pain Relief, of Targinact® Treatment for Patients With Severe Pain Compared to Previous Analgesic Treatment; a Non-interventional Study. [NCT01983137]		1,338 participants (Actual)	Observational	2011-04-30	Completed
A Randomized, Multicenter, Single-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Immediate Release Hydrocodone/Acetaminophen (NORCO®) to Placebo in Subjects With Acute Pain Following [NCT00404222]	Phase 2	90 participants (Actual)	Interventional	2005-11-30	Completed
Reducing the Abuse Liability of Prescription Opioids [NCT04587115]	Early Phase 1	15 participants (Actual)	Interventional	2017-06-16	Completed
Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures [NCT00254631]	Phase 4	65 participants (Actual)	Interventional	2007-04-30	Completed
Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy [NCT04429022]	Phase 3	68 participants (Actual)	Interventional	2020-11-24	Completed
Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty [NCT03859024]	Phase 4	60 participants (Actual)	Interventional	2019-03-22	Completed
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia [NCT03679949]	Phase 1	26 participants (Actual)	Interventional	2019-04-01	Active, not recruiting
A Comparison of the Analgesic Efficacy of Oral Opioid Medication vs. Injected Local Anesthetic in Emergency Department Patients With Toothache [NCT02862691]	Phase 2	2 participants (Actual)	Interventional	2016-08-01	Terminated(stopped due to Difficulty recruiting patients)
Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Thai Pediatric Surgical Patients : a Pilot Study [NCT03145272]	Phase 4	20 participants (Actual)	Interventional	2018-10-08	Active, not recruiting
A Phase 1 Double-Blind, Double-Dummy, Parallel-Group, Randomized, Positive Control Study Using fMRI to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users [NCT03802227]	Phase 1	8 participants (Actual)	Interventional	2018-10-22	Terminated(stopped due to Sponsor Decision)
A Comparison of Nausea and Vomiting in Postoperative Paediatric Patients With Patient-controlled Analgesia (PCA): Morphine vs Oxycodone (POPCORN) [NCT06186141]	Phase 4	690 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
An Open-label Study to Characterize the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release (ORF) Tablets in Pediatric Patients Aged 6 to 16 Years Inclusive, Who Require Opioid Analgesia [NCT01160614]	Phase 1	30 participants (Actual)	Interventional	2010-07-31	Completed
Impact of Tramadol and Oxycodone on Sleep Apnea [NCT03454217]	Phase 4	60 participants (Actual)	Interventional	2018-03-01	Completed
Comparison of Epidural Oxycodone and Epidural Morphine for Post Caesarean Section Analgesia: a Randomised Controlled Trial [NCT02277678]	Phase 3	100 participants (Actual)	Interventional	2013-08-31	Completed
A Randomised, Double-blind, Parallel Group Multicentre Study to Demonstrate Non-inferiority of the Analgesic Efficacy of Oxycodone/Naloxone 10/5 or 20/10 mg Prolonged Release Tablets (OXN PR) BID Compared to Oxycodone 10 or 20 mg Prolonged Release Tablets [NCT01083485]	Phase 4	137 participants (Actual)	Interventional	2010-03-31	Completed
Randomized Trial of Two Analgesics in Elderly ED Patients [NCT02703610]	Phase 4	0 participants (Actual)	Interventional	2024-07-01	Withdrawn(stopped due to No participants were enrolled and the study will not be conducted.)
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients [NCT00600405]		81 participants (Actual)	Interventional	2006-08-31	Completed
A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP) [NCT01313780]	Phase 4	128 participants (Actual)	Interventional	2011-05-31	Completed
Evaluation of Multimodal Oral Strategies Using Sequential Analysis (Tramadol, Opioid) After Shoulder Ambulatory Surgery [NCT04110665]	Phase 4	200 participants (Anticipated)	Interventional	2017-09-01	Recruiting
Impact of Reduced Initial Prescription Size on Opioid Consumption in Postoperative Pain Management for Scheduled Cesarean Deliveries [NCT05360433]	Phase 4	170 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Examining the Relationship Amongst Opioid Subjective Effects and Pharmacokinetics of Extended Release Opioids at Shortened Dosing Intervals in Patients With Chronic Pain: a Randomized, Blinded, N-of-1 Case Series Feasibility Study [NCT04132011]	Phase 4	0 participants (Actual)	Interventional	2019-05-01	Withdrawn(stopped due to No recruitment (Feasibility study).)
Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery [NCT04246541]	Phase 3	48 participants (Actual)	Interventional	2019-04-23	Completed
Effect of Oxycodone Combined With Ultrasound Guided Thoracic Paravertebral Nerve Block on Postoperative Analgesia in Patients With Lung Cancer Undergoing Thoracoscopic Surgery [NCT05742256]	Phase 1	159 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial [NCT02601586]	Phase 2/Phase 3	67 participants (Actual)	Interventional	2016-09-30	Completed
Open-Label Trial Comparing Oxycodone Medications for Effectiveness and Satisfaction (OUTCOMES) [NCT01162304]	Phase 4	18 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to unable to enroll subjects meeting Eligibility criteria)
Influence of Intraoperative Opioids (Oxycodone/Fentanyl) Usage on the Post-operative Pain Management of Peroral Endoscopic Myotomy (POEM) [NCT04177342]	Phase 4	196 participants (Anticipated)	Interventional	2020-01-01	Not yet recruiting
A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 80-mg [NCT01101321]	Phase 1	58 participants (Actual)	Interventional	2008-06-30	Completed
A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets [NCT01101165]	Phase 1	92 participants (Actual)	Interventional	2007-02-28	Completed
A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK0663/Etoricoxib and Ibuprofen in the Treatment of Postorthopedic Knee Replacement Surgery Pain [NCT00820027]	Phase 3	776 participants (Actual)	Interventional	2008-12-15	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid [NCT03657810]	Phase 3	349 participants (Actual)	Interventional	2017-08-02	Completed
Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis: A Prospective, Pilot, Cohort Study [NCT03055507]	Phase 2/Phase 3	42 participants (Actual)	Interventional	2017-04-01	Completed
Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain [NCT00637975]	Phase 2	80 participants (Anticipated)	Interventional	2007-09-30	Completed
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia [NCT05988710]	Phase 4	72 participants (Anticipated)	Interventional	2023-10-19	Recruiting
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-i [NCT01427270]	Phase 3	455 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain [NCT00092326]	Phase 3	269 participants (Actual)	Interventional	2002-06-30	Completed
A Randomised, Double-blind, Double-dummy, Parallel-group Multicenter Study to Demonstrate Improvement in Symptoms of Constipation and Non-inferiority in Analgesic Efficacy in Subjects With Non-malignant or Malignant Pain That Require Around-the-clock Opio [NCT01438567]	Phase 3	270 participants (Actual)	Interventional	2011-09-30	Completed
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Pr [NCT00853268]	Phase 1	34 participants (Actual)	Interventional	2005-04-30	Completed
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Pr [NCT00853892]	Phase 1	34 participants (Actual)	Interventional	2005-04-30	Completed
A Double-blind, Double-dummy, Parallel Group, Randomised Study to Compare the Efficacy & Tolerability of Oxycodone/Naloxone Prolonged Release (OXN PR) & Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoa [NCT00784810]	Phase 4	247 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized Clinical Trial Comparing Oral Conscious Sedation With Intravenous Conscious Sedation for First Trimester Surgical Abortion [NCT00337792]		132 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to DSMB review at 50% recruitment, further recruitment unlikely to change result)
A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee [NCT01709214]	Phase 2	619 participants (Actual)	Interventional	2012-12-04	Completed
Are Opioids Needed: A Double-Blinded, Randomized Controlled Trial and Examination of Predictors of Opioid Use Following ACL Reconstruction [NCT04285853]	Phase 4	98 participants (Actual)	Interventional	2020-09-16	Completed
A Pilot Randomized Trial of Opioids Versus Nonopioids for Pain Control After Osmotic Dilator Placement for Abortion Care [NCT03545893]	Phase 4	70 participants (Actual)	Interventional	2018-06-19	Completed
"A Randomized Comparison of Oral Methadone as a First-Switch Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The Simply Rotate Study" [NCT00726830]		1 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Low Accrual.)
A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects [NCT02391571]	Phase 3	26 participants (Actual)	Interventional	2015-02-28	Completed
A Single Dose PK Study of Oxycodone Hydrochloride Injection 2.5, 5, and 10mg in Chinese Patients With Cancer Pain or Post-operation Patients [NCT01482936]	Phase 1	44 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Double-Blind, Study of the Analgesic Efficacy and Safety of Flexible Dose Q8003 Versus Low Dose Q8003 in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty [NCT01055015]	Phase 3	141 participants (Actual)	Interventional	2010-02-28	Completed
Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction [NCT03105518]	Phase 4	100 participants (Actual)	Interventional	2011-03-01	Active, not recruiting
A Randomized, Double-Blind, Parallel-Group Study of NUCYNTA (Tapentadol) Immediate Release vs. Oxycodone Immediate Release for the Treatment of Acute Low Back Pain [NCT00986180]	Phase 3	667 participants (Actual)	Interventional	2009-09-30	Completed
Oxycodone in Treatment of Early Labour Pain Efficacy and Safety [NCT02575677]		90 participants (Anticipated)	Observational	2012-10-31	Recruiting
[NCT02936934]	Phase 4	64 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
Effects of an Opioid Sparing Care Pathway for Patients Undergoing Obesity Surgery [NCT03756961]		220 participants (Anticipated)	Interventional	2019-05-01	Recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]		3,520 participants (Actual)	Observational	2011-11-30	Completed
Multimodal Analgesia With NSAID vs. Narcotics Alone for Post-operative Meniscectomy: A Prospective Observational Study [NCT02915055]		77 participants (Actual)	Observational	2016-09-01	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared With Oxycodone Immediate-Release Tablets and Placebo in Non-Dependent Recreational Opioid Users [NCT05571345]	Phase 1	32 participants (Actual)	Interventional	2022-10-05	Completed
The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain [NCT00260260]	Phase 4	300 participants (Anticipated)	Interventional	2005-06-30	Completed
Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study [NCT04246697]	Phase 4	30 participants (Actual)	Interventional	2019-11-01	Completed
A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain [NCT00092313]	Phase 3	271 participants (Actual)	Interventional	2002-06-30	Completed
A Randomized, Multicenter, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) to Placebo in Subjects With Acute Pain Following Bunionectomy [NCT00402792]	Phase 3	150 participants (Actual)	Interventional	2006-12-31	Completed
Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy : Prospective Double Blind, Randomized, Placebo-Controlled Study [NCT00480142]	Phase 4	100 participants (Anticipated)	Interventional	2007-07-31	Not yet recruiting
An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 10 mg and OXYCONTIN® Tablet 10 mg in Chinese Subjects With Chronic Pain [NCT03403504]	Phase 1	24 participants (Actual)	Interventional	2017-02-01	Completed
A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Analgesic Activity of Hydrocodone/Acetaminophen Extended Release and Placebo in Subjects With Pain Following Bunionectomy Surgery [NCT00404391]	Phase 2	210 participants (Actual)	Interventional	2003-10-31	Completed
A Randomized, Multi-center, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen and Placebo in Subjects With Osteoarthritis [NCT00404183]	Phase 2	120 participants (Actual)	Interventional	2004-08-31	Completed
A Phase 4 Randomized Double-blind Double-dummy Placebo & Active-controlled Single-dose Six-way Crossover Study Evaluating Abuse Potential of NEURONTIN® Taken Orally With Oxycodone HCL in Healthy Non-drug Dependent Recreational Opioid Users [NCT05319756]	Phase 4	54 participants (Actual)	Interventional	2021-04-30	Completed
A Randomized Controlled Trial to Study Reduced Opioid Prescription After Laparoscopic Hysterectomy [NCT05548582]		120 participants (Anticipated)	Interventional	2023-01-12	Recruiting
Non-intrusive Detection of Temporary Neurologic Impairment By Opioids [NCT04223609]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2020-02-28	Completed
Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users [NCT02945293]		128 participants (Actual)	Observational	2015-11-30	Active, not recruiting
A Randomised, Double-blind, Parallel-group, Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of >20 mg/Day and <50 mg/Day as Oxycodone/Naloxone Prolonged Release Compa [NCT00412152]	Phase 3	0 participants	Interventional	2006-01-31	Completed
A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cance [NCT01165281]	Phase 3	343 participants (Actual)	Interventional	2010-08-31	Completed
New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone [NCT00999544]		9 participants (Actual)	Interventional	2009-10-31	Completed
[NCT00478101]	Phase 2	2,006 participants (Actual)	Interventional	2006-02-28	Completed
Phase 4: A Comparison of Intravenous Administration of Morphine vs. Oxycodone for Postoperative Pain Management Following Laparoscopic Hysterectomy or Myomectomy [NCT00528177]	Phase 4	90 participants (Anticipated)	Interventional	2007-09-30	Completed
A Randomised, Double-blind, Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Cancer Pain [NCT00513656]	Phase 2	230 participants (Anticipated)	Interventional	2007-09-30	Completed
The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures [NCT01328782]		124 participants (Actual)	Interventional	2008-06-30	Completed
Open-Label, Single-Dose, Randomized, 5-Period, 5-Way Crossover Study To Evaluate The Dose Proportionality And The Effects Of Food On The Bioavailability Of Acurox Tablets In Healthy Volunteers [NCT01530542]	Phase 1	35 participants (Actual)	Interventional	2010-07-31	Completed
Evaluation of Oxycodone Hydrochloride Versus Intravenous Morphine Hydrochloride for Postoperative Analgesia After Hip Prosthetic Surgery [NCT01536301]	Phase 4	246 participants (Actual)	Interventional	2012-06-30	Completed
Risk of Shopping Behavior of Tapentadol IR Immediate-Release (IR) Compared to Oxycodone IR Immediate-Release (IR) [NCT01545778]		646,620 participants (Actual)	Observational	2010-02-28	Completed
An Open-Label, Single-Dose, Randomized, Crossover Pharmacokinetics And Relative Bioavailability Study Of Three Modified 40 Mg Oxycodone Formulations Compared With 40 Mg Pf-00345439 Capsule Formulation In Healthy Volunteers [NCT01552850]	Phase 1	18 participants (Actual)	Interventional	2012-04-30	Completed
Open-Label, Single-Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Oxycodone Following Oral Administration Of PF-00345439 Under Fed Conditions In Healthy Volunteers [NCT01552863]	Phase 1	21 participants (Actual)	Interventional	2012-03-31	Completed
Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences [NCT05468671]	Phase 4	34 participants (Actual)	Interventional	2021-01-04	Completed
Pharmacogenetics and Pharmacokinetics of Oxycodone to Personalize Postoperative Pain Management Following Major Inpatient Surgery in Children [NCT03495388]		500 participants (Anticipated)	Observational	2018-04-01	Active, not recruiting
Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery [NCT03959969]		48 participants (Actual)	Interventional	2019-07-17	Completed
The Effect of Oxycodone to the Placental Circulation at Early Labour [NCT02573831]	Phase 4	22 participants (Actual)	Interventional	2015-02-01	Active, not recruiting
Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section [NCT02571881]	Phase 4	57 participants (Actual)	Interventional	2012-10-31	Active, not recruiting
Herb-Opioid Interactions [NCT00027014]	Phase 4	54 participants	Interventional	2001-09-30	Completed
A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis [NCT00399048]	Phase 3	140 participants (Actual)	Interventional		Completed
Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer [NCT03317730]	Early Phase 1	28 participants (Actual)	Interventional	2018-05-01	Completed
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL COMPARING OXYCODONE, IBUPROFEN AND ACETAMINOPHEN AFTER WIDE AWAKE HAND SURGERY [NCT03597308]		210 participants (Actual)	Interventional	2017-03-17	Completed
Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain [NCT01672112]	Phase 4	40 participants (Actual)	Interventional	2012-07-31	Completed
Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy: A Randomized Controlled Trial [NCT04939987]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2022-08-31	Withdrawn(stopped due to PI left institution and study was not transferred to new PI)
Effects of Chronic Musculoskeletal Pain and Opioidergic Versus Placebo Interventions on Neuroendocrine Function in Men [NCT00737737]	Phase 4	8 participants (Actual)	Interventional	2008-08-31	Completed
Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain in the ED [NCT00685295]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2008-08-31	Completed
Dose Response Study of Patient Controlled Analgesia (PCA) of S-ketamine in Orthopaedic Spine Surgery Patients [NCT02994173]	Phase 4	100 participants (Actual)	Interventional	2017-02-01	Completed
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway: A Single-Blinded, Randomized, Controlled Study [NCT02740114]	Phase 3	105 participants (Actual)	Interventional	2016-08-31	Terminated(stopped due to Per PIs request)
Postoperative Pain Control in Septum and Sinus Surgery: A Novel Approach. [NCT04149964]	Phase 4	65 participants (Actual)	Interventional	2019-11-27	Completed
An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery [NCT04522206]	Phase 4	44 participants (Actual)	Interventional	2020-08-20	Completed
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Abuse Potential and Safety of Orally Administered Samidorphan in Non-Dependent Recreational Opioid Users [NCT02218021]	Phase 1	59 participants (Actual)	Interventional	2014-08-31	Completed
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-i [NCT01427283]	Phase 3	450 participants (Actual)	Interventional	2011-08-31	Completed
Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1) [NCT05447286]	Phase 1	9 participants (Anticipated)	Interventional	2023-05-15	Recruiting
The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models [NCT00271973]	Phase 4	32 participants	Interventional	2006-02-28	Completed
A Single-dose, Randomized, Double-blind, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of Two Doses of Cebranopadol in Adult Nondependent Recreational Opioid Users [NCT05256108]	Phase 1	38 participants (Actual)	Interventional	2022-03-28	Completed
An Open-label, Single-dose, Randomized, Two-way Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Heal [NCT01677065]		14 participants (Actual)	Observational	2012-09-30	Completed
Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee Arthroplasty (TKA). Prospective, Randomized, Open-label Trial to Determine if Switching From Oral to Intravenous Acetaminophen and Orphenadrine for 48 Hours After TKA Improves Outcomes. [NCT02449369]	Phase 4	180 participants (Actual)	Interventional	2015-04-30	Completed
The Evaluation of Targinact® in Daily Practice, With Regards to Pain Relief and Constipation, in Chronic Severe Pain Patients Compared to Previous Prolonged Release Oxycodone Treatment: a Non-interventional, Observational Study. [NCT01710904]		68 participants (Actual)	Observational	2012-09-30	Completed
Open Label, Single Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics And Relative Bioavailability Of Oxycodone Following Oral Administration Of 40 Mg Doses Of PF 00345439 Taken Whole Under Fed Conditions And After Chewing Under Fasted Con [NCT01717027]	Phase 1	19 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers [NCT01779492]	Phase 1	24 participants (Actual)	Interventional	2013-04-30	Completed
Multimodal Analgesia Effect on Post Surgical Patient [NCT04240626]	Phase 4	60 participants (Anticipated)	Interventional	2021-01-20	Recruiting
Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency [NCT01810458]		109 participants (Actual)	Observational	2013-10-31	Completed
A Placebo-controlled, Randomized, Double-blind Study of the Safety and Efficacy of Q8003 in the Management of Post-bunionectomy Pain [NCT00560183]	Phase 3	256 participants (Actual)	Interventional	2007-11-30	Completed
A Blinded, Randomized Controlled Trial of Opioid Analgesics for the Management of Acute Fracture Pain in Adults Discharged From the Emergency Department [NCT03478423]		5 participants (Actual)	Interventional	2018-02-05	Terminated(stopped due to Study failed to recruit in sufficient numbers and was determined to not be feasible.)
A Randomized, Single-Dose, Placebo-Controlled, Double-Blind, 3-Way Crossover Study to Determine the Relative Abuse Potential of Intravenous Oxycodone Hydrochloride Alone or in Combination With Intravenous Naltrexone Hydrochloride in Opioid Experienced Non [NCT01825447]	Phase 1	89 participants (Actual)	Interventional	2013-07-31	Completed
Reducing the Abuse Liability of Prescription Opioids in Recreational Drug Users: A Pilot Study [NCT03837860]	Early Phase 1	3 participants (Actual)	Interventional	2019-04-01	Terminated(stopped due to PI leaving institution)
Prove the Feasibility of a Non-invasive Means to Identify Temporary Neurological Impairment Resulting From the Use of a Commonly Prescribed Opioid by Identifying an Oculomotor Biosignature Associated With Temporary Neurologic Impairment in Pain-free Opioi [NCT05489601]		17 participants (Actual)	Observational	2020-02-28	Completed
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of Oxycodone DETERx™ Versus Placebo in Opioid-Experienced and Opioid-Naive Subjects With Moderate-to-Severe Chronic Low Back Pain [NCT01685684]	Phase 3	740 participants (Actual)	Interventional	2012-08-31	Completed
Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial [NCT03978767]	Phase 2	286 participants (Anticipated)	Interventional	2019-06-10	Recruiting
Doxazosin: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in Humans [NCT03415581]	Phase 2	13 participants (Actual)	Interventional	2017-02-12	Terminated(stopped due to Study terminated by sponsor due to bad risk/benefit ratio.)
A Laboratory Model for Heroin Abuse Medications [NCT00000273]	Phase 2	8 participants (Actual)	Interventional	1995-08-31	Completed
Pain Outcomes of Non-opioid Analgesia After Ureteroscopy or Percutaneous Nephrolithotomy for Nephrolithiasis: a Prospective Randomized Controlled Trial. [NCT03584373]	Phase 3	119 participants (Actual)	Interventional	2018-07-27	Completed
[NCT01439100]	Phase 3	172 participants (Anticipated)	Interventional	2011-10-31	Completed
An Open-Label, Single-Dose, Randomized, Three-Way Crossover Study in Healthy Volunteers to Estimate the Effects of Food and of Sprinkling ALO-02 Pellets on Applesauce on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Relea [NCT01456507]	Phase 1	24 participants (Actual)	Interventional	2011-10-31	Completed
Responsiveness Index Versus the RASS Based Method for Adjusting Sedation in Critically Ill Patients [NCT03250481]		32 participants (Actual)	Interventional	2013-03-31	Completed
An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain [NCT03398278]	Phase 1	38 participants (Actual)	Interventional	2017-06-30	Completed
Rebound Pain at Block Resolution After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block [NCT03011905]	Phase 3	53 participants (Actual)	Interventional	2017-01-31	Completed
Post-tonsillectomy Pain Control in Adults: a Randomized Prospective Study [NCT02358850]	Phase 4	27 participants (Actual)	Interventional	2016-01-31	Terminated(stopped due to low enrollment)
An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With Targin® in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY) [NCT01811186]	Phase 4	261 participants (Actual)	Interventional	2012-12-31	Completed
Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge [NCT01402375]	Phase 3	720 participants (Actual)	Interventional	2012-01-31	Completed
Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial [NCT01270659]	Phase 3	60 participants (Actual)	Interventional	2011-05-31	Completed
Study of Parecoxib Versus Celecoxib Versus Oxycodone on Perioperative Pain Control of Transcatheter Chemoembolization Procedure for Patients With Hepatocelullar Carcinoma [NCT03059238]	Phase 3	213 participants (Actual)	Interventional	2016-09-30	Completed
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure [NCT05463367]	Phase 2	80 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Prospective Randomized Study Evaluating the Effect of Postoperative Ketorolac on Bone Healing and Opioid Consumption After First Metatarsophalangeal Joint Fusion [NCT04872283]	Phase 3	140 participants (Anticipated)	Interventional	2019-05-23	Enrolling by invitation
A Randomized, Multicenter, Single-blind, Placebo-controlled Study Comparing the Analgesic Efficacy and Safety of Hydrocodone/ Acetaminophen Extended-release Tablets and Hydrocodone/Acetaminophen (NORCO) to Placebo in Subjects With Acute Pain Following Thi [NCT00935311]	Phase 2	122 participants (Actual)	Interventional	2009-06-30	Completed
An Open-label, Single-dose and Multiple-dose, Randomized, Crossover Study to Evaluate Pharmacokinetics, Safety and Tolerability After Administration of ALO-02 40 Mg Twice Daily Compared to ALO-02 80 Mg Once Daily and to Oxycontin 40 Mg Twice Daily in Heal [NCT01557257]	Phase 1	13 participants (Actual)	Interventional	2012-03-31	Completed
Narcotic Versus Non-narcotic Medication for Pain Management After Wrist/Hand Fractures: a Randomized Controlled Trial [NCT03375593]	Phase 4	250 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery [NCT04246554]	Phase 3	49 participants (Actual)	Interventional	2019-05-21	Completed
Levorphanol as a Second Line Opioid in Cancer Patients Undergoing Opioid Rotation: An Open Label Study [NCT03579446]	Early Phase 1	43 participants (Actual)	Interventional	2018-11-29	Completed
A Phase 3, Open-Label Period Followed By a Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) Compared to Placebo in Subjects With Chronic Low Back Pain [NCT00325949]	Phase 3	770 participants (Actual)	Interventional	2006-05-31	Completed
Post-Op Pain Control for Prophylactic Intramedullary Nailing. [NCT03823534]	Phase 3	60 participants (Anticipated)	Interventional	2019-02-20	Recruiting
An Evaluation of the Tolerability of Switching Subjects on Chronic Around-the-Clock (ATC) Opioid Therapy to Buprenorphine HCl Buccal Film [NCT01871285]	Phase 2	39 participants (Actual)	Interventional	2013-06-30	Completed
Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (LUTS) Post Ureteroscopy for Stone Management [NCT01381120]	Phase 4	84 participants (Actual)	Interventional	2010-10-31	Completed
MEASURES OF GAIT AND SELF-REPORTED PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED, SINGLE-BLIND WASHOUT, DOUBLE-BLIND TREATMENT, DOUBLE DUMMY CROSS-OVER PILOT TRIAL USING PLACEBO, OXYCODONE AND CELECOXIB (A9011030) [NCT00484718]	Phase 4	6 participants (Actual)	Interventional	2008-01-17	Terminated(stopped due to See termination reason in detailed description.)
An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach [NCT00378937]	Phase 4	30 participants (Anticipated)	Interventional	2004-01-31	Completed
Relieving Acute Pain (RAP): A Pilot Study [NCT03426137]	Phase 2	3 participants (Actual)	Interventional	2018-09-17	Terminated(stopped due to The focus of the project has shifted to publishing a protocol for future trials because we were unable to recruit. Three participants signed the consent forms but withdrew before the randomization.)
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults [NCT05761860]	Early Phase 1	45 participants (Anticipated)	Interventional	2023-09-12	Recruiting
Intercostal Nerve Cryoablation Versus Thoracic Epidural Analgesia for Minimal Invasive Nuss Repair of Pectus Excavatum: a Randomized Clinical Trial (ICE Trial) [NCT05731973]		46 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
OxyNorm® Capsules (Immediate-Release) PK Study [NCT01643772]	Phase 1	61 participants (Actual)	Interventional	2011-05-31	Completed
Celecoxib for Pain Management After Tonsillectomy [NCT02934191]	Phase 2	172 participants (Actual)	Interventional	2016-06-30	Completed
A Phase 4 Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Single-Dose Six-Way Crossover Study Evaluating the Abuse Potential of Lyrica® Taken Orally With Oxycodone HCL in Healthy Non-Drug Dependent Recreational Opioid Users [NCT05053126]	Phase 4	60 participants (Actual)	Interventional	2021-07-27	Completed
Narcotic-Free Percutaneous Nephrolithotomy [NCT05924165]	Phase 4	90 participants (Anticipated)	Interventional	2023-05-19	Recruiting
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients [NCT04194528]		2 participants (Actual)	Interventional	2020-01-22	Terminated(stopped due to Study sponsor withdrew support.)
Transversus Abdominis Plane (TAP) Infiltration vs. Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Assisted Hysterectomy [NCT02519023]	Phase 4	87 participants (Actual)	Interventional	2016-07-31	Completed
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]		27,034 participants (Actual)	Interventional	2016-07-31	Completed
Clinical Study to Investigate the Effect of Administration of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation [NCT05470465]	Phase 1	27 participants (Actual)	Interventional	2022-09-01	Completed
Comparative Study of Oxycodone and Fentanyl Given Intravenously in the Treatment of Early Postoperative Pain After Laparoscopic Cholecystectomy [NCT00369811]	Phase 4	80 participants (Anticipated)	Interventional	2006-08-31	Completed
Oral Sedation During Cervical Dilator Placement: A Randomized Controlled Trial [NCT03202550]	Phase 4	27 participants (Actual)	Interventional	2017-06-28	Completed
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills [NCT03588806]	Phase 4	11 participants (Actual)	Interventional	2018-05-01	Terminated(stopped due to Study halted permanently and will not resume; participants are no longer being examined or receiving intervention.)
An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fed State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain [NCT03398330]	Phase 1	42 participants (Actual)	Interventional	2017-03-16	Completed
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans [NCT01500317]	Phase 4	38 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized Trial Comparing Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Outpatient Soft Tissue Hand Surgery [NCT03111186]	Phase 2	40 participants (Actual)	Interventional	2017-04-24	Completed
A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis Versus Oxycodone [NCT02892591]	Phase 3	100 participants (Anticipated)	Interventional	2017-06-01	Recruiting
A Randomized Controlled Trial of Continuous Gastrocnemius Plane Block and Intravenous Analgesia After Foot and Ankle Surgery [NCT05463809]	Phase 3	60 participants (Anticipated)	Interventional	2022-07-14	Not yet recruiting
Dose Response Study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in Orthopaedic Spine Surgery Patients [NCT02454881]	Phase 4	107 participants (Actual)	Interventional	2015-06-30	Completed
A Phase III Study of Pre-operative Transversus Abdominis Plane Blocks Using the Nimbus Ambulatory Infusion System in Patients Undergoing Abdominal Free Flap-based Breast Reconstruction [NCT02601027]	Phase 3	120 participants (Actual)	Interventional	2015-11-30	Completed
Randomized, Double-blind, Four Period, Six-treatment, Double-dummy, Placebo Controlled, Partial-crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH) of Cebranopadol, Oxycodone, and Placebo in Healthy Subjects [NCT05491785]	Phase 1	30 participants (Anticipated)	Interventional	2022-07-29	Recruiting
An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia [NCT02680847]	Phase 4	32 participants (Actual)	Interventional	2016-01-21	Terminated(stopped due to The trial was terminated on 08FEB2018. Pfizer has decided to withdraw the New Drug Application and has notified FDA. There are no efficacy or safety concerns.)
To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine [NCT02440399]		200 participants (Actual)	Interventional	2015-07-31	Completed
NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial [NCT05842044]	Phase 2	110 participants (Anticipated)	Interventional	2023-09-15	Recruiting
A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of TARGIN(R) (Oxycodone/Naloxone) in Korean Patients With Spinal Disorders [NCT01811238]	Phase 4	240 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized Study of Ibuprofen + Oxycodone/Acetaminophen Versus Ibuprofen + Acetaminophen for ED Patients With Insufficient Relief of Acute Musculoskeletal Pain After Treatment With Prescription Strength Ibuprofen [NCT04122443]	Phase 4	154 participants (Actual)	Interventional	2019-12-01	Completed
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Repeat-dose Study of the Safety and Efficacy of Acuroc Tablets Following Bunionectomy Surgery in Adult Patients [NCT00654069]	Phase 3	405 participants (Actual)	Interventional	2007-09-30	Completed
A Multicenter, 12-month, Open-label, Single-arm, Safety Study Of Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-release Capsules In Subjects With Moderate To Severe Chronic Noncancer Pain [NCT01428583]	Phase 3	395 participants (Actual)	Interventional	2010-12-31	Completed
Prescription Opioid Effects in Drug and Non-drug Abusers - 1 [NCT00158184]	Phase 2	27 participants (Actual)	Interventional	2004-06-30	Completed
Phase 4 Study, Open, Observational, to Evaluate the Safety and Tolerability of Hydrochloride Controlled-release Oxycodone in Moderate and Severe Postoperative Pain in Oncologic Head and Neck Surgery. [NCT01834898]		83 participants (Actual)	Observational	2010-10-31	Completed
Oxycodone vs. Fentanyl in the Treatment of Early Postoperative Pain After Total Hip Replacement [NCT03019562]	Phase 4	46 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Comparative Efficacy of 4 Oral Analgesics for the Initial Management of Acute Musculoskeletal Extremity Pain [NCT02455518]	Phase 4	416 participants (Actual)	Interventional	2015-07-31	Completed
A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Capsules Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride [NCT02401750]	Phase 3	163 participants (Actual)	Interventional	2015-06-30	Completed
Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery [NCT04121416]		50 participants (Actual)	Interventional	2019-04-01	Completed
A Randomized Blinded Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function After Colorectal Surgery [NCT02109640]	Phase 3	50 participants (Actual)	Interventional	2014-10-31	Completed
Efficacy of Erector Spinae Plane Block and Pectoral Fascia Block in Patients Undergoing Mitral Valve Repair Through the Right Mini-thoracotomy [NCT03592485]	Phase 4	33 participants (Actual)	Interventional	2018-06-28	Completed
A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse [NCT00699010]	Phase 2	30 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-blind, Double-dummy, Placebo Controlled, Single-dose, 6-way Crossover Study To Determine The Relative Abuse Potential Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-release Capsules) Compared To Oxycodone Imm [NCT01746901]	Phase 1	81 participants (Actual)	Interventional	2013-02-28	Completed
A 4-week, Open Label, Multi-center, Prospective, Single-arm, Non-interventional Phase IV Study to Evaluate the Efficacy of Targin for the Treatment of Korean Patients With Cancer Pain Under Conditions of Daily Practice [NCT01719757]	Phase 4	359 participants (Actual)	Interventional	2012-07-31	Completed
Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery [NCT02240602]	Phase 3	0 participants (Actual)	Interventional	2015-07-31	Withdrawn(stopped due to Lack of internal resources)
Assessment of Postoperative Pain in Boys Undergoing Hypospadias Repair [NCT04423107]	Phase 3	150 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment [NCT01675531]	Phase 4	73 participants (Actual)	Interventional	2012-12-31	Completed
Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Patients With Spinal Cord Injury, Polytrauma and Burn Injury: A Pilot Study [NCT03906721]	Phase 2	30 participants (Actual)	Interventional	2019-02-20	Completed
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination [NCT04218409]	Early Phase 1	45 participants (Anticipated)	Interventional	2021-09-02	Recruiting
A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain [NCT01885182]	Phase 3	232 participants (Actual)	Interventional	2013-06-01	Completed
A Randomized Controlled Trial of Acetaminophen and Ibuprofen Versus Acetaminophen and Oxycodone for Postoperative Pain Control in Operative Pediatric Supracondylar Humerus Fracture [NCT03759028]	Phase 4	90 participants (Anticipated)	Interventional	2019-02-26	Recruiting
The Effect of Decreased Opioid Prescribing on Pain Control and Patient Satisfaction Following Cesarean Section [NCT03355248]		60 participants (Actual)	Interventional	2017-08-18	Completed
RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder. [NCT01809106]	Phase 4	518 participants (Actual)	Interventional	2011-04-30	Completed
Successful Implementation of an Opioid Reduction Toolkit in Pancreatectomy Patients Significantly Decreases Number of Opioids Prescribed and Consumed [NCT05363436]	Phase 4	159 participants (Actual)	Interventional	2018-01-01	Suspended(stopped due to Recruitment Reorganzing)
A Randomized, Double-blind, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended Release Capsules) Compared To Oxycodone Immediate Release [NCT01775189]	Phase 1	45 participants (Actual)	Interventional	2013-02-28	Completed
A Randomized Double-blinded Study to Evaluate Preincisional Dextromethorphan in Patients Undergoing Total Knee Arthroplasty and Its Effect on Postoperative Opioid Use [NCT02987920]	Phase 4	23 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to The surgeon changed pain control protocol for all patients. Continued enrollment impossible under approved protocol.)
Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain [NCT01458015]	Phase 4	5 participants (Actual)	Interventional	2011-10-31	Terminated
Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus Oxycodone/Naloxone PR in Non-opioid Pre-treated Subjects With Uncontrolled Severe Chronic Low Back Pain With a Neuropathic Pain Component. [NCT01838616]	Phase 4	367 participants (Actual)	Interventional	2013-04-30	Completed
Pharmacokinetics of Anesthetics and Analgesics in Children and Adolescent [NCT03427736]		460 participants (Anticipated)	Observational	2018-12-13	Recruiting
Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain [NCT02293525]		0 participants (Actual)	Interventional		Withdrawn(stopped due to No subjects were enrolled and the sponsor suspended support at this time)
Influences on the Nutrition Statuses and Clinical Outcomes of Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients [NCT02309437]	Phase 2	200 participants (Actual)	Interventional	2015-01-01	Completed
A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicentre Study To Assess The Efficacy And Tolerability Of PF-00592379 In Patients With Moderate To Severe Pain Due To Osteoarthritis [NCT00483977]	Phase 2	113 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Met criteria for study futility at interim analysis)
A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation [NCT02480114]	Phase 3	79 participants (Actual)	Interventional	2015-07-31	Completed
A Study Comparing Recurrent Use of Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at Discharge From the ED in Opioid-naïve Adult Patients With Moderate to Severe Pain. [NCT03529331]	Phase 4	0 participants (Actual)	Interventional	2019-09-01	Withdrawn(stopped due to The ED physicians no longer prescribe opioids at discharge; not feasible to conduct the study)
Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? [NCT02307305]	Phase 2	168 participants (Anticipated)	Interventional	2014-08-31	Recruiting
A 5-day, Multicentre, Randomized, Open-label, Parallel Group, Active Control Pilot Study to Evaluate the Efficacy and Safety of OxyNorm® (Oxycodone Hydrochloride Injection) in Comparison With Morphine Sulfate Through the IV Continuous Infusion Regimen in [NCT02660229]	Phase 4	66 participants (Actual)	Interventional	2015-11-30	Completed
Oxycodone or Ibuprofen for Suspected Isolated Forearm Fractures in Pediatric Patients: A Randomized Noninferiority Trial [NCT04523623]		200 participants (Anticipated)	Interventional	2020-09-30	Not yet recruiting
Pain Management in Head and Neck Surgery Patients [NCT03121963]	Phase 4	0 participants (Actual)	Interventional	2017-11-10	Withdrawn(stopped due to This protocol was difficult to enroll into, and changes to personnel have made it difficult to main this study. Data collection was not completed and therefore, no data analysis was performed. The PI has made the decision to close this study.)
Effectiveness of the Erector Spinae Plane Block in Patients Undergoing Breast Surgery Due to Cancer [NCT04726878]	Phase 4	75 participants (Actual)	Interventional	2021-02-01	Completed
Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms [NCT01502644]	Phase 4	81 participants (Actual)	Interventional	2009-02-28	Completed
Hepatic Cytochrome Drug Interactions in Emergency Department Patients [NCT01859715]		502 participants (Actual)	Interventional	2012-06-30	Completed
Optimal Multimodal Pain Management Package Versus Regular Bottled Pain Formulation for Outpatient Use Following Microdiscectomies , Foraminotomies, and Spinal Decompressions: A Randomized Control Trial Comparing Two Strategies [NCT05965492]	Phase 3	100 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial [NCT02516059]	Phase 4	90 participants (Actual)	Interventional	2015-09-14	Completed
Pain Management After Cardiac Surgery - Opioids or NSAID? A Randomized Prospective Study [NCT02479165]	Phase 4	182 participants (Actual)	Interventional	2009-05-31	Completed
Effect of Pregabalin on Immediate Post-operative and Longterm Pain and Spinal Cord Monitoring in Children Undergoing Instrumented Spinal Surgery. [NCT02464813]	Phase 4	64 participants (Actual)	Interventional	2015-08-01	Completed
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms [NCT05142267]		120 participants (Anticipated)	Interventional	2022-03-02	Recruiting
A Randomized Three-armed Comparative Effectiveness Study of Various Medications for Musculoskeletal Low Back Pain: Defining the Added Benefit of Muscle Relaxants and Opioids. [NCT01587274]	Phase 4	323 participants (Actual)	Interventional	2012-04-30	Completed
A Double-Blinded Randomized Controlled Trial Examining Multimodal Opioid-Free Orthopaedic Procedures [NCT04659317]	Phase 3	80 participants (Anticipated)	Interventional	2020-12-11	Recruiting
Achieving Peri-Operative Pain Control Without Opioids [NCT04813991]	Phase 3	0 participants (Actual)	Interventional	2022-03-15	Withdrawn(stopped due to Enrollment was never initiated and the PI is leaving the institution so the study is closing.)
A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chron [NCT01571362]	Phase 3	410 participants (Actual)	Interventional	2012-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00158184 (2) [back to overview]	Drug Liking
NCT00158184 (2) [back to overview]	Breakpoint
NCT00261495 (79) [back to overview]	Number of Subjects Indicating That They Had Optimal Sleep at Week 24
NCT00261495 (79) [back to overview]	Number of Subjects With Dose Escalation at Week 24 (ITT Population)
NCT00261495 (79) [back to overview]	Number of Subjects With Dose Escalation at Week 4 (ITT Population)
NCT00261495 (79) [back to overview]	Change From Baseline in BPI Pain Relief Score (BPI Item 8) at Week 24
NCT00261495 (79) [back to overview]	Amount of add-on Pain Medication
NCT00261495 (79) [back to overview]	"Change From Baseline in Subject Diary Morning Mean Pain Score Pain Right Now at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Subject Diary Evening Mean Pain Score Pain Right Now at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Quality of Life (QoL) Bodily Pain at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Vitality at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Interference Score Interfered With General Activity (BPI Item 9a) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Average Pain (BPI Item 5) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Average Pain (BPI Item 5) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Pain at Its Least (BPI Item 4) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Pain at Its Worst (BPI Item 3) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Score Pain at Its Least (BPI Item 4) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Pain Severity Sub-score Pain at Its Worst (BPI Item 3) at Week 24 (ITT Population)"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Questionnaire Item 6 Pain Right Now Score at Week 24 (Intent to Treat [ITT] Population)"
NCT00261495 (79) [back to overview]	"Change From Baseline in BPI Severity Score Pain Right Now (BPI Item 6) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 Pain Right Now Score at Week 24 (Per Protocol [PP] Population)"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Enjoyment of Life (BPI Item 9g) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Enjoyment of Life (BPI Item 9g) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Physical Functioning at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With General Activity (BPI Item 9a) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Mood (BPI Item 9b) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Mood (BPI Item 9b) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Normal Work (BPI Item 9d) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Normal Work (BPI Item 9d) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Relations With Other People (BPI Item 9e) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Relations With Other People (BPI Item 9e) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Sleep (BPI Item 9f) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Sleep (BPI Item 9f) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Walking Ability (BPI Item 9c) at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in Pain Interference Pain Interfered With Walking Ability (BPI Item 9c) at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Bodily Pain at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL General Health Perceptions at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL General Health Perceptions at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Health Transition at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Health Transition at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Mental Health at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Mental Health at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Vitality at Week 24"
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Snoring at Week 24
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Social Functioning at Week 4"
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Sleep Somnolence at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Sleep Shortness of Breath or Headache at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Sleep Quantity at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Sleep Disturbance at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality, Sleep Adequacy at Week 24
NCT00261495 (79) [back to overview]	Equi-analgesic Dose at Steady State (ITT Population)
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Social Functioning at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Role Physical at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Role Physical at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Physical Functioning at Week 24"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Role Emotional at Week 4"
NCT00261495 (79) [back to overview]	"Change From Baseline in QoL Role Emotional at Week 24"
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality (MOS Index II) at Week 4
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality (MOS Index II) at Week 24
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality (MOS Index I) at Week 4
NCT00261495 (79) [back to overview]	Equi-analgesic Dosage of OROS Hydromorphone Once-daily and SR Oxycodone Twice-daily (ITT Population)
NCT00261495 (79) [back to overview]	Equi-analgesic Dosage of OROS Hydromorphone Once-daily and SR Oxycodone Twice-daily (PP Population)
NCT00261495 (79) [back to overview]	Number of Drop-outs
NCT00261495 (79) [back to overview]	Equi-analgesic Dose at Steady-state (PP Population)
NCT00261495 (79) [back to overview]	Number of Days With add-on Pain Medication
NCT00261495 (79) [back to overview]	Resource Utilization of Pain Management
NCT00261495 (79) [back to overview]	"Change From Baseline in Subject Diary Mean Pain Score for Pain at Its Worst From Morning to Evening at Weeks 4, 8, 12, 16, 20, and 24"
NCT00261495 (79) [back to overview]	Change From Baseline in BPI Pain Severity, Relief and Interference Scores (Extension Phase)
NCT00261495 (79) [back to overview]	Change From Baseline in QoL at Week 52
NCT00261495 (79) [back to overview]	Change From Baseline in Sleep Quality at Week 52
NCT00261495 (79) [back to overview]	Change From Baseline in Subject Diary Mean Pain Evening, Morning, and All Day Scores at Week 24
NCT00261495 (79) [back to overview]	Change in Dose of Study Treatment
NCT00261495 (79) [back to overview]	Change From Baseline in BPI Pain Severity Score (Mean of BPI Items 3 to 6) at Week 4
NCT00261495 (79) [back to overview]	Change From Baseline in BPI Pain Severity Score (Mean of BPI Items 3 to 6) at Week 24
NCT00261495 (79) [back to overview]	Change in Dose of Study Treatment During Titration Phase (First 4 Weeks of Study) and Overall Treatment Phase I (First 24 Weeks of Study)
NCT00261495 (79) [back to overview]	Clinical Global Assessment of Efficacy
NCT00261495 (79) [back to overview]	Mode and Convenience of Drug Intake.
NCT00261495 (79) [back to overview]	Number of Subjects Indicating Optimal Sleep at Week 52
NCT00261495 (79) [back to overview]	Change From Baseline in BPI Pain Relief Score (BPI Item 8) at Week 4
NCT00261495 (79) [back to overview]	Number of Subjects With Dose Escalation
NCT00312221 (4) [back to overview]	The Mean Daily Number of Supplemental Analgesic Medication Tablets
NCT00312221 (4) [back to overview]	The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase
NCT00312221 (4) [back to overview]	The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase
NCT00312221 (4) [back to overview]	"Average Pain Over the Last 24 Hours Scores at Weeks 4, 8, and 12 of the Double-blind Phase."
NCT00313014 (4) [back to overview]	Mean Daily Number of Supplemental Analgesic Tablets
NCT00313014 (4) [back to overview]	Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.
NCT00313014 (4) [back to overview]	Oswestry Disability Index (ODI) Score (V 2.0)
NCT00313014 (4) [back to overview]	The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.
NCT00315445 (22) [back to overview]	Therapeutic Response - Investigator: Mean ± SEM (Day 84)(LOCF)
NCT00315445 (22) [back to overview]	The Time to Discontinuation Due to Lack of Efficacy
NCT00315445 (22) [back to overview]	"Sensitivity Analysis: Pain on the Average Change From Baseline to End of Treatment (Day 84) (Hybrid BOCF/LOCF)"
NCT00315445 (22) [back to overview]	Subject Satisfaction: Mean ± SEM (Day 84)(LOCF)
NCT00315445 (22) [back to overview]	Subject Comparison to Prestudy Analgesic: Mean ± SEM (Day 84)(LOCF)
NCT00315445 (22) [back to overview]	Pain Right Now, Mean Change From Baseline, Days 21-84 (LOCF)
NCT00315445 (22) [back to overview]	Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF])
NCT00315445 (22) [back to overview]	"Vitality (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"Social Functioning (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"Sensitivity Analysis: Pain Right Now Change From Baseline to End of Treatment (Day 84) (Hybrid BOCF/LOCF)"
NCT00315445 (22) [back to overview]	"Sensitivity Analysis: Pain Right Now Change From Baseline in the Maintenance Period (Days 21-84), BOCF"
NCT00315445 (22) [back to overview]	"Sensitivity Analysis: Pain Right Now Change From Baseline in the Maintenance Period (Days 21-84) (Hybrid BOCF/LOCF)"
NCT00315445 (22) [back to overview]	"Emotional Role (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"General Health (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"Mental Health (MOS SF-36):Mean Percent ± SEM at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"Physical Functioning Scale of the Medical Outcomes Survey (MOS) 36 Item Short-Form Health Survey (SF-36): Mean Percent ± Standard Error of the Mean (SEM) at Day 84 (LOCF)"
NCT00315445 (22) [back to overview]	"Physical Role Scale (MOS SF-36): Mean Percent ± SEM at Day 84(LOCF)"
NCT00315445 (22) [back to overview]	"Sensitivity Analysis Pain on the Average Change From Baseline in the Maintenance Period (Days 21-84) (Hybrid BOCF/LOCF)"
NCT00315445 (22) [back to overview]	"Sensitivity Analysis: Pain on the Average Change From Baseline in the Maintenance Period (Days 21 - 84) Baseline Observation Carried Forward (BOCF)"
NCT00315445 (22) [back to overview]	Therapeutic Response - Subject: Mean ± SEM (Day 84) (LOCF)
NCT00315445 (22) [back to overview]	Time to Stable Pain Management
NCT00315445 (22) [back to overview]	"Bodily Pain (MOS SF-36): Mean Percent at Day 84 (LOCF)"
NCT00361504 (2) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT00361504 (2) [back to overview]	Change From Baseline in Average Pain Intensity Scores at Week 52 Using the Numerical Rating Scale (NRS)
NCT00364533 (1) [back to overview]	Sum of Pain Intensity Difference Over 48 Hours (SPID48)
NCT00421928 (6) [back to overview]	Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.
NCT00421928 (6) [back to overview]	Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.
NCT00421928 (6) [back to overview]	Change From Baseline in Responder Analysis 50% Improvement to Week 12
NCT00421928 (6) [back to overview]	Change From Baseline in EuroQol-5 (EQ-5D) Health Status Index to Week 12
NCT00421928 (6) [back to overview]	Change From Baseline in Western Ontario McMaster Questionnaire (WOMAC) Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12
NCT00421928 (6) [back to overview]	Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12
NCT00449176 (7) [back to overview]	Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.
NCT00449176 (7) [back to overview]	Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.
NCT00449176 (7) [back to overview]	Number of Participants With Treatment Discontinuation Due to Lack of Efficacy
NCT00449176 (7) [back to overview]	Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12
NCT00449176 (7) [back to overview]	Responder Analysis 50% Improvement
NCT00449176 (7) [back to overview]	Change From Baseline in EuroQol-5® (EQ-5D) Health Status Index to Week 12
NCT00449176 (7) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Total Pain Score Over the Last Week of the Maintenance Period at Week 12.
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID 60) at 60 Minutes
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID15) At 15 Minutes
NCT00463047 (41) [back to overview]	Pain Relief (PR) Score at 5 Minutes
NCT00463047 (41) [back to overview]	Pain Relief Score (PR) at 10 Minutes
NCT00463047 (41) [back to overview]	Pain Relief Score (PR) at 15 Minutes
NCT00463047 (41) [back to overview]	Pain Relief Score (PR) at 30 Minutes
NCT00463047 (41) [back to overview]	Pain Relief Score (PR) at 45 Minutes
NCT00463047 (41) [back to overview]	Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (%PID) at 10 Minutes
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (%PID) at 15 Minutes
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (%PID) at 30 Minutes
NCT00463047 (41) [back to overview]	Percentage Change in Pain Intensity Difference (%PID) at 60 Minutes
NCT00463047 (41) [back to overview]	Standard Rescue Medication Usage
NCT00463047 (41) [back to overview]	Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)
NCT00463047 (41) [back to overview]	Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <= 5 Minutes
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <=10 Minutes
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <=15 Minutes
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <=30 Minutes
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <=45 Minutes
NCT00463047 (41) [back to overview]	Time to Any Pain Relief (APR) by Treatment, <=60 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <= 5 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <=10 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <=15 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <=30 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <=45 Minutes
NCT00463047 (41) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment, <=60 Minutes
NCT00463047 (41) [back to overview]	Total Pain Relief (TOTPAR60) at 60 Minutes
NCT00463047 (41) [back to overview]	Breakthrough Pain Preference Questionnaire
NCT00463047 (41) [back to overview]	Medication Performance Assessment 30 Minutes After-treatment
NCT00463047 (41) [back to overview]	Medication Performance Assessment 60 Minutes After-treatment
NCT00463047 (41) [back to overview]	Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at Endpoint (End of Second Double-blind Treatment Period or Last Observation After Start of Treatment Period)
NCT00463047 (41) [back to overview]	Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the First Double-blind Treatment Period (Visit 5)
NCT00463047 (41) [back to overview]	Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the Second Double-blind Treatment Period (Visit 6)
NCT00463047 (41) [back to overview]	Pain Relief Score (PR) at 60 Minutes
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID 10) at 10 Minutes
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID 30) at 30 Minutes
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID 45) at 45 Minutes
NCT00463047 (41) [back to overview]	Pain Intensity Difference (PID 5) at 5 Minutes
NCT00486811 (11) [back to overview]	Patient Global Impression of Change
NCT00486811 (11) [back to overview]	Patient Assessment of Constipation Symptoms (PAC-SYM) Over Time
NCT00486811 (11) [back to overview]	Sleep Questionnaire: Number of Awakenings During Sleep
NCT00486811 (11) [back to overview]	Number of Participants Reporting a Category From the Quality of Sleep (Sleep Questionnaire)
NCT00486811 (11) [back to overview]	Change in the Health Survey Scores Form (SF-36)
NCT00486811 (11) [back to overview]	Change From Baseline of the Average Pain Intensity Overall in the 12-week Maintenance Period of the Daily Pain Intensity on an 11-point Numeric Rating Scale (NRS).
NCT00486811 (11) [back to overview]	Sleep Questionnaire: Change From Baseline in Sleep Latency Time in Hours to the Last Week of the Maintenance Period.
NCT00486811 (11) [back to overview]	Sleep Questionnaire: Amount of Time Slept in Hours
NCT00486811 (11) [back to overview]	EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
NCT00486811 (11) [back to overview]	Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.
NCT00486811 (11) [back to overview]	Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12
NCT00499460 (6) [back to overview]	Somatic Side Effects Total Score
NCT00499460 (6) [back to overview]	Cognitive-Affective Side Effects Total Score
NCT00499460 (6) [back to overview]	Cold Pressor Tolerance AUC
NCT00499460 (6) [back to overview]	Oral Digoxin Test
NCT00499460 (6) [back to overview]	Oral Midazolam Test
NCT00499460 (6) [back to overview]	Oxycodone Oral Clearance
NCT00613938 (5) [back to overview]	Total Pain Relief (TOTPAR)at 48 Hours
NCT00613938 (5) [back to overview]	The SPID at 12 Hours Relative to First Dose.
NCT00613938 (5) [back to overview]	SPID at 24 Hours Relative to First Dose
NCT00613938 (5) [back to overview]	Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change to Day 3
NCT00613938 (5) [back to overview]	Sum of Pain Intensity Difference Over 48 Hours (SPID48)
NCT00654069 (1) [back to overview]	SPID48
NCT00685295 (3) [back to overview]	Pain Reduction
NCT00685295 (3) [back to overview]	Time to Analgesia
NCT00685295 (3) [back to overview]	Occurrence of Untoward Opioid Side Effects
NCT00699010 (1) [back to overview]	Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)
NCT00737737 (2) [back to overview]	Is Chronic Opioid Treatment Associated With Changes in Adrenocorticotropic Hormone (ACTH), Cortisol, Luteinizing Hormone (LH) and Testosterone Secretion?
NCT00737737 (2) [back to overview]	Is Placebo Analgesia Associated With a Similar Hormonal Response as Elicited by an Opioid Analgesic?
NCT00771758 (45) [back to overview]	Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) Over 5 Days
NCT00771758 (45) [back to overview]	Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) Over 3 Days
NCT00771758 (45) [back to overview]	Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) Over 2 Days
NCT00771758 (45) [back to overview]	Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) Over 10 Days
NCT00771758 (45) [back to overview]	Sum of Pain Intensity Difference Over 3 Days (SPID72)
NCT00771758 (45) [back to overview]	Sum of Pain Intensity Difference Over 2 Days (SPID48)
NCT00771758 (45) [back to overview]	Sum of Pain Intensity Difference Over 10 Days
NCT00771758 (45) [back to overview]	Change From Baseline in Physical Performance: Measured Walk - Change in Time Taken Per Meter to Take Walk in the End of Study
NCT00771758 (45) [back to overview]	Change From Baseline in Physical Performance: Measured Walk - Change in Distance Walked in the End of Study
NCT00771758 (45) [back to overview]	Sleep Quality - Shift From Baseline to End of Study (Placebo)
NCT00771758 (45) [back to overview]	Summary of Subject Satisfaction With Treatment on Day 2
NCT00771758 (45) [back to overview]	Change From Baseline in Physical Performance: Chair Stand - Change in Number of Chair Stands Completed in the End of Study
NCT00771758 (45) [back to overview]	50% Responder Rate on Day 5.
NCT00771758 (45) [back to overview]	50% Responder Rate on Day 3.
NCT00771758 (45) [back to overview]	50% Responder Rate on Day 10.
NCT00771758 (45) [back to overview]	30% Responder Rate on Day 3.
NCT00771758 (45) [back to overview]	30% Responder Rate on Day 10.
NCT00771758 (45) [back to overview]	Change From Baseline in Physical Performance: Chair Stand - Change in Time Taken to Complete Chair Stands in the End of Study
NCT00771758 (45) [back to overview]	Summary of Functionality: Chair - Proportion With at Least 2 Points of Improvement From Baseline to Day 10
NCT00771758 (45) [back to overview]	Summary of Functionality: Chair - Proportion With at Least 2 Points of Improvement From Baseline to Day 2
NCT00771758 (45) [back to overview]	Summary of Functionality: Bath/Shower - Proportion With at Least 2 Points of Improvement From Baseline to Day 5
NCT00771758 (45) [back to overview]	Summary of Functionality: Chair - Proportion With at Least 2 Points of Improvement From Baseline to Day 5
NCT00771758 (45) [back to overview]	Summary of Functionality: Dressing - Proportion With at Least 2 Points of Improvement From Baseline to Day 10
NCT00771758 (45) [back to overview]	Summary of Functionality: Dressing - Proportion With at Least 2 Points of Improvement From Baseline to Day 2
NCT00771758 (45) [back to overview]	Summary of Functionality: Dressing - Proportion With at Least 2 Points of Improvement From Baseline to Day 3
NCT00771758 (45) [back to overview]	Summary of Functionality: Dressing - Proportion With at Least 2 Points of Improvement From Baseline to Day 5
NCT00771758 (45) [back to overview]	Summary of Subject Satisfaction With Treatment on Day 10
NCT00771758 (45) [back to overview]	Summary of Subject Satisfaction With Treatment on Day 3
NCT00771758 (45) [back to overview]	Summary of Subject Satisfaction With Treatment on Day 5
NCT00771758 (45) [back to overview]	Total Pain Relief (TOTPAR) Over 10 Days
NCT00771758 (45) [back to overview]	Total Pain Relief (TOTPAR) Over 2 Days
NCT00771758 (45) [back to overview]	Total Pain Relief (TOTPAR) Over 3 Days
NCT00771758 (45) [back to overview]	Total Pain Relief (TOTPAR) Over 5 Days
NCT00771758 (45) [back to overview]	Clinician Global Impression of Change (CGIC) at End of Study
NCT00771758 (45) [back to overview]	Patient Global Impression of Change (PGIC) at End of Study
NCT00771758 (45) [back to overview]	Sum of Pain Intensity Difference Over 5 Days (SPID120)
NCT00771758 (45) [back to overview]	Sleep Quality - Shift From Baseline to End of Study (Oxycodone IR)
NCT00771758 (45) [back to overview]	Summary of Functionality: Chair - Proportion With at Least 2 Point of Improvement From Baseline to Day 3
NCT00771758 (45) [back to overview]	30% Responder Rate on Day 5.
NCT00771758 (45) [back to overview]	Sleep Quality - Shift From Baseline to End of Study (Tapentadol IR)
NCT00771758 (45) [back to overview]	Summary of Clinician Ease-of-Care at the End of Study: Bothersome
NCT00771758 (45) [back to overview]	Summary of Clinician Ease-of-Care at the End of Study: Time Comsuming
NCT00771758 (45) [back to overview]	Summary of Functionality: Bath/Shower - Proportion With at Least 2 Points of Improvement From Baseline to Day 3
NCT00771758 (45) [back to overview]	Summary of Functionality: Bath/Shower - Proportion With at Least 2 Points of Improvement From Baseline to Day 2
NCT00771758 (45) [back to overview]	Summary of Functionality: Bath/Shower - Proportion With at Least 2 Points of Improvement From Baseline to Day 10
NCT00784277 (2) [back to overview]	5-Day Sum of Pain Intensity Difference (SPID5)
NCT00784277 (2) [back to overview]	Spontaneous Bowel Movements Per Week (SBMs/Week)
NCT00784810 (2) [back to overview]	Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)
NCT00784810 (2) [back to overview]	Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.
NCT00813488 (46) [back to overview]	Total Pain Relief at 60 Minutes (TOTPAR60)
NCT00813488 (46) [back to overview]	Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment
NCT00813488 (46) [back to overview]	Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment
NCT00813488 (46) [back to overview]	Clinician Global Impression of Change (CGIC)Endpoint
NCT00813488 (46) [back to overview]	Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 10 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 30 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 45 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 5 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Intensity Difference (PID) at 60 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief (PR) Score at 5 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief Score at 10 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief Score at 15 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief Score at 30 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief Score at 45 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Pain Relief Score at 60 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment
NCT00813488 (46) [back to overview]	Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment
NCT00813488 (46) [back to overview]	Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment
NCT00813488 (46) [back to overview]	Patient Global Impression of Change (PGIC) Endpoint
NCT00813488 (46) [back to overview]	Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)
NCT00813488 (46) [back to overview]	Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment <=10 Minutes
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment <=15 Minutes
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment <=30 Minutes
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment <=45 Minutes
NCT00813488 (46) [back to overview]	Time to Any Pain Relief (APR) by Treatment <=60 Minutes
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes
NCT00813488 (46) [back to overview]	Use of Standard Rescue Medication
NCT00813488 (46) [back to overview]	Breakthrough Pain Preference Questionnaire
NCT00813488 (46) [back to overview]	Medication Performance Assessment 30 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Medication Performance Assessment 60 Minutes Post-treatment
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes
NCT00813488 (46) [back to overview]	Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes
NCT00814580 (34) [back to overview]	Clinician Global Impression of Change (CGIC) at End of Study
NCT00814580 (34) [back to overview]	Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
NCT00814580 (34) [back to overview]	Patient Global Impression of Change (PGIC) at End of Study
NCT00814580 (34) [back to overview]	Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
NCT00814580 (34) [back to overview]	Subject Satisfaction With Treatment
NCT00814580 (34) [back to overview]	Summary of Medical Resource Utilization - Number of Calls by the Subject to Study Site Personnel
NCT00814580 (34) [back to overview]	Summary of Medical Resource Utilization - Number of Other Types of Contacts With Healthcare Professionals
NCT00814580 (34) [back to overview]	Summary of Kaplan-Meier Estimates for Time to Achieve 30% Reduction in Pain Intensity From Baseline
NCT00814580 (34) [back to overview]	Summary of 50% Responder Rate (With Imputation) on Day 7
NCT00814580 (34) [back to overview]	Summary of 50% Responder Rate (With Imputation) on Day 3
NCT00814580 (34) [back to overview]	Summary of 30% Responder Rate (With Imputation) on Day 7
NCT00814580 (34) [back to overview]	Summary of 30% Responder Rate (With Imputation) on Day 3
NCT00814580 (34) [back to overview]	Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 7 Days
NCT00814580 (34) [back to overview]	Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 3 Days (72hours)
NCT00814580 (34) [back to overview]	Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 2 Days (48 Hours)
NCT00814580 (34) [back to overview]	Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 7 Days
NCT00814580 (34) [back to overview]	Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 3 Days (72 Hours)
NCT00814580 (34) [back to overview]	Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 2 Days (48 Hours)
NCT00814580 (34) [back to overview]	Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 7 Days
NCT00814580 (34) [back to overview]	Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)
NCT00814580 (34) [back to overview]	Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 2 Days (48 Hours)
NCT00814580 (34) [back to overview]	Summary of Kaplan-Meier Estimates for Time to Achieve 50% Reduction in Pain Intensity From Baseline
NCT00820027 (9) [back to overview]	Percentage of Participants With at Least One Hypertension-Related AE
NCT00820027 (9) [back to overview]	Percentage of Participants With at Least One Opioid-Related AE
NCT00820027 (9) [back to overview]	Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)
NCT00820027 (9) [back to overview]	Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)
NCT00820027 (9) [back to overview]	Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)
NCT00820027 (9) [back to overview]	Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)
NCT00820027 (9) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT00820027 (9) [back to overview]	Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure
NCT00820027 (9) [back to overview]	Percentage of Participants With at Least One Edema-Related AE
NCT00935311 (4) [back to overview]	Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS)
NCT00935311 (4) [back to overview]	Time to First Rescue Medication
NCT00935311 (4) [back to overview]	TOTPAR (Total Pain Relief)
NCT00935311 (4) [back to overview]	Participants With Adverse Events (AEs)
NCT00941304 (11) [back to overview]	Change From Baseline in Cognitive Assessment Using CNS-VS
NCT00941304 (11) [back to overview]	Duration of Analgesia
NCT00941304 (11) [back to overview]	"Percentage of Participants With Excellent Investigator Global Rating of Study Drug"
NCT00941304 (11) [back to overview]	Onset of Analgesia
NCT00941304 (11) [back to overview]	Peak Pain Intensity Difference
NCT00941304 (11) [back to overview]	Peak Pain Relief
NCT00941304 (11) [back to overview]	Sum of Pain Intensity Difference From Baseline to 8 Hours
NCT00941304 (11) [back to overview]	Sum of Pain Relief and Intensity Differences Over 2 Hours
NCT00941304 (11) [back to overview]	Sum of Pain Relief and Intensity Differences Over 8 Hours
NCT00941304 (11) [back to overview]	Total Pain Relief Over 8 Hours
NCT00941304 (11) [back to overview]	"Percentage of Participants Reporting a Global Rating of Study Drug as Excellent"
NCT00944697 (1) [back to overview]	Short Form McGill Pain Score.
NCT00955110 (1) [back to overview]	High VAS - Emax (mm)
NCT00979953 (1) [back to overview]	Change From Baseline in the Average Pain Score (NPRS) for Week 2
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in WOMAC Pain Subscale Item (Pain When Going Up or Down Stairs) at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in WOMAC Pain Subscale Item (Pain When Going Up or Down Stairs) at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in WOMAC Pain Subscale Item (Pain When Walking on a Flat Surface) at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in WOMAC Pain Subscale Item (Pain When Walking on a Flat Surface) at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Number of Days With Rescue Medication (RM) Usage
NCT00985621 (47) [back to overview]	Number of Participants With Adverse Event of Abnormal Peripheral Sensation According to Severity
NCT00985621 (47) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00985621 (47) [back to overview]	Number of Participants With Anti-Drug (Tanezumab) Antibody (ADA)
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Number of Participants With At Least (>=) 30 Percent (%), 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Change From Baseline in Euro Quality of Life-5 Dimension (EQ-5D) - Individual Dimensions at Week 12: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Change From Baseline in Euro Quality of Life-5 Dimension (EQ-5D) - Individual Dimensions at Week 12: mITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants Who Discontinued From Study Due to Lack of Efficacy
NCT00985621 (47) [back to overview]	Time to Discontinuation From Study Due to Lack of Efficacy
NCT00985621 (47) [back to overview]	Amount of Rescue Medication Used
NCT00985621 (47) [back to overview]	Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: mITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Improvement of At Least (>=) 2 Points From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8 12 and 16: mITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Improvement of At Least (>=) 2 Points From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Intravenous (IV) Doses of Study Medication
NCT00985621 (47) [back to overview]	Number of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: Modified Intent-to-Treat (mITT) Population
NCT00985621 (47) [back to overview]	Number of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Pre-Specified Opioid-Related Adverse Events According to Severity
NCT00985621 (47) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12: ITT Population
NCT00985621 (47) [back to overview]	Tanezumab Plasma Concentration
NCT00985621 (47) [back to overview]	Total Nerve Growth Factor (NGF) Serum Concentration
NCT00985621 (47) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Aggregate Scores at Week 12: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Aggregate Scores at Week 12: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Average Pain Score in the Index Knee or Index Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Euro Quality of Life-5 Dimension (EQ-5D) - Health State Profile Utility Score at Week 12: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants With At Least (>=) 30 Percent (%), 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Euro Quality of Life-5 Dimension (EQ-5D) - Health State Profile Utility Score at Week 12: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, and 18
NCT00985621 (47) [back to overview]	Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, and 16: mITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Average Pain Score in the Index Knee or Index Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, and 16: ITT Population
NCT00985621 (47) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: ITT Population
NCT00985621 (47) [back to overview]	Number of Participants With Rescue Medication (RM) Usage
NCT00986180 (36) [back to overview]	Summary of Subjects Having Nausea as a Treatment-Emergent Adverse Event
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Affective Descriptors Day 5
NCT00986180 (36) [back to overview]	Summary of Subjects Having Constipation as a Treatment-Emergent Adverse Event
NCT00986180 (36) [back to overview]	Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 2 Days (With Imputation)
NCT00986180 (36) [back to overview]	Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 120 Hours (With Imputation)
NCT00986180 (36) [back to overview]	SPID for Low Back Pain - Summary Statistics at 3 Days (With Imputation)
NCT00986180 (36) [back to overview]	SPID for Low Back Pain - Summary Statistics at 10 Days (With Imputation)
NCT00986180 (36) [back to overview]	SPID for Index Leg Pain - Summary Statistics at 3 Days (With Imputation)
NCT00986180 (36) [back to overview]	SPID for Index Leg Pain - Summary Statistics at 2 Days (With Imputation)
NCT00986180 (36) [back to overview]	SPID for Index Leg Pain - Summary Statistics at 10 Days (With Imputation)
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Total Score Day 5
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Total Score Day 10/Last Visit
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Neuropathic Pain Day 5
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Neuropathic Pain Day 10/Last Visit
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Intermittent Pain Day 5
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Intermittent Pain Day 10/Last Visit
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Continuous Pain Day 5
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Continuous Pain Day 10/Last Visit
NCT00986180 (36) [back to overview]	Patient Global Impression of Change at End of Study
NCT00986180 (36) [back to overview]	Summary of Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation
NCT00986180 (36) [back to overview]	Satisfaction With Treatment at End of Study
NCT00986180 (36) [back to overview]	Satisfaction With Treatment at Day 5
NCT00986180 (36) [back to overview]	SPID for Index Leg Pain - Summary Statistics at 5 Days (With Imputation)
NCT00986180 (36) [back to overview]	Clinician Global Impression of Change at End of Study
NCT00986180 (36) [back to overview]	Total Pain Relief (TOTPAR) for Low Back Pain - Summary Statistics at 5 Days
NCT00986180 (36) [back to overview]	Summary of Subjects Having Vomiting as a Treatment-Emergent Adverse Event
NCT00986180 (36) [back to overview]	Summary of Subjects Having Pruritus as a Treatment-Emergent Adverse Event
NCT00986180 (36) [back to overview]	Clinician Global Impression of Change at End of Study
NCT00986180 (36) [back to overview]	Incidence of 30% Responders Without Nausea or Vomiting at Day 5
NCT00986180 (36) [back to overview]	Incidence of 50% Responders Without Nausea or Vomiting at Day 5
NCT00986180 (36) [back to overview]	Kaplan-Meier First Time to 30% Response From Baseline for Low Back Pain
NCT00986180 (36) [back to overview]	Kaplan-Meier First Time to 50% Response From Baseline for Low Back Pain
NCT00986180 (36) [back to overview]	Patient Global Impression of Change at End of Study
NCT00986180 (36) [back to overview]	Satisfaction With Treatment at Day 5
NCT00986180 (36) [back to overview]	Satisfaction With Treatment at End of Study
NCT00986180 (36) [back to overview]	SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Affective Descriptors Day 10/Last Visit
NCT00999544 (2) [back to overview]	Abuse Liability Proxy
NCT00999544 (2) [back to overview]	Respiration Depression
NCT01063868 (1) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAE)
NCT01083485 (2) [back to overview]	Mean Dose (mg) of Rescue Analgesia for the Treatment Phase for Subjects Taking 20/10mg OXN PR Tablets or 20mg OXY PR Tablets
NCT01083485 (2) [back to overview]	Mean of 4 NRS Scores for 24 Hour Pain Intensity at Rest, Shown as Absolute Change From Baseline (i.e. a Decrease From the Baseline Value)
NCT01099709 (3) [back to overview]	AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01099709 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01099709 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01100086 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01100086 (3) [back to overview]	AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01100086 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01100320 (3) [back to overview]	AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01100320 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01100320 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101165 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101165 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01101165 (3) [back to overview]	AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01101178 (3) [back to overview]	AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01101178 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01101178 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101191 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101191 (3) [back to overview]	AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01101191 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01101308 (3) [back to overview]	AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01101308 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01101308 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101321 (3) [back to overview]	Cmax - Maximum Observed Plasma Concentration
NCT01101321 (3) [back to overview]	AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
NCT01101321 (3) [back to overview]	AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT01160614 (8) [back to overview]	Single-dose PK Metric: Time to Maximum Plasma Concentration (Tmax)
NCT01160614 (8) [back to overview]	Single- and Multiple-dose PK Metric: Maximum Observed Plasma Concentration From Hour 0 to 12 Hours of the First Dose of ORF (Cmax 0-12)
NCT01160614 (8) [back to overview]	Multiple-dose PK Metric: Minimum Observed Plasma Concentration Just Prior to the Next Dose (Cmin)
NCT01160614 (8) [back to overview]	Single- and Multiple-dose PK Metric: Mean Area Under the Plasma Concentration During Each Dosing Interval-time Curve From Hour 0 to 12 Hours of the First Dose of ORF (AUC 0-12)
NCT01160614 (8) [back to overview]	Single- and Multiple-dose PK Metric: Time to Maximum Plasma Concentration From Hour 0 to 12 Hours of the First Dose of ORF (Tmax 0-12)
NCT01160614 (8) [back to overview]	Single-dose PK Metric: Area Under the Plasma Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration [AUCt]
NCT01160614 (8) [back to overview]	The Number of Patients With Adverse Events as a Measure of Safety
NCT01160614 (8) [back to overview]	Single-dose PK Metric: Maximum Observed Plasma Concentration (Cmax)
NCT01165281 (7) [back to overview]	Proportion of Patients With Various Levels of Pain Improvement (Responders)
NCT01165281 (7) [back to overview]	Number of Patients Who Discontinued Due to Lack of Efficacy
NCT01165281 (7) [back to overview]	Percentage of Patients in Patient Global Impression of Change (PGIC) Score Categories
NCT01165281 (7) [back to overview]	Total Daily Dose of Rescue Medication Use for the Double-blind Treatment Period
NCT01165281 (7) [back to overview]	Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical Rating Scale
NCT01165281 (7) [back to overview]	Frequency of Rescue Medication Use for the Double-blind Treatment Period
NCT01165281 (7) [back to overview]	Proportion of Patients Entering the Maintenance Period
NCT01192295 (11) [back to overview]	Use of Supplemental Pain Medication
NCT01192295 (11) [back to overview]	Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Accumulation Ratio
NCT01192295 (11) [back to overview]	Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets
NCT01192295 (11) [back to overview]	Parent/ Caregiver-Assessed Global Impression of Change (PGIC)
NCT01192295 (11) [back to overview]	Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Time to Maximum Concentration (Tmax)
NCT01192295 (11) [back to overview]	Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged ≥ 12 to ≤ 16 Years
NCT01192295 (11) [back to overview]	Pain Right Now Assessment by Patients Aged 6 to < 12 Years
NCT01192295 (11) [back to overview]	Pain Right Now Assessment by Patients Aged ≥ 12 to ≤ 16 Years
NCT01192295 (11) [back to overview]	The Number of Participants With Adverse Events as a Measure of Safety.
NCT01192295 (11) [back to overview]	Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged 6 to < 12 Years
NCT01192295 (11) [back to overview]	Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - AUCtau and AUCss
NCT01205126 (6) [back to overview]	Breakthrough Pain Medication (Rescue Medication) Doses Taken
NCT01205126 (6) [back to overview]	Change From Baseline in Average Pain, in the Past 24 Hours Assessed by BPI Short Form Questionnaire Score at Day 29
NCT01205126 (6) [back to overview]	Change From Baseline in Pain at Its Least, in the Past 24 Hours Assessed by BPI Short Form Questionnaire Score at Day 29
NCT01205126 (6) [back to overview]	Change From Baseline in Pain Relief, in the Past 24 Hour Recorded Assessed by BPI Short Form Questionnaire at Day 29
NCT01205126 (6) [back to overview]	Change From Baseline in Pain Right Now Assessed by BPI Short Form Questionnaire Score at Day 29
NCT01205126 (6) [back to overview]	Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29
NCT01270659 (3) [back to overview]	Number of Participants Experiencing Any Adverse Events
NCT01270659 (3) [back to overview]	Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level)
NCT01270659 (3) [back to overview]	Nausea Level
NCT01313780 (2) [back to overview]	Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)
NCT01313780 (2) [back to overview]	Change in Bowel Habits.
NCT01328782 (5) [back to overview]	The Faces Pain Scale-Revised (FSP-R) Scores (Scored 0-10).
NCT01328782 (5) [back to overview]	Total Quality Pain Management Survey (TQPM) Scores for Questions # 16: Child's Current Level of Pain, Question # 17: Child's Worst Level of Pain When Moving Around After Surgery and Question # 18: Child's Worst Level of Pain While Resting
NCT01328782 (5) [back to overview]	Total Dosage in Morphine Equivalents (mg/kg) of All Analgesics Received in Prior to Discharge
NCT01328782 (5) [back to overview]	Time (in Minutes) to First Narcotic Administration
NCT01328782 (5) [back to overview]	Need for IV Morphine of Fentanyl
NCT01358526 (5) [back to overview]	Patient Global Impression of Change (PGIC)
NCT01358526 (5) [back to overview]	Responder Analysis for Subjects With a ≥ 30% Reduction in Pain Compared to Baseline
NCT01358526 (5) [back to overview]	The Sleep Disturbance Subscale of the MOS Sleep Scale at Weeks 4, 8, and 12
NCT01358526 (5) [back to overview]	Responder Analysis for Subjects With a ≥ 50% Reduction in Pain Compared to Baseline
NCT01358526 (5) [back to overview]	"The Average Pain Over the Last 24 Hours at Week 12 of the Double-blind Period"
NCT01369615 (1) [back to overview]	The Number of Participants With Adverse Events as a Measure of Safety.
NCT01381120 (2) [back to overview]	Change in Post-ureteroscopy Stent-induced Pain
NCT01381120 (2) [back to overview]	Change in Post-ureteroscopy Stent-induced Lower Urinary Tract Symptoms.
NCT01402375 (4) [back to overview]	50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score
NCT01402375 (4) [back to overview]	Difference in Pain Intensity Score Before and After Last Dose.
NCT01402375 (4) [back to overview]	Time to Follow up
NCT01402375 (4) [back to overview]	Overall Satisfaction With the Pain Medicine
NCT01428583 (14) [back to overview]	Number of Participants With Rescue Medication (Acetaminophen Tablets)
NCT01428583 (14) [back to overview]	Mean Change From Baseline in Worst Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
NCT01428583 (14) [back to overview]	Mean Daily Dose of Study Medication (Oxycodone Component)
NCT01428583 (14) [back to overview]	Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) Based on Intensity
NCT01428583 (14) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions
NCT01428583 (14) [back to overview]	Subjective Opiate Withdrawal Scale (SOWS) Score
NCT01428583 (14) [back to overview]	Percentage of Participants With Response to Urine Drug Test
NCT01428583 (14) [back to overview]	Percentage of Participants With Current Opioid Misuse Measure (COMM) Score of 9 or Above
NCT01428583 (14) [back to overview]	Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score
NCT01428583 (14) [back to overview]	Participants Global Assessment of Treatment Satisfaction
NCT01428583 (14) [back to overview]	Duration of Exposure to Study Medication
NCT01428583 (14) [back to overview]	Time to Stabilization of Study Medication
NCT01428583 (14) [back to overview]	Mean Change From Baseline in Average Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
NCT01428583 (14) [back to overview]	Mean Change From Baseline in Pain Right Now Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
NCT01500317 (5) [back to overview]	Colonic Geometric Center at 8 and 48 Hours
NCT01500317 (5) [back to overview]	Ascending Colon Emptying (AC t1/2)
NCT01500317 (5) [back to overview]	Colonic Filling at 6 Hours
NCT01500317 (5) [back to overview]	Colonic Transit, Geometric Center at 24 Hours
NCT01500317 (5) [back to overview]	Gastric Emptying Half-time (t1/2) at 24 Hours
NCT01502644 (1) [back to overview]	Percent Change in Average Daily Pain Score
NCT01571362 (101) [back to overview]	Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Screening Period to End of Open-Label Titration Period in Hospitalization Because of Low Back Pain as Assessed Using the Healthcare Resource Use (HRU) Questionnaire
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Screening Period to Randomization Baseline in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
NCT01571362 (101) [back to overview]	Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
NCT01571362 (101) [back to overview]	Satisfaction With Treatment at Randomization Baseline
NCT01571362 (101) [back to overview]	Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
NCT01571362 (101) [back to overview]	SOWS Total Score During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	SOWS Total Score During the Post-Treatment Period
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D VAS
NCT01571362 (101) [back to overview]	Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Open-Label Titration Period in Roland-Morris Disability Questionnaire (RMDQ) Total Score for All Participants
NCT01571362 (101) [back to overview]	Area Under the Curve (AUC) of eDiary NRS-Pain Scores From Randomization Baseline to Final 2 Weeks of the Double-Blind Treatment Period (Weeks 11 and 12)
NCT01571362 (101) [back to overview]	Average Daily Use of Rescue Acetaminophen (Milligrams Per Day [mg/Day]) During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D Summary Index
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using the EQ-5D VAS
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D Summary Index
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D VAS
NCT01571362 (101) [back to overview]	Change in Roland-Morris Disability Questionnaire (RMDQ) Total Score From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit).
NCT01571362 (101) [back to overview]	Change in Weekly Average Electronic Diary (eDiary) Numeric Rating Scale -Pain (NRS-Pain) Score From Randomization Baseline to Final 2 Weeks (Average of Weeks 11 and 12)
NCT01571362 (101) [back to overview]	Mean Oxycodone Average Daily Dose During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Mean Oxycodone Average Daily Dose During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	Mean Oxycodone Duration of Titration During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	Mean Oxycodone Duration of Treatment During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Median Oxycodone Average Daily Dose During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Median Oxycodone Average Daily Dose During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	Median Oxycodone Duration of Titration During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	Median Oxycodone Duration of Treatment During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Median Time to Treatment Discontinuation for Investigator-Reported Lack of Efficacy During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Percentage of Participants Discontinuing Treatment for Investigator-Reported Lack of Efficacy
NCT01571362 (101) [back to overview]	Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥30%
NCT01571362 (101) [back to overview]	Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥40%
NCT01571362 (101) [back to overview]	Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥50%
NCT01571362 (101) [back to overview]	Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction of Greater or Equal to (≥) 20%
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
NCT01571362 (101) [back to overview]	Change From Randomization Baseline to the End of Double-Blind Weeks 2, 4, and 8 in RMDQ Total Score
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in RMDQ Total Score
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Open-Label in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP): % Work Time Missed, % Impairment, % Overall Work Impairment, % Activity Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D Summary Index
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in RMDQ Total Score
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
NCT01571362 (101) [back to overview]	Change From Screening Period to Randomization Baseline in WPAI:SHP: Percent Work Time Missed, Percent Impairment, Percent Overall Work Impairment, Percent Activity Impairment Due to Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EQ-5D VAS
NCT01571362 (101) [back to overview]	Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EuroQol 5-Dimensions (EQ-5D) Summary Index
NCT01571362 (101) [back to overview]	Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
NCT01571362 (101) [back to overview]	Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
NCT01571362 (101) [back to overview]	Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
NCT01571362 (101) [back to overview]	Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Nights Stayed in Hospital
NCT01571362 (101) [back to overview]	Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Change From Screening to Randomization Baseline in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
NCT01571362 (101) [back to overview]	Change From Screening to Randomization Baseline in HRU Questionnaire: Nights Stayed in Hospital
NCT01571362 (101) [back to overview]	Change From Screening to Randomization Baseline in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
NCT01571362 (101) [back to overview]	Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
NCT01571362 (101) [back to overview]	COWS Total Score During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	COWS Total Score During the Post-Treatment Period
NCT01571362 (101) [back to overview]	Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
NCT01571362 (101) [back to overview]	Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
NCT01571362 (101) [back to overview]	Median Time to 20%, 30%, 40%, or 50% Loss of Analgesic Response From Baseline During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
NCT01571362 (101) [back to overview]	Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Titration Period
NCT01571362 (101) [back to overview]	Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Titration Period
NCT01571362 (101) [back to overview]	Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
NCT01571362 (101) [back to overview]	Percentage of Participants Who Reported Being Satisfied/Very Satisfied With Treatment on the Satisfaction With Treatment Questionnaire During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
NCT01571362 (101) [back to overview]	Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
NCT01571362 (101) [back to overview]	Percentage of Participants With a 20%, 30%, 40%, or 50% Loss of Analgesic Response From Randomization Baseline During the Double-Blind Treatment Period
NCT01571362 (101) [back to overview]	Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
NCT01571362 (101) [back to overview]	Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
NCT01587274 (1) [back to overview]	Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire
NCT01643772 (22) [back to overview]	ke for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	CL for Participants Who Received Multiple Dose
NCT01643772 (22) [back to overview]	Tmax,t1/2 for Participants Who Received Multiple Dose
NCT01643772 (22) [back to overview]	AUC0-t and AUC0-∞ for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose)
NCT01643772 (22) [back to overview]	Tmax,t1/2 for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Cmax,Clast for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Mutilple Dose)
NCT01643772 (22) [back to overview]	Tmax,t1/2 for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose)
NCT01643772 (22) [back to overview]	Fluctuation Index (DF) for Participants Who Received Multiple Dose
NCT01643772 (22) [back to overview]	ke for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Vd for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Css_min,Css_max and Css_av for Participants Who Received Multiple Dose
NCT01643772 (22) [back to overview]	Cmax,Clast for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Clearance Rate for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Clearance Rate for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Average Cumulative Excretion Rate of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose)
NCT01643772 (22) [back to overview]	The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Multiple Dose)
NCT01643772 (22) [back to overview]	AUCss for Participants Who Received Multiple Dose
NCT01643772 (22) [back to overview]	AUC0-t and AUC0-∞ for Participants Who Received a Single Dose
NCT01643772 (22) [back to overview]	Vd for Participants Who Received a Single Dose
NCT01675531 (4) [back to overview]	Physician's Overall Satisfaction
NCT01675531 (4) [back to overview]	Patient's Overall Satisfaction
NCT01675531 (4) [back to overview]	NRS (Numeric Rating Scale)
NCT01675531 (4) [back to overview]	Mean Change in FACT-GOG/NTX From Visit1(Week 0) to Visit 4(Week 4 Post-treatment).
NCT01675622 (9) [back to overview]	Degree of Pain Relief Within 24hrs After Treatment
NCT01675622 (9) [back to overview]	Numerical Rating Scale (NRS)
NCT01675622 (9) [back to overview]	The Average Dose of Study Medicine Used During Double Blind Treatment Period
NCT01675622 (9) [back to overview]	Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment
NCT01675622 (9) [back to overview]	Average Number of Titrations
NCT01675622 (9) [back to overview]	Times of Breakthrough Pain Occurrence
NCT01675622 (9) [back to overview]	Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment
NCT01675622 (9) [back to overview]	Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period
NCT01675622 (9) [back to overview]	the Total Dose of Rescue Medicine for Breakthrough Pain.
NCT01685684 (9) [back to overview]	Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind Maintenance Phase
NCT01685684 (9) [back to overview]	Change in Level of Physical Disability Using the Roland Morris Disability Questionnaire (RMDQ)
NCT01685684 (9) [back to overview]	Time-to-exit From the Study for All Causes
NCT01685684 (9) [back to overview]	Changes in Quality of Life
NCT01685684 (9) [back to overview]	Percent Reduction in Pain Intensity for Responders
NCT01685684 (9) [back to overview]	Rescue Medication Usage by Dose
NCT01685684 (9) [back to overview]	Rescue Medication Use by Dosage
NCT01685684 (9) [back to overview]	Weekly Changes in Pain Intensity
NCT01685684 (9) [back to overview]	Patient Global Impression of Change (PGIC)
NCT01719757 (4) [back to overview]	Overall Satisfaction Assessment About Efficacy and Tolerability of Oxycodone/Naloxone by the Investigator and Subject
NCT01719757 (4) [back to overview]	Change of Constipation Assessment From Baseline to Visit 2(End Visit)
NCT01719757 (4) [back to overview]	Change in Numeric Rating Scales (NRS) Score
NCT01719757 (4) [back to overview]	Change of Eastern Cooperative Oncology Group(ECOG) Performance Status
NCT01746901 (52) [back to overview]	Overall Drug Liking: Minimum Effect (Emin)
NCT01746901 (52) [back to overview]	Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour, 0-8 Hour 0-12 Hour and 0-24 Hour of Oxycodone
NCT01746901 (52) [back to overview]	Number of Participants With Clinically Significant Change in Oxygen Saturation of Hemoglobin (SpO2)
NCT01746901 (52) [back to overview]	Number of Participants With Clinically Significant Change in End Tidal Carbon Dioxide (EtCO2)
NCT01746901 (52) [back to overview]	Nausea: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour
NCT01746901 (52) [back to overview]	Bad Drug Effects: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Oxycodone
NCT01746901 (52) [back to overview]	Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Overall Drug Liking: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Overall Drug Liking: Mean Effect (Emean)
NCT01746901 (52) [back to overview]	Plasma Terminal Half-Life (t1/2) of Oxycodone
NCT01746901 (52) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone, Oxymorphone and Noroxycodone
NCT01746901 (52) [back to overview]	Number of Participants With Clinically Significant Change in Vital Sign Examinations
NCT01746901 (52) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone and 6-beta-naltrexol
NCT01746901 (52) [back to overview]	Take Drug Again Effect at Hours 12, 24 and 36
NCT01746901 (52) [back to overview]	Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Overall Drug Liking Effect at Hours 12, 24 and 36
NCT01746901 (52) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT01746901 (52) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Naltrexone and 6-beta-naltrexol
NCT01746901 (52) [back to overview]	Nausea: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	High: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of Oxycodone, Oxymorphone and Noroxycodone
NCT01746901 (52) [back to overview]	Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	Take Drug Again: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Take Drug Again: Minimum Effect (Emin)
NCT01746901 (52) [back to overview]	Take Drug Again: Mean Effect (Emean)
NCT01746901 (52) [back to overview]	Sleepy: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Sleepy: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Any Drug Effects: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)dn] of Oxycodone
NCT01746901 (52) [back to overview]	Drug Liking: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Drug Liking: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Feel Sick: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Feel Sick: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Pupillometry: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Good Drug Effects: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	High: Area Under Effect Curve (AUE) From 0-2 Hour
NCT01746901 (52) [back to overview]	Nausea: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	High: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour, 0-12 Hour, 0-24 Hour and 0-36 Hour
NCT01746901 (52) [back to overview]	High: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Pupillometry: Peak Effect (Emax)
NCT01746901 (52) [back to overview]	Dizzy: Time to Maximum (Peak) Effect (TEmax)
NCT01746901 (52) [back to overview]	Dizzy: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Dizzy: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Subject Rating Scale for Nasal Effects: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Sleepy: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour and 0-2 Hour
NCT01775189 (58) [back to overview]	Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Plasma Decay Half-Life (t1/2) of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Plasma Decay Half-Life (t1/2) of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	Overall Drug Liking Effect at Hours 12 and 24
NCT01775189 (58) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT01775189 (58) [back to overview]	Nausea: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	High: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hours
NCT01775189 (58) [back to overview]	Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour
NCT01775189 (58) [back to overview]	Take Drug Again: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Take Drug Again: Mean Effect (Emean)
NCT01775189 (58) [back to overview]	Sleepy: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Pupillometry: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Pupillometry: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Percentage of Dose (Drug Powder) Insufflated
NCT01775189 (58) [back to overview]	Overall Drug Liking: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Overall Drug Liking: Mean Effect (Emean)
NCT01775189 (58) [back to overview]	Number of Participants With Clinically Significant Change in Vital Sign Examinations
NCT01775189 (58) [back to overview]	Number of Participants With Clinically Significant Change in Oxygen Saturation of Hemoglobin (SpO2)
NCT01775189 (58) [back to overview]	Number of Participants With Clinically Significant Change in End Tidal Carbon Dioxide (EtCO2)
NCT01775189 (58) [back to overview]	Nausea: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Nausea: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	High: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	High: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	High: Area Under Effect Curve (AUE) From 0-2 Hour
NCT01775189 (58) [back to overview]	Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Good Drug Effects: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Feel Sick: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Feel Sick: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Drug Liking: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Drug Liking: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour
NCT01775189 (58) [back to overview]	Dizzy: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Take Drug Again Effect at Hours 12 and 24
NCT01775189 (58) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone and 6-beta-naltrexol
NCT01775189 (58) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone, Oxymorphone and Noroxycodone
NCT01775189 (58) [back to overview]	Bad Drug Effects: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01775189 (58) [back to overview]	Any Drug Effects: Peak Effect (Emax)
NCT01775189 (58) [back to overview]	Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax)
NCT01809106 (3) [back to overview]	The Opioid Escalation Index
NCT01809106 (3) [back to overview]	Proportion of Full-responder
NCT01809106 (3) [back to overview]	Proportion of Non-Responder (NR) Participants
NCT01811186 (6) [back to overview]	Assessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
NCT01811186 (6) [back to overview]	Assessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
NCT01811186 (6) [back to overview]	The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.
NCT01811186 (6) [back to overview]	Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment
NCT01811186 (6) [back to overview]	Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug
NCT01811186 (6) [back to overview]	The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.
NCT01811238 (6) [back to overview]	Change From Baseline in Health-related Quality of Life Assessed by EuroQol Visual Analog Scale (EQ-5D VAS)
NCT01811238 (6) [back to overview]	Change From Baseline in Pain Intensity of Patient With Spinal Disorder as Measured by NRS.
NCT01811238 (6) [back to overview]	Change of Pain Intensity in Patient With Spinal Disorder at Week 4 of Treatment With the Study Drug From Baseline
NCT01811238 (6) [back to overview]	The Change in Quality of Life (EQ-5D) at Week 8 of Treatment With the Study Drug From Baseline
NCT01811238 (6) [back to overview]	Clinical Global Impression of Change(CGIC)
NCT01811238 (6) [back to overview]	Patient Global Impression of Change(PGIC)
NCT01838616 (31) [back to overview]	Change in Worst Pain Intensity Over the Past 24 Hours at the End of Treatment
NCT01838616 (31) [back to overview]	Change of Average Pain Intensity Over Three Days for Pain Radiating Towards or Into the Leg at the End of Treatment
NCT01838616 (31) [back to overview]	Comparison of the Number of Participants Affected by Gastrointestinal Treatment Emergent Adverse Events (TEAEs) Typical for Opioids
NCT01838616 (31) [back to overview]	Composite Event Based Comparison of Gastrointestinal Treatment Emergent Adverse Events (TEAEs) Typical for Opioids
NCT01838616 (31) [back to overview]	Sleep Evaluation at the End of Treatment: Change in Latency (Change in the Time Taken to Fall Asleep)
NCT01838616 (31) [back to overview]	Sleep Evaluation at the End of Treatment: Change in the Number of Awakenings
NCT01838616 (31) [back to overview]	Sleep Evaluation at the End of Treatment: Change in the Number of Hours Slept
NCT01838616 (31) [back to overview]	Average Pain Intensity Over Three Days for Pain Radiating Towards or Into the Leg
NCT01838616 (31) [back to overview]	Changes in the Short Form Health Survey (SF-12) at the End of Treatment
NCT01838616 (31) [back to overview]	Clinician Global Impression of Change at the End of Treatment
NCT01838616 (31) [back to overview]	EuroQol-5 (EQ-5D) Health Status Index Outcome
NCT01838616 (31) [back to overview]	Hospital Anxiety and Depression Scale: Anxiety
NCT01838616 (31) [back to overview]	Hospital Anxiety and Depression Scale: Depression
NCT01838616 (31) [back to overview]	Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score Assessment
NCT01838616 (31) [back to overview]	painDETECT Final Assessment
NCT01838616 (31) [back to overview]	Patient Global Impression of Change at the End of Treatment
NCT01838616 (31) [back to overview]	Recalled Average Pain Intensity
NCT01838616 (31) [back to overview]	Short Form Health Survey (SF-12)
NCT01838616 (31) [back to overview]	Sleep Evaluation at the End of Treatment: Change in the Overall Quality of Sleep
NCT01838616 (31) [back to overview]	Sleep Evaluation: Latency (Time Taken to Fall Asleep)
NCT01838616 (31) [back to overview]	Sleep Evaluation: Number of Awakenings
NCT01838616 (31) [back to overview]	Sleep Evaluation: Number of Hours Slept
NCT01838616 (31) [back to overview]	Worst Pain Intensity Over the Past 24 Hours
NCT01838616 (31) [back to overview]	Change in EuroQol-5 (EQ-5D) Health Status Index Outcome at the End of Treatment
NCT01838616 (31) [back to overview]	Change in Hospital Anxiety and Depression Scale at the End of Treatment: Depression
NCT01838616 (31) [back to overview]	Change in Hospital Anxiety and Depression Scale at the End of Treatment: Anxiety
NCT01838616 (31) [back to overview]	Change in painDETECT Final Assessment at the End of Treatment
NCT01838616 (31) [back to overview]	Change in Recalled Average Pain Intensity at the End of Treatment
NCT01838616 (31) [back to overview]	Change in the Average Pain Intensity Score on an 11-point Numeric Rating Scale (NRS-3)
NCT01838616 (31) [back to overview]	Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) Total Score
NCT01838616 (31) [back to overview]	Change in Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score Assessment at the End of Treatment
NCT01859715 (2) [back to overview]	Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users
NCT01859715 (2) [back to overview]	Adverse Drug Events
NCT01871285 (5) [back to overview]	Change From Baseline in Maximum COWS Total Score
NCT01871285 (5) [back to overview]	Number of Responders
NCT01871285 (5) [back to overview]	Change From Baseline in COWS Total Score Over Time
NCT01871285 (5) [back to overview]	"Change From Baseline in Pain Now Over Time Using NRS"
NCT01871285 (5) [back to overview]	Maximum COWS Total Score
NCT01885182 (9) [back to overview]	The Change of BPI-SF at visit8
NCT01885182 (9) [back to overview]	The Chage of Symptoms of Constipation Based on Laxative Use From visit5 to visit8
NCT01885182 (9) [back to overview]	The Change of Bowel Movement by Visit
NCT01885182 (9) [back to overview]	The Change of Individual Items in BPI-SF(Except for Pain in Average) by Visit
NCT01885182 (9) [back to overview]	The Change of Modified Subjective Opiate Withdrawal Scale (SOWS) From Visit1 to visit3,visit1 to visit9
NCT01885182 (9) [back to overview]	To Assess Quality of Life Based on EQ-5D
NCT01885182 (9) [back to overview]	The Change of BFI-Bowel Function Index at visit8
NCT01885182 (9) [back to overview]	The Change of Symptoms of Constipation Based on Laxative Use From visit5 to visit8
NCT01885182 (9) [back to overview]	The Change of Rescue Medication Use From visit5 to visit8
NCT01959204 (3) [back to overview]	Cmax of Oxycodone Oral Solution.
NCT01959204 (3) [back to overview]	Number of Participants With Adverse Events
NCT01959204 (3) [back to overview]	Tmax of Oxycodone Oral Solution.
NCT02109640 (3) [back to overview]	Pain Scores
NCT02109640 (3) [back to overview]	Prevalence of Postoperative Gut Dysfunction
NCT02109640 (3) [back to overview]	Total Opioid Analgesia Consumption
NCT02455518 (2) [back to overview]	Between Group Difference in Change in Numerical Rating Scale (NRS) Pain Scores
NCT02455518 (2) [back to overview]	Between Group Difference in Change in Numerical Rating Scale (NRS) Pain Scores
NCT02480114 (3) [back to overview]	Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))
NCT02480114 (3) [back to overview]	Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)
NCT02480114 (3) [back to overview]	Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)
NCT02519023 (14) [back to overview]	Total Opioid Taken by Patient as Tabulated and Converted to Morphine Equivalents
NCT02519023 (14) [back to overview]	Total Opioid Use for Pain Control
NCT02519023 (14) [back to overview]	Overall Benefit of Analgesia Score (OBAS)
NCT02519023 (14) [back to overview]	Opioid Used From 24-48 Hours Post Surgery
NCT02519023 (14) [back to overview]	Number of Patients Admitted Post Operatively
NCT02519023 (14) [back to overview]	Number of Participants With Nausea and Vomiting
NCT02519023 (14) [back to overview]	Quality of Recovery 15 (QoR15) Score
NCT02519023 (14) [back to overview]	Total Opioid Taken by Patient as Tabulated and Converted to Morphine Equivalents
NCT02519023 (14) [back to overview]	Maximum Pain Scores as Measured by Numerical Pain Rating Scale (0-10)
NCT02519023 (14) [back to overview]	Maximal Pain Score Patient Felt From 48-72 Hours After Surgery
NCT02519023 (14) [back to overview]	Maximal Pain Score of Patient From Time 0-24 Hours After Surgery
NCT02519023 (14) [back to overview]	Maximal Pain Score for Patient From Time 24-48 Hours After Surgery
NCT02519023 (14) [back to overview]	Length of Time in Phase 1 and Phase 2 of Recovery
NCT02519023 (14) [back to overview]	Patient Satisfaction With Pain Management
NCT02601027 (6) [back to overview]	Time to Ambulation
NCT02601027 (6) [back to overview]	Quality of Life Measurement
NCT02601027 (6) [back to overview]	Time to First Bowel Movement
NCT02601027 (6) [back to overview]	Post-operative Anti-emetic Usage
NCT02601027 (6) [back to overview]	Post-operative Narcotic Usage
NCT02601027 (6) [back to overview]	Post-operative Pain Score
NCT02625181 (4) [back to overview]	Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]	Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02625181 (4) [back to overview]	The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]	PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02660229 (2) [back to overview]	Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration
NCT02660229 (2) [back to overview]	Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.
NCT02680847 (6) [back to overview]	Number of Participants With Clinical Opiate Withdrawal Scale (COWS)
NCT02680847 (6) [back to overview]	Number of Participants With All-causality and Treatment-related Serious Adverse Events (SAEs)
NCT02680847 (6) [back to overview]	Number of Participants With All-causality and Treatment-related Adverse Events (AEs)
NCT02680847 (6) [back to overview]	Number of All-causality and Treatment-related AEs, by Intensity
NCT02680847 (6) [back to overview]	Number of Participants With Maximum Changes in Vital Signs (Blood Pressure, Heart Rate, Respiratory Rate) Meeting Categorical Summarization Criteria
NCT02680847 (6) [back to overview]	Number of Participants With Laboratory (Lab) Abnormalities (Hematology and Chemistry)
NCT02740114 (3) [back to overview]	Participants Opioid-Free After Gynecologic Surgery
NCT02740114 (3) [back to overview]	Symptom Scores
NCT02740114 (3) [back to overview]	Participants Opioid-Free After Gynecologic Surgery for 48 Hours
NCT02741076 (14) [back to overview]	Change in the Mean Average Pain Intensity (PI) Score on the 0-10 Numerical Ratings Scale (NRS)
NCT02741076 (14) [back to overview]	Sexual Function Measured Using the International Index of Erectile Function (IIEF) for Men and the Female Sexual Function Index (FSFI) for Women
NCT02741076 (14) [back to overview]	Patient Global Impression of Change (PGIC)
NCT02741076 (14) [back to overview]	Participants Sleep Quantity Measured by Medical Outcomes Study (MOS)
NCT02741076 (14) [back to overview]	Participant Reported Quality of Life Assessment Using Visual Analog Scale (EQ-5D-5L Standardized Instrument)
NCT02741076 (14) [back to overview]	Sexual Function Measured Using the International Index of Erectile Function (IIEF) for Men and the Female Sexual Function Index (FSFI) for Women
NCT02741076 (14) [back to overview]	Participant Reported Quality of Life Assessment Using EQ-5D-5L Standardized Instrument
NCT02741076 (14) [back to overview]	Number of Suboptimal Responders With Pain Intensity (PI) Score Worsening Relative to Baseline PI Measured on the 0-10 Numerical Ratings Scale (NRS)
NCT02741076 (14) [back to overview]	Number of Suboptimal Responders With Pain Intensity (PI) Score Improvement Relative to Baseline PI Measured on the 0-10 Numerical Ratings Scale (NRS)
NCT02741076 (14) [back to overview]	Number of Participants Reporting Major or Severe Major Depression Using Patient Health Questionnaire Depression Scale (PHQ-8)
NCT02741076 (14) [back to overview]	Digit Symbol Substitution Test
NCT02741076 (14) [back to overview]	Change in Mean Average Pain Intensity Score (PI) Score on the 0-10 Numerical Ratings Scale (NRS)
NCT02741076 (14) [back to overview]	Change From Baseline on Sleep Quality Measured by Medical Outcomes Study (MOS)
NCT02741076 (14) [back to overview]	Change From Baseline in the Patient Health Questionnaire Depression Scale (PHQ-8)
NCT02932579 (2) [back to overview]	Number of Participants That Did Not Need Opioid Analgesic Prescriptions
NCT02932579 (2) [back to overview]	Mean Pain Score
NCT02934191 (2) [back to overview]	Difference in Amount of Rescue Pain Medication Consumed
NCT02934191 (2) [back to overview]	Difference in Number of Days Requiring Rescue Pain Medication
NCT03055507 (6) [back to overview]	Pain Visual Analogue Scale (VAS)
NCT03055507 (6) [back to overview]	Pain Visual Analogue Scale
NCT03055507 (6) [back to overview]	Pain Visual Analogue Scale
NCT03055507 (6) [back to overview]	Number of Opioid Pills
NCT03055507 (6) [back to overview]	Bleeding Visual Analogue Scale
NCT03055507 (6) [back to overview]	0-4 Bleeding Scale
NCT03088826 (1) [back to overview]	Pain Reduction at 60 Minutes (Baseline Pain Score - Pain Score at 60 Minutes)
NCT03105518 (2) [back to overview]	Amount of Discomfort Following Discharge Until Embryo Transfer
NCT03105518 (2) [back to overview]	Amount of Discomfort
NCT03139240 (3) [back to overview]	<7 Weeks of Gestation - Maximum Self-reported Pain Score
NCT03139240 (3) [back to overview]	7-10 Weeks Gestation - Maximum Self-reported Pain Score
NCT03139240 (3) [back to overview]	Overall Maximum Self-reported Pain Score
NCT03173456 (6) [back to overview]	Percentage of Patients Who Received Rescue Medication
NCT03173456 (6) [back to overview]	Percentage of Patients Who Experience Side Effects Within One Hour of Ingestion of Study Medication
NCT03173456 (6) [back to overview]	Percentage of Patients Who Would Choose to Take the Study Medication Again if They Returned to the ED With Similar Pain
NCT03173456 (6) [back to overview]	Percentage of Patients Who Experience Side Effects in Two Hours After Ingestion of Study Medication
NCT03173456 (6) [back to overview]	Change in Pain From Before Medication Administered (Baseline) to Two Hour Post-baseline
NCT03173456 (6) [back to overview]	Change in Pain From Before Medication Administered (Baseline) to One-hour Post-baseline
NCT03202550 (9) [back to overview]	Baseline Pain Score Before Drugs Were Administered
NCT03202550 (9) [back to overview]	Number of Participants With Desired Number of Dilators Inserted
NCT03202550 (9) [back to overview]	Cervical Dilator Placement Pain as Assessed by VAS on a Tablet Device
NCT03202550 (9) [back to overview]	Pain Score During Paracervical Block
NCT03202550 (9) [back to overview]	Pain Score Before Speculum Placement
NCT03202550 (9) [back to overview]	Pain Score at Tenaculum Placement
NCT03202550 (9) [back to overview]	Pain Score After Speculum Placement
NCT03202550 (9) [back to overview]	Pain Score After First Dilator Placement
NCT03202550 (9) [back to overview]	Pain Score 15 Minutes After Last Dilator Placed
NCT03254459 (7) [back to overview]	Percentage of Participants Provided Rescue Medication for Nausea
NCT03254459 (7) [back to overview]	Total Use of Rescue Medication for Nausea Over 0 to 24 Hours, Over 0 to 48 Hours, Over 0-72 Hours and 0-7 Days
NCT03254459 (7) [back to overview]	Pulse Oximetry Levels at 90 Minutes,12, 24, 48 and 72 Hours
NCT03254459 (7) [back to overview]	Number of Participants With Abnormal Oral Cavity Examinations
NCT03254459 (7) [back to overview]	Number of Participants With Abnormal Electrocardiograms (ECGs) Findings at 90 Minutes,12, 24, 48 and 72 Hours
NCT03254459 (7) [back to overview]	Time to First Use of Rescue Medication for Nausea Following Each Dose of the Investigational Product (IP)
NCT03254459 (7) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT03389750 (1) [back to overview]	"Positive Subjective Drug Effects (i.e., Drug Liking)."
NCT03398278 (8) [back to overview]	Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State
NCT03398278 (8) [back to overview]	AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State
NCT03398278 (8) [back to overview]	AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State
NCT03398278 (8) [back to overview]	Number of AEs Related to Vital Sign
NCT03398278 (8) [back to overview]	Number of AEs Related to ECGs
NCT03398278 (8) [back to overview]	Number of AEs Related to Physical Examination
NCT03398278 (8) [back to overview]	Number of Lab Tests With Clinical Significance
NCT03398278 (8) [back to overview]	Adverse Event of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State
NCT03398330 (8) [back to overview]	Number of AEs Related to Vital Signs
NCT03398330 (8) [back to overview]	Number of AEs Related to Physical Examination
NCT03398330 (8) [back to overview]	Number of AEs Related to ECGs
NCT03398330 (8) [back to overview]	AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State
NCT03398330 (8) [back to overview]	AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State
NCT03398330 (8) [back to overview]	Number of Lab Tests With Clinical Significance
NCT03398330 (8) [back to overview]	Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State
NCT03398330 (8) [back to overview]	Adverse Events of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fed State
NCT03403504 (8) [back to overview]	AUCINF of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State
NCT03403504 (8) [back to overview]	AUCt of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State
NCT03403504 (8) [back to overview]	Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State
NCT03403504 (8) [back to overview]	Number of AEs Related to ECGs
NCT03403504 (8) [back to overview]	Number of AEs Related to Physical Examination
NCT03403504 (8) [back to overview]	Number of Lab Tests With Clinical Significance
NCT03403504 (8) [back to overview]	Adverse Events of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State
NCT03403504 (8) [back to overview]	Number of AEs Related to Vital Signs
NCT03415581 (2) [back to overview]	Opioid Craving
NCT03415581 (2) [back to overview]	Opioid Self-administration
NCT03435692 (6) [back to overview]	Muscle Spasm
NCT03435692 (6) [back to overview]	Maximum Pain Score
NCT03435692 (6) [back to overview]	Itching
NCT03435692 (6) [back to overview]	Hospital Length of Stay
NCT03435692 (6) [back to overview]	Nausea
NCT03435692 (6) [back to overview]	Total Perioperative Morphine Equivalents
NCT03480009 (4) [back to overview]	Mean Pain Scores Via Numeric Rating Scale (NRS-11)
NCT03480009 (4) [back to overview]	Worst Pain Measurement Via Numeric Rating Scale (NRS-11)
NCT03480009 (4) [back to overview]	Analgesic Usage During Medication Abortion
NCT03480009 (4) [back to overview]	Analgesic Usage During Medication Abortion
NCT03545893 (1) [back to overview]	Maximum Pain Score
NCT03584373 (7) [back to overview]	Unused Medications - Proportion of Prescribed Pills Unused at 1 Week Post-Surgery
NCT03584373 (7) [back to overview]	Rates of Constipation
NCT03584373 (7) [back to overview]	Peak Pain Intensity Level
NCT03584373 (7) [back to overview]	Average Pain Intensity Level
NCT03584373 (7) [back to overview]	Perception of an Acceptable Pain Intensity Level
NCT03584373 (7) [back to overview]	Satisfaction With Pain Relief
NCT03584373 (7) [back to overview]	Current Pain Intensity Level
NCT03588806 (8) [back to overview]	Patient Global Impression of Change (PGIC)
NCT03588806 (8) [back to overview]	Opioid Medication Satisfaction
NCT03588806 (8) [back to overview]	Effect of Xtampza ER Conversion on Pain Intensity in the Last 7 Days
NCT03588806 (8) [back to overview]	PROMIS Physical Function
NCT03588806 (8) [back to overview]	Change in Pill Swallowing Difficulty Score
NCT03588806 (8) [back to overview]	Effect of Xtampza ER Conversion on Pain Intensity in the Last 24 Hours
NCT03588806 (8) [back to overview]	PROMIS Depression, Anxiety, Satisfaction With Social Roles, and Sleep Disturbance
NCT03588806 (8) [back to overview]	Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference
NCT03588910 (5) [back to overview]	Self Reported Pain Score on Post Operative Day 7 (Numeric Pain Reporting Score: NRS)
NCT03588910 (5) [back to overview]	Self Reported Pain Score on Post Operative Day 1 (Numeric Pain Reporting Score: NRS)
NCT03588910 (5) [back to overview]	Number of Oxycodone Tablets Used Day 1
NCT03588910 (5) [back to overview]	Additional Contacts With Provider
NCT03588910 (5) [back to overview]	Number of Oxycodone Tablets Used as Reported by Participants 1 Week After Surgery
NCT03599089 (3) [back to overview]	Change in Postsurgical Pain Based on the Weighted Sum of Pain Intensity (SPI) Assessments Over 96 Hours of the NRS Scores = Area Under the Curve (AUC)
NCT03599089 (3) [back to overview]	Percentage of Subjects Opioid Free
NCT03599089 (3) [back to overview]	Total Opioid Consumption (in Daily Morphine Equivalents)
NCT03618823 (9) [back to overview]	Mean of Total Quantity of Pain Medications Taken
NCT03618823 (9) [back to overview]	Non-opioid Group Switching to Opioid Group
NCT03618823 (9) [back to overview]	Number of Participants With ED (Emergency Department) or Urgent Care Visits
NCT03618823 (9) [back to overview]	Number of Participants With Readmissions
NCT03618823 (9) [back to overview]	Overall Pain Relief Satisfaction
NCT03618823 (9) [back to overview]	Post-operative Nursing Phone Calls
NCT03618823 (9) [back to overview]	Average Dose of Each Analgesic Used
NCT03618823 (9) [back to overview]	Average Pain Burden
NCT03618823 (9) [back to overview]	Duration of Each Analgesic Used
NCT03657810 (9) [back to overview]	Number of Doses of Study Medication Taken Over Days 3to7
NCT03657810 (9) [back to overview]	Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours
NCT03657810 (9) [back to overview]	Number of Doses of Study Medication Taken Per Day Over Days 3to7
NCT03657810 (9) [back to overview]	The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48)
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Vomiting Over 48 Hours
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV)
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Nausea Over 48 Hours
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Nausea or Vomiting Over 48 Hours
NCT03657810 (9) [back to overview]	Percentage of Participants With OINV Over 48 Hours
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Pain Severity
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Medication Log
NCT03783702 (25) [back to overview]	Severity of Epistaxis
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Brief Pain Inventory (BPI) Score
NCT03783702 (25) [back to overview]	Pain Severity
NCT03789318 (5) [back to overview]	Weighted Sum of Pain Intensity (SPI) Assessments = AUC of NRS Scores
NCT03789318 (5) [back to overview]	Percent of Opioid Free Subjects
NCT03789318 (5) [back to overview]	Pain Intensity Scores at 96 Hours at Rest Using Numerical Rating Scale (NRS)
NCT03789318 (5) [back to overview]	Total Opioid Consumption
NCT03789318 (5) [back to overview]	Time to Opioid Cessation or Freedom
NCT03802227 (5) [back to overview]	Change in Pupil Diameter Via Pupillometry
NCT03802227 (5) [back to overview]	Treatment-Emergent Adverse Events (TEAEs)
NCT03802227 (5) [back to overview]	Brain Activity Measured Via fMRI
NCT03802227 (5) [back to overview]	Time to Maximum Concentration (Tmax)
NCT03802227 (5) [back to overview]	Plasma Drug Concentration
NCT03996694 (4) [back to overview]	Change in Ratio of Minute Ventilation
NCT03996694 (4) [back to overview]	Respiratory Drive
NCT03996694 (4) [back to overview]	Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.
NCT03996694 (4) [back to overview]	Pupil Diameter
NCT04149964 (8) [back to overview]	Participant Use of Additional Pain Medication
NCT04149964 (8) [back to overview]	Participant Use of Acetaminophen as Needed
NCT04149964 (8) [back to overview]	Number of Doses of Opiate (Narcotic) Pain Medication
NCT04149964 (8) [back to overview]	Lowest Subjective Pain Score
NCT04149964 (8) [back to overview]	Highest Subjective Pain Score
NCT04149964 (8) [back to overview]	Chronic Use of Pain Medication
NCT04149964 (8) [back to overview]	Percentage of Time Participant Experienced Severe Pain
NCT04149964 (8) [back to overview]	Participant Use of Scheduled Acetaminophen Around the Clock
NCT04194528 (1) [back to overview]	Feasibility Determined by Accrual, Adherence and Patient Retention.
NCT04223609 (8) [back to overview]	Saccadic Latency
NCT04223609 (8) [back to overview]	Fixation Time - High Cognitive Workload
NCT04223609 (8) [back to overview]	Vertical Saccadic Velocity
NCT04223609 (8) [back to overview]	Fixation Time - Low Cognitive Workload
NCT04223609 (8) [back to overview]	Fixation Time - Medium Cognitive Workload
NCT04223609 (8) [back to overview]	Horizontal Saccadic Velocity
NCT04223609 (8) [back to overview]	Oculo-Cognitive Addition Test (OCAT) Completion Time
NCT04223609 (8) [back to overview]	Diagonal Saccadic Velocity
NCT04246541 (2) [back to overview]	Narcotic Medication Consumed
NCT04246541 (2) [back to overview]	Pain Levels Recorded With a Visual Analogue Scale
NCT04246554 (2) [back to overview]	Narcotic Medication
NCT04246554 (2) [back to overview]	Postoperative Visual Analogue Scale Scores
NCT04285853 (1) [back to overview]	Pain Level: Numeric Rating Scale
NCT04296396 (9) [back to overview]	Number of Morphine Milligram Equivalents Used at 2 Weeks Post Discharge
NCT04296396 (9) [back to overview]	Number of Participants Who Filled One or More Opioid Prescriptions Beyond the Amount Prescribed at Discharge
NCT04296396 (9) [back to overview]	Number of Participants Who Indicated an Improved Global Impression of Change
NCT04296396 (9) [back to overview]	Number of Participants With Worst Pain Score of Moderate to Severe on the Brief Pain Inventory
NCT04296396 (9) [back to overview]	Pain Interference Score ≥ 4 at 2 Weeks Post Discharge
NCT04296396 (9) [back to overview]	Worst Pain Severity Score at 2 Weeks Post Discharge
NCT04296396 (9) [back to overview]	Number of Opioid Tablets Unused Since Discharge
NCT04296396 (9) [back to overview]	Infant Hospital Readmissions
NCT04296396 (9) [back to overview]	Maternal Depression Score ≥ 13
NCT04399122 (2) [back to overview]	Post-operative Uncorrected Visual Acuity Right and Left Eye
NCT04399122 (2) [back to overview]	Post-operative Average Pain Score
NCT04429022 (8) [back to overview]	Operative Time
NCT04429022 (8) [back to overview]	Length of Stay in Hours
NCT04429022 (8) [back to overview]	Estimated Blood Loss
NCT04429022 (8) [back to overview]	Total Opioid Pain Medications Required Through 3-24h Post op in MME
NCT04429022 (8) [back to overview]	Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME)
NCT04429022 (8) [back to overview]	Pain Scores
NCT04429022 (8) [back to overview]	Number of Patients With Return to the Clinic, Emergency Department Due to Post Operative Pain Within a 2 Week Period
NCT04429022 (8) [back to overview]	Pain Scores
NCT04522206 (3) [back to overview]	Length of Stay in Hospital
NCT04522206 (3) [back to overview]	Opioid Sparing and Rescue Time
NCT04522206 (3) [back to overview]	Visual Analogue Scale (VAS) for Pain
NCT05053126 (5) [back to overview]	"Bipolar VAS for Overall Drug Liking"
NCT05053126 (5) [back to overview]	"Bipolar VAS for Take Drug Again"
NCT05053126 (5) [back to overview]	"Bipolar Visual Analog Scale (VAS) for Drug Liking Maximum Effect (Emax)."
NCT05053126 (5) [back to overview]	"Unipolar VAS for Any Drug Effect"
NCT05053126 (5) [back to overview]	"Unipolar VAS for High - Maximum Effect (Emax)"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve to 8 Hours (AUEC8)"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve to 4 Hours (AUEC4)"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve to 3 Hours (AUEC3)"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve to 2 Hours (AUEC2)"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve to 1 Hour (AUEC1)"
NCT05319756 (26) [back to overview]	"Unipolar VAS for Bad Drug Effect"
NCT05319756 (26) [back to overview]	"Unipolar VAS for Any Drug Effect"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking - Time to Maximum Effect (TEmax)"
NCT05319756 (26) [back to overview]	"Area Under the Effect Curve for High VAS (AUEClast)"
NCT05319756 (26) [back to overview]	Tmax of Oxycodone
NCT05319756 (26) [back to overview]	Tmax of Gabapentin
NCT05319756 (26) [back to overview]	Half-life (t½) of Oxycodone
NCT05319756 (26) [back to overview]	Half-life (t½) of Gabapentin
NCT05319756 (26) [back to overview]	Cmax of Oxycodone
NCT05319756 (26) [back to overview]	Cmax of Gabapentin
NCT05319756 (26) [back to overview]	AUClast of Oxycodone
NCT05319756 (26) [back to overview]	AUClast of Gabapentin
NCT05319756 (26) [back to overview]	AUCinf of Oxycodone
NCT05319756 (26) [back to overview]	AUCinf of Gabapentin
NCT05319756 (26) [back to overview]	"Unipolar VAS for High: Time to Maximum Effect (TEmax)"
NCT05319756 (26) [back to overview]	"Unipolar VAS for High - Maximum Effect (Emax)"
NCT05319756 (26) [back to overview]	"Unipolar VAS for Good Drug Effect"
NCT05319756 (26) [back to overview]	"Bipolar Visual Analog Scale (VAS) for Drug Liking Maximum Effect (Emax)."
NCT05319756 (26) [back to overview]	"Bipolar VAS for Take Drug Again"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Overall Drug Liking"
NCT05319756 (26) [back to overview]	"Bipolar VAS for Drug Liking: Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)"
NCT05327777 (2) [back to overview]	Satisfaction Scores Ranging From 1 - 10
NCT05327777 (2) [back to overview]	Morphine Milligram Equivalents Taken by Participants

Drug Liking

"Subjective rating of drug Liking on a scale of 0 to 100. Greater numbers indicate greater subjective report of Liking." (NCT00158184)
Timeframe: Highest rating obtained following adminstration of each of the 3 test doses.

Intervention	units on a scale (Mean)
	Placebo: 0 mg	Oxycodone: 15 mg	Oxycodone: 30 mg
Rx Opioid Abusers	23	60	59
Rx Opioid Non-Abusers	21	53	40

Intervention	Mouse Clicks (Mean)
	Placebo: 0 mg	Oxycodone: 15mg	Oxycodone: 30mg
Rx Opioid Abusers	25	1400	1100
Rx Opioid Non-Abusers	400	850	900

Intervention	Subjects (Number)
	Adverse events (core)	Adverse events (extension)	Consent withdrawn (core)	Consent withdrawn (extension)	Inadequate pain relief (core)	Inadequate pain relief (extension)	Investigator withdrew patient (core)	Investigator withdrew patient (extension)	Lost to follow up (core)	Lost to follow up (extension)	Non compliance (core)	Non compliance (extension)	Other (core)	Other (extension)	Protocol violation (core)	Protocol violation (extension)	Treatment completed no follow up visit (core)	Treatment completed no follow up visit (extension)	Inefficacy at maximal dosage (core)
OROS Hydromorphone HCl	57	4	12	0	22	0	4	0	2	1	3	1	6	4	6	0	2	0	17
Oxycodone	56	1	16	1	18	1	2	0	0	0	10	0	5	2	6	0	0	0	12

Intervention	Units on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
OROS Hydromorphone HCl	0.7	0.5	0.4	0.3	0.2	0.3	0.3
Oxycodone	0.4	0.4	0.4	0.3	0.2	0.2	0.3

Intervention	Units on a scale (Mean)
	Pain severity, BPI items 3 to 6	Pain relief, BPI item 8	Pain right now, BPI item 6	Pain at its worst, BPI item 3	Pain at its least, BPI item 4	Average pain, BPI item 5	Pain interfered general activity, BPI item 9a	Pain interfered mood, BPI item 9b	Pain interfered walking ability, BPI item 9c	Pain interfered normal work, BPI item 9d	Pain interfered relation other people, BPI item 9e	BPI pain interfered sleep, BPI item 9f	BPI pain interfered enjoyment of life, BPI item 9g
OROS Hydromorphone HCl	-2.4	17.7	-2.9	-2.8	-1.9	-2.6	-2.5	-2.3	-2.3	-2.9	-1.6	-2.4	-2.4
Oxycodone	-2.4	23.6	-2.8	-2.4	-2.3	-2.6	-2.6	-2.7	-2.5	-3.2	-1.9	-3.0	-2.6

Intervention	Units on a scale (Mean)
	SF-36 bodily pain index	SF-36 general health perceptions	SF-36 health transition	SF-36 mental health	SF-36 physical functioning	SF-36 role emotional	SF-36 role physical	SF-36 social functioning	SF-36 vitality
OROS Hydromorphone HCl	23.1	9.6	-0.3	11.7	11.4	22.1	17.0	15.4	11.5
Oxycodone	19.6	5.5	-0.1	6.9	9.2	7.3	15.0	12.8	11.9

Intervention	Units on a scale (Mean)
	MOS sleep disturbance	MOS snoring	MOS sleep shortness of breath or headache	MOS sleep adequacy	MOS sleep somnolence	MOS sleep quantity
OROS Hydromorphone HCl	-17.6	-2.5	-8.4	12.3	-6.5	0.5
Oxycodone	-20.1	-4.7	-7.8	11.9	1.8	0.5

Intervention	Units on a scale (Mean)
	Evening worst pain	Evening least pain	Evening average pain	Morning worst pain	Morning least pain	Morning average pain	All day worst pain	All day least pain	All day average pain	All day pain right now
OROS Hydromorphone HCl	-2.2	-1.6	-2.0	-1.9	-1.5	-1.7	-2.1	-1.5	-1.8	-2.1
Oxycodone	-2.1	-1.4	-1.8	-2.1	-1.2	-1.8	-2.1	-1.3	-1.8	-2.0

Intervention	Subjects (Number)
	0 mg (week 4)	+8 mg (week 4)	+20 mg (week 4)	+24 mg (week 4)	+60 mg (week 4)	-60 mg (week 24)	-40 mg (week 24)	-24 mg (week 24)	-20 mg (week 24)	-16 mg (week 24)	-8 mg (week 24)	0 mg (week 24)	+8 mg (week 24)	+16 mg (week 24)	+20 mg (week 24)	+40 mg (week 24)	-16 mg (week 52)	-8 mg (week 52)	0 mg (week 52)	+40 mg (week 52)
OROS Hydromorphone HCl	79	102	0	73	0	0	0	1	0	4	11	172	6	9	0	0	3	1	56	0
Oxycodone	84	0	108	0	58	2	8	0	6	0	0	144	0	0	8	14	0	0	50	2

Intervention	Subjects (Number)
	Titration phase (on study at least 4 weeks) 0 mg	Titration phase (on study at least 4 weeks) +8 mg	Titration phase (on study at least 4 weeks) +20 mg	Titration phase (on study at least 4 weeks) +24 mg	Titration phase (on study at least 4 weeks) +60 mg	Titration phase (on study <4 weeks) 0 mg	Titration phase (on study <4 weeks) +8 mg	Titration phase (on study <4 weeks) +20 mg	Titration phase (on study <4 weeks) +24 mg	Titration phase (on study <4 weeks) +60 mg	Week 24 (on study at least 4 weeks) 0 mg	Week 24 (on study at least 4 weeks ) +4 mg	Week 24 (on study at least 4 weeks ) +8 mg	Week 24 (on study at least 4 weeks) +20 mg	Week 24 (on study at least 4 weeks ) +24 mg	Week 24 (on study at least 4 weeks) +60 mg	Week 24 (on study <4 weeks) 0 mg	Week 24 (on study <4 weeks) +8 mg	Week 24 (on study <4 weeks) +20 mg	Week 24 (on study <4 weeks) +24 mg	Week 24 (on study <4 weeks) +60 mg
OROS Hydromorphone HCl	50	92	0	65	0	29	10	0	8	0	58	0	76	0	73	0	29	10	0	8	0
Oxycodone	41	0	94	0	54	43	0	14	0	4	40	1	0	87	0	61	43	0	14	0	4

Intervention	Subjects (Number)
	Visit 5, week 4: very good	Visit 5, week 4: good	Visit 5, week 4: moderate	Visit 5, week 4: poor	Visit 5, week 4: very poor	Visit 8, week 24: very good	Visit 8, week 24: good	Visit 8, week 24: moderate	Visit 8, week 24: poor	Visit 8, week 24: very poor	Visit 10, week 52: very good	Visit 10, week 52: good	Visit 10, week 52: moderate	Visit 10, week 52: poor	Visit 10, week 52: very poor
OROS Hydromorphone HCl	49	92	51	12	0	48	91	50	44	16	18	37	5	0	0
Oxycodone	27	92	50	9	3	31	103	41	50	10	11	34	6	1	0

Intervention	Subjects (Number)
	Very convenient, week 4	Convenient, week 4	Neither convenient or inconvenient, week 4	Inconvenient, week 4	Very inconvenient, week 4	Very convenient, week 24	Convenient, week 24	Neither convenient or inconvenient, week 24	Inconvenient, week 24	Very inconvenient, week 24	Very convenient, week 52	Convenient, week 52	Neither convenient or inconvenient, week 52	Inconvenient, week 52	Very inconvenient, week 52
OROS Hydromorphone HCl	57	97	30	7	3	63	96	31	8	7	21	10	2	0	0
Oxycodone	36	94	30	6	1	53	90	33	11	8	11	15	2	0	0

Intervention	Tablets (Mean)
	Prerandomization	Double-blind
Double-blind BTDS 20	1.7	2.3
Double-blind BTDS 5	2.0	3.3
Double-blind Oxycodone Immediate-Release	1.6	2.3

Intervention	Units on a scale (Mean)
	Screening	Prerandomization	Week 4	Week 8	Week 12
Double-blind BTDS 20	37.69	24.19	28.34	28.34	29.35
Double-blind BTDS 5	36.88	25.96	30.60	28.70	29.68
Double-blind Oxycodone Immediate-Release	36.81	24.42	26.65	26.59	27.25

Intervention	score on a scale (Mean)
Tapentadol IR Fixed Dose 50 mg	73.9
Tapentadol IR Fixed Dose 75 mg	54.4
Tapentadol IR Fixed Dose 100 mg	49.3
Oxycodone HCL IR Fixed Dose 10 mg	57.6
Placebo Fixed Dose	-18.6

Intervention	Units on a scale (Least Squares Mean)
Fentanyl Buccal Tablets (FBT)	3.35
Immediate-Release Oxycodone	3.19

Intervention	Units on a scale (Least Squares Mean)
Fentanyl Buccal Tablets (FBT)	0.82
Immediate-Release Oxycodone	0.59

Intervention	Units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	0.10
Immediate-Release Oxycodone	0.09

Intervention	Units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	0.30
Immediate-Release Oxycodone	0.25

Intervention	Units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	0.69
Immediate-Release Oxycodone	0.53

Intervention	Units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	1.50
Immediate-Release Oxycodone	1.23

oxycodone

Description

Cross-References

Synonyms (119)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Pathways (1)

Protein Targets (13)

Inhibition Measurements

Activation Measurements

Biological Processes (106)

Molecular Functions (40)

Ceullar Components (41)

Bioassays (141)

Research

Studies (2,667)

Study Types

Clinical Trials (436)

Trial Overview

Trial Outcomes

Drug Liking

Breakpoint

Number of Subjects Indicating That They Had Optimal Sleep at Week 24

Number of Subjects With Dose Escalation at Week 24 (ITT Population)

Number of Subjects With Dose Escalation at Week 4 (ITT Population)

Change From Baseline in BPI Pain Relief Score (BPI Item 8) at Week 24

Amount of add-on Pain Medication

"Change From Baseline in Subject Diary Morning Mean Pain Score Pain Right Now at Week 24"

"Change From Baseline in Subject Diary Evening Mean Pain Score Pain Right Now at Week 24"

"Change From Baseline in Quality of Life (QoL) Bodily Pain at Week 4"

"Change From Baseline in QoL Vitality at Week 4"

"Change From Baseline in BPI Interference Score Interfered With General Activity (BPI Item 9a) at Week 4"

"Change From Baseline in BPI Pain Severity Average Pain (BPI Item 5) at Week 24"

"Change From Baseline in BPI Pain Severity Average Pain (BPI Item 5) at Week 4"

"Change From Baseline in BPI Pain Severity Pain at Its Least (BPI Item 4) at Week 24"

"Change From Baseline in BPI Pain Severity Pain at Its Worst (BPI Item 3) at Week 4"

"Change From Baseline in BPI Pain Severity Score Pain at Its Least (BPI Item 4) at Week 4"

"Change From Baseline in BPI Pain Severity Sub-score Pain at Its Worst (BPI Item 3) at Week 24 (ITT Population)"

"Change From Baseline in BPI Questionnaire Item 6 Pain Right Now Score at Week 24 (Intent to Treat [ITT] Population)"

"Change From Baseline in BPI Severity Score Pain Right Now (BPI Item 6) at Week 4"

"Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 Pain Right Now Score at Week 24 (Per Protocol [PP] Population)"

"Change From Baseline in Pain Interference Pain Interfered With Enjoyment of Life (BPI Item 9g) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Enjoyment of Life (BPI Item 9g) at Week 4"

"Change From Baseline in QoL Physical Functioning at Week 4"

"Change From Baseline in Pain Interference Pain Interfered With General Activity (BPI Item 9a) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Mood (BPI Item 9b) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Mood (BPI Item 9b) at Week 4"

"Change From Baseline in Pain Interference Pain Interfered With Normal Work (BPI Item 9d) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Normal Work (BPI Item 9d) at Week 4"

"Change From Baseline in Pain Interference Pain Interfered With Relations With Other People (BPI Item 9e) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Relations With Other People (BPI Item 9e) at Week 4"

"Change From Baseline in Pain Interference Pain Interfered With Sleep (BPI Item 9f) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Sleep (BPI Item 9f) at Week 4"

"Change From Baseline in Pain Interference Pain Interfered With Walking Ability (BPI Item 9c) at Week 24"

"Change From Baseline in Pain Interference Pain Interfered With Walking Ability (BPI Item 9c) at Week 4"

"Change From Baseline in QoL Bodily Pain at Week 24"

"Change From Baseline in QoL General Health Perceptions at Week 24"

"Change From Baseline in QoL General Health Perceptions at Week 4"

"Change From Baseline in QoL Health Transition at Week 24"

"Change From Baseline in QoL Health Transition at Week 4"

"Change From Baseline in QoL Mental Health at Week 24"

"Change From Baseline in QoL Mental Health at Week 4"

"Change From Baseline in QoL Vitality at Week 24"

Change From Baseline in Sleep Quality, Snoring at Week 24

"Change From Baseline in QoL Social Functioning at Week 4"

Change From Baseline in Sleep Quality, Sleep Somnolence at Week 24

Change From Baseline in Sleep Quality, Sleep Shortness of Breath or Headache at Week 24

Change From Baseline in Sleep Quality, Sleep Quantity at Week 24

Change From Baseline in Sleep Quality, Sleep Disturbance at Week 24

Change From Baseline in Sleep Quality, Sleep Adequacy at Week 24

Equi-analgesic Dose at Steady State (ITT Population)

"Change From Baseline in QoL Social Functioning at Week 24"

"Change From Baseline in QoL Role Physical at Week 4"

"Change From Baseline in QoL Role Physical at Week 24"

Intervention	Units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	2.08
Immediate-Release Oxycodone	1.89

Intervention	Percent change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	39.48
Immediate-Release Oxycodone	35.28

Intervention	Percent change in units on scale (Mean)
Fentanyl Buccal Tablets (FBT)	40.94
Immediate-Release Oxycodone	37.56

Intervention	Percent change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	1.11
Immediate-Release Oxycodone	0.73

Intervention	Percentage change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	4.08
Immediate-Release Oxycodone	3.16

Intervention	Percent change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	11.40
Immediate-Release Oxycodone	8.59

Intervention	Percent change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	27.83
Immediate-Release Oxycodone	23.06

Intervention	Percent change in units on a scale (Mean)
Fentanyl Buccal Tablets (FBT)	48.08
Immediate-Release Oxycodone	46.16

Intervention	Units on a scale (Least Squares Mean)
Fentanyl Buccal Tablets (FBT)	2.36
Immediate-Release Oxycodone	1.87

Intervention	Units on a scale (Least Squares Mean)
Fentanyl Buccal Tablets (FBT)	8.58
Immediate-Release Oxycodone	7.65